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Summary 
There has been significant reduction in the scale of the global HIV pandemic over the 
last decade due to increased awareness and the effectiveness of Highly Active antiretroviral 
therapy (HAART). However, new challenges have emerged which when not effectively 
addressed may hinder the progress made so far. One important area of difficulty in the 
management of HIV infection is the emergence and transmission of drug resistant mutations 
(DRM), which threatens the long-term use of current HAART. Also, there is a growing need for 
more effective and relatively cheaper markers for monitoring HIV especially in resource-limited 
areas. One of such potential markers is HIV-l intracellular (IC) DNA load. 
We analyzed plasma and buffy coat samples as well as clinical data of 86 HIV-1 
infected drug naïve patients and eight follow-up patients with persistently high viral loads after 
24 weeks of HAART from Nouna in Burkina Faso. The participants were predominantly 
females. Among drug naïve patients, paired RNA and DNA templates were polymerase chain 
reaction (PCR) amplified and Sanger sequenced for the detection of DRMs. Templates 
encompassed 1461 base pairs sequenced from the protease and reverse transcriptase region of 
HIV-1 pol. A total of eight patients harboured transmitted drug resistance mutations (TDRMs). 
Six had TDRMs to non-nucleoside reverse transcriptase inhibitors (NNRTIs), one to nucleoside 
reverse transcriptase inhibitors (NRTIs), and one to protease inhibitors (PIs). Given that interest 
is growing in the use of viral DNA sequencing to complement or replace RNA for DRM 
monitoring, we compared sequences from RNA and DNA templates, for similarities and 
differences in regions with DRMs and for nucleotide differences. A high level of concordance 78 
(94%) was observed in regions with DRMs. Also, nucleotide sequences of paired templates were 
highly similar (84%). Furthermore, observed nucleotide differences greater than 10 within viral 
sequence pairs were resolved with deep sequencing using the so-called “Nextera tagmentation” 
approach. Deep sequencing of thirteen RNA and DNA template pairs revealed predominantly 
major reverse transcriptase (RT) mutations M230I and M184I within the minority viral 
population. It also confirmed differences in DRMs observed in Sanger sequencing and showed 
that patterns of synonymous and non-synonymous nucleotide changes were similar to those seen 
in Sanger sequencing. Predominant HIV-1 subtypes found in patients were CRF02_AG and 
CRF06_cpx. With the eight follow-up patients, DRMs and HIV-1 subtyping were determined 
from RNA templates only. Drug resistance mutations contributing to virological failure after 
HAART were assessed. Major DRMs to RTIs mainly K103N, E138Q, G190A and M230L were 
detected.  
Finally we assessed the utility of HIV-1 IC DNA load as a tool for disease monitoring 
and found that HIV-1 IC DNA levels did not correlate with traditional HIV-1 disease monitoring 
markers such as CD4+ T-cell counts (r2=0.017; p=0.23) and plasma viral loads (r2=0.003; 
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p=0.60), as well as other markers of disease progression. Also, there was no association (p=0.26) 
found between HIV-1 IC DNA levels of drug resistant (median 2.96 log10 copies/10
6 cells, IQR 
2.30-3.52) and drug susceptible (median 2.62 log10 copies/10
6 cells, IQR 2.23-3.06) strains of 
HIV-1, signifying that the presence of TDRMs does not affect HIV-1 IC DNA levels. However, 
a significantly higher baseline HIV-1 IC DNA level (p=0.045) was found in patients failing 
HAART after 24 weeks of therapy (median 3.16 log10 copies/10
6 cells, IQR 2.75-3.62) as 
opposed to those who did not (median 2.63 log10 copies/10
6 cells, IQR, 2.12-3.04). 
Our findings show that the prevalence of TDRMs is high and new DRMs develop over 
time making it necessary to institute resistance testing for more effective clinical management. 
Also the high concordance in DRMs between viral RNA and DNA templates suggests that DNA 
could be used for resistance monitoring, as it is cheaper and relatively easy to handle. HIV-1 IC 
DNA load is an independent marker that could be used alone or together with plasma viral load, 
CD4+ T-cell counts and other markers to monitor disease progression. A larger follow-up study is 
recommended to confirm these findings.  
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Zusammenfassung 
Innerhalb des letzten Jahrzehnts haben sich die Krankheitslast und die Auswirkungen 
der globalen HIV (humanes Immundefizienz-Virus) Pandemie aufgrund des gesteigerten 
Interesses (z.B. die Aufnahme in die Millenium Development Goals der Vereinten Nationen) an 
der Erkrankung und der erhältlichen Therapie, bekannt als hochaktive antiretovirale Therapie 
(HAART), deutlich reduziert. Allerdings haben sich in dieser Zeit neue Herausforderungen 
herauskristallisiert, die, wenn sie nicht wirksam angegangen werden, die bisherigen Fortschritte 
kompromittieren. Ein großes Problem in der Behandlung der HIV-Infektion stellt die Entstehung 
und Übertragung von Mutationen (engl. drug resitant mutations, DRM) dar, die HI-Viren 
resistent gegen antiretrovirale Wirkstoffe machen und so den langfristigen Nutzen der aktuellen 
HAART beeinträchtigen. Auch gibt es einen zunehmenden Bedarf an effektiveren und 
verhältnismäßig billigeren Biomarkern zur Überwachung des Krankheitsverlaufs, insbesondere 
in Ländern mit unzureichenden finanziellen Mitteln. Ein solcher potenzieller Biomarker könnte 
die intrazelluläre DNA-Kopienzahl von HIV-1 darstellen. 
Wir analysierten Buffy-Coat- (Leukozytenfilm) und Plasmaproben mit den 
dazugehörigen klinischen Daten von 86 HIV-1-infizierten Therapie-naiven Patienten sowie 
longitudinale Daten von acht Patienten mit einer weiterhin hohen Viruslast nach einer 
24wöchigen hochaktiven antiretoviralen Therapie in Nouna, Burkina Faso. In der Gruppe der 
Therapie-naiven Patienten amplifizierten wir je RNA- und DNA-Abschnitte (engl.: templates) 
mittels Polymerase-Kettenreaktion (PCR) und sequenzierten diese mit der Sanger-Methode zum 
Nachweis von DRMs, die Abschnitte umfassten 1461 Basenpaare aus der HIV-1 pol-Region. Bei 
insgesamt acht Patienten konnten wir übertragbare Resistenzmutationen (engl. transmitted drug 
resistance mutations, TDRMs) nachweisen. Sechs hatten TDRMs für nicht-nukleosidische 
Reverse-Transkriptase-Hemmer (NNRTI), je ein Patient für nukleosidischen Reverse-
Transkriptase-Hemmer (NRTI) und für Proteaseinhibitoren (PIs). Da ein großes Interesse daran 
besteht, die DNA-Sequenzierung des HI-Virus als Ergänzung oder gar als Ersatz für die aktuell 
durchgeführte Therapiekontrolle mittels RNA-Amplifikation zu verwenden, verglichen wir 
zusätzlich die Sequenzen von RNA und DNA-templates in den Regionen, die für Resistenzen 
gegen antiretrovirale Wirkstoffe kodieren. Bei 78 Proben (94%) haben wir ein hohes Maß an 
Übereinstimmung zwischen den beiden templates in Regionen mit DRMs beobachtet. Auch 
wiesen die Nucleotidsequenzen von Proben, die als RNA- und DNA-template vorlagen, große 
Ähnlichkeiten (84%) auf. Bei mehr als zehn unterschiedlichen Nukleotiden zwischen DNA- und 
RNA-template haben wir noch weiterführende Untersuchungen mittels deep sequencing, dem 
sogenannten „Nextera tagmentation“ Verfahren, durchgeführt. Diese zusätzlichen 
Untersuchungen bei dreizehn Paaren von RNA und DNA-templates ergaben überwiegend die 
„major“ Mutationen M230I und M184I der reversen Transkriptase (Mutationen, die mit sehr 
wahrscheinlichen Auswirkungen auf die Resistenz gegen antiretrovirale Wirkstoffe assoziiert 
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sind) und die „minor“ Protease-Inhibitor (PI) Mutationen V11I und L89I (Mutationen, die nur 
wenig zur Resistenzentstehung beitragen) innerhalb einer kleinen Anzahl von Viren der 
Gesamtviruspopulation. Hiermit wurden auch die Unterschiede in den Sequenzen der 
Sangermethode bestätigt und zeigte, dass die Muster von synonymen und nicht-synonymen 
Nukleotidänderungen große Ähnlichkeiten mit der Sanger-Sequenzierung aufzeigten. Die 
überwiegend gefundenen HIV-1-Subtypen unserer Patienten waren CRF02_AG und 
CRF06_cpx. Für unsere acht longitudinalen Proben wurden DRMs und HIV-1 Subtypen von 
RNA-templates ermittelt. Extrahierte cDNA Amplikons von Patienten dienten zur 
Untersuchungen der Entstehung von DRMs, die möglicherweise zum virologischen Versagen 
nach HAART beitrugen. Wir detektierten hauptsächlich die „major“ Mutationen für RTIs: 
K103N, E138Q, G190A und M230L. Änderungen des dominierenden HIV-1-Subtyps wurde 
nicht beobachtet. 
Zum Abschluss haben wir noch den Nutzen der HIV-1-IC DNA Viruslast zur 
Therapieüberwachung untersucht. Hier zeigte sich, dass diese Methode keine Korrelation mit 
den herkömmlichen Methoden wie CD4+T-Zellzahl, RNA-Viruslast im Plasma oder anderen 
Biomarker aufweist. Des Weiteren haben wir keinen Zusammenhang zwischen HIV-1-IC-DNA-
Kopienzahl von resistenten und nicht-resistenten Virusstämmen von HIV-1 beobachtet. Dies 
könnte damit erklärt werden, dass die Anwesenheit von TDRMs die intrazelluläre HIV-1-DNA-
Kopienzahl nicht beeinflusst. Allerdings haben wir bei Patienten mit virologischem Versagen 
nach 24 Wochen HAART signifikant höhere HIV-1 IC DNA-Kopienzahlen beobachtet, als bei 
Patienten ohne virologischen Versagen. 
Unsere Ergebnisse zeigen, dass die Prävalenz von TDRMs bereits hoch ist und sich 
neue DRMs im Laufe der Zeit entwickeln. Dies erfordert wohl die Einführung von 
Resistenztestungen für ein effektiveres klinisches Management von HIV-infizierten Patienten. 
Die hohe Übereinstimmung zwischen viraler RNA und DNA in Bezug auf die Erkennung von 
DRMs könnte bedeuten, dass diese Methode mit viraler DNA zur Verlaufskontrolle von 
Resistenzen eingesetzt werden kann, zumal diese kostengünstig und relativ einfach in der 
Handhabung ist. Die HIV-1 IC DNA-Kopienzahl stellt einen unabhängigen Marker dar, der das 
Potenzial haben könnte, alleine oder in Kombination mit Plasma-Viruslast, CD4+T-Zellzahl und 
anderen Biomarkern  in der klinischen Überwachungen einer HIV-Infektion verwendet zu 
werden. Hierfür sind jedoch noch weitere Untersuchungen an einem größeren Patientenkollektiv 
notwendig. 
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1 Introduction 
1.1 The human immunodeficiency virus type 1  
The Human Immunodeficiency Virus was first discovered in the early 1980s at which 
time it was referred to as lymphadenopathy associated virus (Barre-Sinoussi et al., 1983) and as 
well as human T -cell lymphotropic virus III (HTLVIII). It was shown to be the etiological factor 
in Acquired Immune Deficiency Syndrome (AIDS) (Broder and Gallo, 1984; Essex et al., 1985), 
a condition in humans which compromises the immune system and makes patients liable to life-
threatening opportunistic infections (Coffin et al., 1986). HIV belongs to the retrovirus family 
and lentivirus group of viruses (Petropoulos, 1997). 
1.2 Global epidemiology of HIV 
HIV/AIDS has been a global pandemic for the past 3 to 4 decades (Maartens et al., 
2014; Piot and Quinn, 2013). In comparison to other global pandemics, HIV/AIDS has been the 
largest with an estimated 78 million infected since the initial case diagnosis and an estimated 39 
million deaths (UNAIDS, 2013b, 2014b). Since the advent of antiretroviral drugs (ARDs), the 
dynamics of HIV epidemiology has significantly changed with reducing incidence and 
increasing prevalence as mortality has drastically reduced (Maartens et al., 2014; Piot and Quinn, 
2013). The reason for this pattern of epidemiological change is that, while ARVs are effective in 
reducing viral load and preventing full blown AIDS, so far, they are unable to completely 
eradicate the virus from the system of a sufferer (Piot and Quinn, 2013). The incidence of HIV 
infections has fallen by 33% since 2001 (Maartens et al., 2014). According to the UNAIDS HIV 
epidemic update report in 2013 as indicated in figure 1, the worldwide estimation of people 
living with HIV at the end of 2012 were 35.3 million, an increase from 31 million within a 
decade. Sub-Saharan Africa has the largest population of infected people with an estimated 25.0 
million people presently living with HIV infection (Maartens et al., 2014; UNAIDS, 2013b, 
2014b).  Also in 2013, a total of 1.6 million new HIV infections and 1.2 million deaths among 
infected adults and children in sub-Saharan Africa were reported (UNAIDS, 2013b).  
           Introduction  
2 
 
 
Figure 1: Worldwide HIV epidemic update in 2013.  
Reproduced from https://www.aids.gov/images/global-hivaids-overview.jpg. 
1.2.1 Worldwide distribution of HIV-1   
Due to its heterogeneity, HIV-1 has been subdivided into three major groups, M, N and 
O. Of the groups, group M accounts for majority of global infections. Group M is further divided 
into 10 subtypes or clades named subtypes A-K (Buonaguro et al., 2007). The distribution of the 
major HIV-1 subtypes across the globe varies widely (Abecasis et al., 2013; Lau and Wong, 
2013; Lihana et al., 2012). Global trends have shown changing patterns of recombination and 
spread of strains since the inception of the pandemic thus making it imperative that a keen 
interest should be taken to understand the dynamics of global subtype diversity (Lau and Wong, 
2013; Lihana et al., 2012). HIV-1 subtype diversity can affect viral fitness and pathogenicity and 
pose difficulties for vaccine development and optimal therapy (Lau and Wong, 2013; Lihana et 
al., 2012). Subtypes differ from each other by an average nucleotide percentage ranging from 
25–35% while intrasubtype variations are between 15-20% (Lau and Wong, 2013). The 
classification and distribution of HIV-1 is made more complex by the existence of many 
recombinant forms between the various clades of viruses. Circulating recombinant forms (CRFs) 
are defined as those viruses that have been fully sequenced and found in 3 or more 
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epidemiologically unlinked individuals (Hemelaar, 2012). Currently, there are 72 CRFs for HIV-
1. The recombined viruses that do not fall in the criteria of CRFs are called unique recombinant 
forms (URFs).  Also recombination may occur between CRFs and these are called second-
generation recombinants (SGRs) (Hemelaar, 2012). 
The West and Central African sub-regions harbour the widest diversity of HIV-1 
strains however, only a few subtypes and recombinant forms account for most infections 
worldwide (Lihana et al., 2012). The important global subtypes include A, B, C, D, G and CRFs 
(CRF01_AE, CRF02_AG and CRF07_BC) (Lau and Wong, 2013; Lihana et al., 2012).  In 
Europe, North America, Australia as well as parts of Asia and North Africa, Subtype B is the 
predominant HIV-1 subtype (Hemelaar, 2012). Subtype B is predominantly transmitted among 
homosexual men. It is therefore not surprising that a male to female ratio of 3:2 prevails in 
Europe (WHO, 2013b). The other major subtypes that circulate in Europe are A, C and G 
(Abecasis et al., 2013; Hemelaar et al., 2011) while the main circulating recombinant forms 
found in Europe includes CRF02_AG and CRFO2_AE (Abecasis et al., 2013; Hemelaar et al., 
2011).  
All the subtypes of HIV-1 have been reported in Africa (Buonaguro et al., 2007; 
Hemelaar et al., 2011) with significant regional variation in regional distribution (Lihana et al., 
2012). There is also a high recombination rate with increasing circulating and unique 
recombinant forms especially in West and Central Africa, the epicenter of HIV-1 diversity 
(Lihana et al., 2012). The HIV-1 epidemic in Africa is most severe in Southern Africa with the 
predominant strain being subtype C (Buonaguro et al., 2007). The predominance of subtype C in 
southern Africa and in India has contributed to subtype C becoming the most predominant HIV-1 
strain worldwide (Buonaguro et al., 2007; Neogi et al., 2012). Transmission is driven by 
heterosexual intercourse in Africa with more females infected than males (Muula, 2008). In West 
Africa, CRF02_AG (Buonaguro et al., 2007) is the dominant strain of HIV-1 involved in the 
epidemic with subtype G being the next most dominant (Hemelaar, 2012). Central Africa has the 
highest diversity of HIV-1 globally with the dominant strain being CRF01_AE. CRF01_AE 
originated in Central Africa and is becoming the most dominant recombinant form globally (Lau 
and Wong, 2013). Subtype A is the predominant HIV-1 subtype in East Africa followed by 
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subtype D (Buonaguro et al., 2007; Hemelaar, 2012). In south east Asia, CRF01_AE has been 
shown to be the predominant form of HIV-1 (figure 2) (Buonaguro et al., 2007). 
 
Figure 2: Distribution of HIV-1 subtypes around the world.  
Pie chart representing the distribution of major HIV subtypes in the various continents of the world  
Reproduced from (Hemelaar, 2012). 
1.3 HIV-1 genome structure and organization 
HIV-1 is composed at its core of two copies of positive sense single-stranded RNA, 
which constitutes its genome, and associated proteins enclosed by a fullerene conical capsid 
(Dudek, 2007). The capsid is further enclosed by a matrix, which has on the outer surface the 
viral envelope (env) protein (Dudek, 2007). The genome of HIV-1 is quite complex with 
multiple reading frames (Cohen et al., 1990), splice sights (Mueller et al., 2014), internal 
ribosomal entry sites and pseudoknots (Watts et al., 2009). The RNA is about 9.5 kilobases (Li et 
al., 1992; Ratner et al., 1985) with a 5′ cap and a poly A tail (Ratner et al., 1985). The RNA 
genome comprises of major genes as well as minor genes, as is characteristic of retroviruses 
(Watts et al., 2009). The three major genes code for gag pol and env proteins, responsible for 
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structure, enzymes and envelope protein synthesis respectively. These major genes are unspliced 
except to for env (Lutzelberger et al., 2006; Watts et al., 2009). On the other hand, minor and 
accessory proteins including vif, vpu and nef are expressed through a complicated system of 
alternate splicing of the genes ((Lutzelberger et al., 2006; Schwartz et al., 1990). The 5’ and 3’ 
ends of HIV-1 proviral DNA have repeat sequences called long terminal repeats (Ferrer et al.). 
LTR sites are important for binding of primers during proviral transcription and integration of 
viral DNA into the host genome (Delviks-Frankenberry et al., 2011). They also serve as 
promoter and enhancer regions for viral RNA synthesis (Delviks-Frankenberry et al., 2011). 
LTRs of HIV-1 are segmented into U3, R and U5 regions at both the 5’ and 3’ regions of the 
proviral DNA. While the LTR regions are complete in the proviral DNA, the HIV-1 viral RNA 
only contains the R and U5 segments at the 5’ end and U3 and R at the 3’ ends (figure 5) 
(Delviks-Frankenberry et al., 2011).  
Proteins that make up the viral particle are generally divided into structural, enzyme 
and accessory proteins. Structural proteins facilitate the integrity of the virus particle, support the 
internal organization and facilitate anchoring and infection of host cells (Frankel and Young, 
1998). Structural proteins include matrix proteins, capsid proteins and membrane proteins. The 
matrix proteins form a layer on the inner side of the membrane and help to organize the 
transmembrane part of the envelope proteins as well as trafficking viral replication particles early 
in its life cycle (Hill et al., 1996). Capsid proteins deliver the viral RNA into cells during 
infection (Pornillos et al., 2009). Envelope proteins gp41 and gp120 ensure viral binding and 
penetration into host cells (Kwong et al., 2000). The protein p7 associates and supports the RNA 
genome (Dawson and Yu, 1998) while p6 is an important membrane interacting protein for viral 
assembly (figure 3) (Solbak et al., 2013).  
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Figure 3: Genome organization of HIV-1.  
The figure illustrates the HIV genome above with the corresponding components of the viral particle they 
form below. (Reproduced from http://www.sciencedaily.com/releases/2011/12/111221140349.htm). 
1.4 Clinical presentation of HIV 
The clinical presentation of HIV/AIDS varies widely from persistently asymptomatic 
to a severe immune compromise and wasting with many opportunistic infections and ultimately 
death (WHO, 2007). For clinical and research purposes HIV-1 infection has been classified into 
stages by the CDC and WHO. Staging of the disease is important for timing of management 
strategies and monitoring of disease progression during therapy as well as for research and 
epidemiological purposes (Schneider et al., 2008).  
1.4.1 WHO clinical staging 
The WHO staging of HIV/AIDS is based essentially on clinical manifestations of the 
disease (Kassa et al., 1999; WHO, 1993, 2007). There is also an immunological classification 
based on CD4+ T-cell count (WHO, 2007).  The clinical emphasis enables clinicians in resource 
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poor environments, where many laboratory parameters cannot be readily assessed, to effectively 
stage the disease and make good judgment on initiation of opportunistic disease prophylaxis and 
ART (WHO, 2007). WHO has divided HIV-1 infection into four clinical stages (1-4) based on 
the severity of clinically staged HIV-1 infection, according to the following categories: 
Asymptomatic, mild symptoms, advanced symptoms and severe symptoms which generally 
coincide to four stages (WHO, 2007). 
1.4.2 CDC classification system of HIV-1 infection  
While the WHO classification is essential for clinical management and patient care, the 
CDC staging is essentially based on measurement of CD4+ T-cell counts with other associated 
clinical conditions (CDC, 1992; Schneider et al., 2008). Case definitions based on the CDC 
criteria are mainly oriented at public health surveillance, epidemiologic monitoring and control 
rather than for clinical management (Schneider et al., 2008). The CDC stages are also further 
classified based on age groups, namely; adults, adolescents and children (Schneider et al., 2008). 
Initial CDC classification for adults and adolescents is in three categories (1, 2 and 3) based on 
CD4+ T-cell counts. Category 1 represents laboratory diagnoses of HIV-1 infection with CD4+ 
T-cell counts greater than 500 cells/µl of blood. CD4+ T-cell counts between 499 and 200 
cells/µl of blood and counts less than 200 cells/µl of blood represent categories 2 and 3 
respectively (CDC, 1992). The CD4+ T-cell counts categories were further placed under 3 
clinical groups categorized as A, B and C (CDC, 1992). 
The CDC revised the classification using a simpler classification and retaining all the 
AIDS defining conditions of category C. The stages are as follows: stage 1, stage 2, stage 3 and 
stage unknown (Schneider et al., 2008). Since the CD4+ T-cell count or percentage are critical 
for CDC staging, it is recommended that every effort should be made to acquire CD4+ T-cell 
count information although the stage can still be classified as unknown. CDC stage 1 is defined 
as laboratory diagnosed HIV-1 infection with a CD4+ T-cell count greater than 500 cells/µl of 
blood or CD4 percentage of greater than twenty-nine. Stage 2 refers to CD4+ T-cell counts 
between 200 and 499 cells/µl of blood or a CD4 percentage between 14 and 28. In stage 3, the 
CD4+ T-cell count is less than 200 cells/µl of blood or a CD4 percentage of less than 14 
(Schneider et al., 2008). 
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1.5 Life cycle  
HIV-1 gains access to the body mainly via parenteral routes. By far most of the cases 
in the global pandemic were transmitted through heterosexual intercourse (Maartens et al., 
2014). On gaining entrance into the body, HIV-1 primarily infects mononuclear cells (Fu et al., 
2011). The cells mainly targeted by HIV-1 are CD4+T helper cells, monocytes, macrophages and 
dendritic cells (Coleman and Wu, 2009). These cells express CD4 on their cell surface, which 
serves as the major receptor for the viral membrane protein gp120 (Weiss, 2013). Besides CD4, 
co-receptors that facilitate viral attachment and tropism include the chemokine receptors CCR5 
and CXCR4 (Weiss, 2013). CCR5 facilitates viral entry early during infection while CXCR4 is 
thought to be more important in the later stages of the infection (Weiss, 2013). However some 
HIV-1 strains can utilize both CCR5 and CXCR4 and are referred to as R5X4 viruses (Lamers et 
al., 2008).  
Upon receptor recognition and attachment using gp120, the HIV-1 surface 
glycoprotein gp41 is important in membrane fusion and eventual entry onto the cells (Garg and 
Blumenthal, 2008). Within the cytoplasm of infected cells, the HIV-1 genome is reverse 
transcribed by reverse transcriptase to DNA (Hu and Hughes, 2012). Reverse transcription is a 
complicated process that involves two obligated template-switching steps involving both the 
minus and plus strands of the synthesized DNA (Delviks-Frankenberry et al., 2011).  
The resulting HIV-1 DNA product of reverse transcription is referred to as a pre-
integration complex (PIC), which is actively transported into the nucleus for integration into the 
genome as provirus (Engelman, 2009; Piller et al., 2003). Integration is effected by the virus 
encoded protein integrase (Albanese et al., 2008). Figure 4 illustrates the entire process. 
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Figure 4: The HIV life cycle.  
The figure illustrates viral entry followed by reverse transcription and integration into the host genome. Viral 
RNA transcription follows with assembly and formation of a new infectious particle.  (Reproduced from 
http://www.slideshare.net/sudhakorwar/presentation-6608205) 
1.5.1 The fate of HIV viral DNA 
A small percentage of the linearized dsDNA gets integrated into the genome of the 
host to form the provirus.  The provirus acts as a latent reservoir and ensures persistence of 
infection (Demetriou et al., 2010). The remaining linearized dsDNA is circularized to form 2-
LTR circles (Butler et al., 2001; Vandegraaff et al., 2001). Homologous recombination in 2-LTR 
circles results in 1-LTR circles. Auto integration into LTR circles can also result in various 
rearranged circular products. Also, most of the HIV-1 DNA remain un-circularized and un-
integrated and add up to the episomal population of HIV-1 viral DNA. The entire nonintegrated 
DNA is a dead end product, which may be degraded or persists in the nucleus of the cell (Butler 
et al., 2001; Vandegraaff et al., 2001). The HIV-1 DNA forms are illustrated in figure 5 
(Kostrikis et al., 2002a) 
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Figure 5: Schematic representation of the intermediate products formed during the process of HIV-1 reverse 
transcription of the viral RNA to form the HIV-1 second template switch DNA. 
The figure illustrates the formation of the linear dsDNA and its possible outcomes; the various LTR circles 
and the integrated provirus. Reproduced from (Kostrikis et al., 2002a). 
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1.6 Management of HIV/AIDS  
Management of HIV/AIDS has evolved significantly since the initial diagnosis in the 
early 1980s. While clinical management was ineffective in the early stages of the pandemic, the 
development of effective antiretroviral drugs has significantly improved clinical outcomes over 
the last couple of decades (Maartens et al., 2014). Till date, over 24 licensed drugs have been 
approved for treatment of HIV/AIDS (Maartens et al., 2014).  
Antiretroviral drugs are generally classified based on the stage of the viral life cycle 
targeted. Currently there are 5 main classes of ARVs approved by the FDA for clinical use, 
which are: Viral Entry inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and viral 
integration inhibitors (figure 6) (Arts and Hazuda, 2012). HIV-1 drug resistance mutations are 
quite common and with over 70% resistant rates for some individual ARVs (Nii-Trebi et al., 
2013; Richman et al., 2004). Drug resistant mutations arise from key changes in base pairs that 
confer an escape for a sub population of the virus from the ARV effects. While resistance may 
develop rapidly to some antiretroviral drugs, the process can be slow and occur over time with 
accumulation of mutations that will ultimately confer resistance (Das and Arnold, 2013). 
Mechanisms of drug resistance development vary between drug families (Das and Arnold, 2013). 
Below are descriptions of the actions of the various groups of ARTs and their mechanisms of 
action and resistance. 
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Figure 6: The HIV-1 life cycle and drug targets at different stages of viral processing. 
The figure illustrates the various points in the HIV-1 life cycle targeted by the various approved classes of 
drugs with specific examples of each group. Reproduced from (Chabria et al., 2014).  
1.6.1 Nucleoside/Nucleotide reverse transcriptase inhibitors 
The critical importance of RT to the life cycle of HIV-1 has led to the development of 
many drugs targeting it. Nucleoside reverse transcriptase inhibitors (NRTIs) are nucleoside 
analogues that incorporate into the DNA chain synthesized by RT and hence interrupt 
elongation. NRTIs lack a 3’ OH group and thus prevent the addition of additional nucleotides 
(figure 7A and 7B). Examples of NRTIs include zidovudine, lamivudine and abacavir (Das and 
Arnold, 2013).  
Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) occurs through two 
basic mechanisms. The primary mechanism involves mutations (M184V, Q151M) in the drug 
binding site that increases discrimination against drug binding and hence resistance (Johnson et 
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al., 2010; Larder and Kemp, 1989). The other mechanism involves increased ability of the 
reverse transcriptase enzyme to remove incorporated NRTIs from the chain by a process called 
pyrophosphorolysis and hence reduces their ability to inhibit reverse transcription of viral RNA 
(Arion and Parniak, 1999; Sluis-Cremer et al., 2000) (figure 7A and 7B). Some studies have 
demonstrated that pyrophosphorolysis is augmented by the presence of thymidine analogue 
mutations (TAMs) in reverse transcriptase (Ray et al., 2003; von Kleist et al., 2012). Common 
TAMs include M41L and L210W among several others (Hu et al., 2006).  
Development of resistance to NRTIs has been shown to vary based on virus subtype 
and region (Wainberg et al., 2011). For example patients with subtype C treated in Botswana 
with zidovudine and didanosine were shown to have higher TAMs as compared to patients 
infected with subtype C in India, South Africa and Malawi (Wainberg et al., 2011). Also, it was 
shown that patients with CRF06_cpx viruses are predisposed to having higher TAMs than those 
carrying CRF02_AG recombinant viruses in Burkina Faso (Wainberg et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Mechanisms of action of nucleoside reverse transcriptase inhibitors and development of resistance. 
 NRTIs are incorporated into the growing chain and prevent elongation. Mutations in the binding pocket of 
the enzyme prevent incorporation of the NRTI thereby leading to resistance development (A). NNRTIs can 
also prevent ATP binding to prevent reverse transcription. Mutations that allow ATP to bind can result in 
removal of the NRTI for generation of resistance. Reproduced from (Clavel and Hance, 2004). 
A B
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1.6.2 Non-nucleoside reverse transcriptase inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNRTI) bind to a hydrophobic pocket 
of reverse transcriptase and allosterically reduce the catalytic ability of the enzyme (Das and 
Arnold, 2013) (Figure 8A, 8B and 8C). Examples of NNRTIs include nevirapine and efavirenz 
(Das and Arnold, 2013). Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
occurs due to mutations that lower drug binding and prevents allosteric inhibition of reverse 
transcriptase (Akinsete et al., 2004; Tambuyzer et al., 2009). The mutation K103N is one of 
several mutations that confer resistance against almost all NNRTIs (Akinsete et al., 2004; 
Tambuyzer et al., 2009). 
 
A.  
 
 
 
B. 
 
 
 
C. 
 
 
 
Figure 8: Mechanism of action and resistance of HIV to Non-nucleoside Reverse-Transcriptase Inhibitors.  
NNRTIs bind to an allosteric pocket of the RT and reduce activity at the active site of the enzyme. Mutations 
that preventing drug binding of the enzyme in the binding pocket confers resistance. Reproduced from 
(Clavel and Hance, 2004).  
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1.6.3 Protease inhibitors 
Protease inhibitors inhibit the HIV-1 protease enzyme, a heterodimer that cleaves HIV-
1 polyproteins into functional forms without which the infectious virus cannot be formed (Fun et 
al., 2012). Protease cleaves the HIV-1 large precursor polyproteins gag and gag-pol into 
functional proteins, which include p7, p24, p17 and p6 as well as viral enzymes reverse 
transcriptase, protease and integrase (Baca and Kent, 1993; Fun et al., 2012). Protease inhibitors 
bind the substrate-binding site of the enzyme heterodimer and by that they inhibit cleavage of the 
polyproteins (Fun et al., 2012). Mutations in the substrate-binding pocket of the enzymes reduce 
affinity for the drugs but not the natural substrates and thus confer resistance to the protease 
inhibitors (Fun et al., 2012). 
1.7 HIV Resistance Development and Transmission of Resistance 
The high rate of mutation in HIV-1 generates numerous HIV-1 strains within a patient 
referred to as viral quasispecies (Domingo et al., 2012). In a patient, one of HIV quasispecies is 
predominant at the initial stages of infection (Metzner, 2006). In ARV treated individuals, the 
balance of the quasispecies is altered and minority species that can overcome the bottleneck due 
to the ARVs become the dominant species, as they are fitter under the unique circumstance of 
therapy (Metzner, 2006). The ability of a strain of HIV to overcome adverse conditions in the 
host, based on its unique DNA alterations, is referred to as viral fitness (Buckheit, 2004). The 
concept of viral fitness is described by the Red Queen hypothesis where viral quasispecies in 
competition tend to increase in replication ability (Fitness) with successive generations 
(Domingo et al., 2012). Understanding of HIV resistance mutation development and viral fitness 
is critical to understanding the long term virulence and transmission as well as drug susceptibility 
and therapeutic strategies (Arnott et al., 2010; Domingo et al., 2012). 
1.7.1 Transmitted drug resistance mutations 
Highly active antiretroviral drugs (HAART) have in recent times become increasingly 
available to patients infected with the human immunodeficiency virus (HIV-1) in Africa and 
large scale programs have been implemented in many African countries for the administration of 
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these drugs (UNAIDS, 2013a). The implementation of HAART has evidently led to a significant 
decrease in morbidity and mortality among infected individuals. However, the increasing use of 
HAART across the world has led to the emergence of drug resistant virus strains, known to 
reduce susceptibility to the ART and which can also be transmitted to treatment naive patients 
(Avila-Rios et al., 2014) (Johnson et al., 2010). This implies that an increasing number of drug 
naive patients are being infected with viruses that are already resistant to ARTs termed 
transmitted drug resistant viruses (Pillay et al., 2006). These viruses pose a major clinical and 
public health issue. On the other hand, resistant mutations developed by an individual on ART 
are termed acquired drug resistance mutations (DRMs). These mutations usually occur as a result 
of a drug selection pressure (Metzner et al., 2009).   
1.7.2  Prevalence of transmitted drug resistant mutations in HIV-1 newly 
diagnosed patients 
Transmitted drug resistant mutations surveillance is becoming an important factor in 
the global management of HIV-1. In 2012, The WHO HIV-1 drug resistance report estimates 
indicate increasing trends in TDRM globally due to increasing use of ARVs (WHO, 2013b). In 
developed territories like Europe, USA and Japan, 10 to 17 percent of newly diagnosed HIV-1 
patients have at least one TDRM (WHO, 2012). In developing countries as well, the WHO 
reports an increasing trend of TDRM between 2003 and 2010 (WHO, 2012). The implications of 
TDRMs to success of ARV therapy was demonstrated in a large European study which showed 
significant increase in treatment failure in patients who had TDRMs as compared to those who 
did not (Wittkop et al., 2011). 
With increasing ARV therapy availability in Africa, it follows that the prevalence of 
TDRMs will also increase, highlighting the importance of TDRM monitoring (WHO, 2012). 
Recent studies conducted among a cohort of sub-Saharan Africans in eight clinical research 
centers (Kigali, Rwanda; Lusaka, and Copperbelt, Zambia; Masaka and Entebbe, Uganda; 
Nairobi and Kilifi, Kenya; and Cape Town, South Africa) have confirmed low but increasing 
trends of TDRM (Price et al., 2011b). The prevalence of transmitted drug resistant mutations 
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(TDRM) in newly diagnosed patients in most African countries ranges from 3% and 17% 
(Derache et al., 2008; Ndembi et al., 2011; Ojesina et al., 2006).  
1.8 Assays for HIV drug resistance 
The development of assays that can detect resistant mutations has enabled testing for 
drug resistance and enable decision-making on the choice of ARVs and alterations in therapy 
(Hirsch et al., 2008). Phenotypic and genotypic resistance assays are the two types of assays that 
are currently in use for the assessment of DRMs. Genotypic resistance assays use data from 
sequenced HIV genes from patients to detect mutations that may confer resistance to a given 
ARV. Phenotypic resistance assays are cell culture based assays that assess viral replication 
capabilities in the presence or absence of a given ARV (Hirsch et al., 2008).   
1.8.1 Genotypic resistance assays  
Genotypic resistance assays can be done using standard kits or in-house assays based 
on resources of a given lab. In-house assays use regular sequencing techniques like the Sanger 
sequencing to determine nucleotide sequences of patient derived viruses. To perform Sanger 
sequencing, the viral RNA is reverse transcribed to DNA prior to sequencing usually targeting 
the RT and PR regions (Geretti et al., 2014; Hirsch et al., 2008). The FDA approved the 
Truegene HIV-1 kit for use in genotypic monitoring in 2001 (Grant et al., 2003). In genotypic 
assays, rule-based algorithms on HIV databases (Hirsch et al., 2008) are used for predictions on 
the relevance of mutations for clinical decision-making.   
Genotypic resistance testing is recommended for routine resistant mutation testing 
among drug naïve patients (WHO, 2006). However several limitations are recognized with 
genotypic resistance assays. First, there is the general difficulty in predicting clinical outcomes 
entirely based on algorithms. Secondly, there is the difficulty in assessing viral strains due to the 
heterogeneity of the viral genome of an infected patient (Hirsch et al., 2008). This normally leads 
to the production of patient derived viral chromatographs that are difficult to interpret. Since 
most tests have been based on B-subtypes, non-B and C subtypes pose some difficulty in 
interpreting mutations that affect drug susceptibility (Hirsch et al., 2008). There is also the 
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difficulty of detection when HIV viral load is low. Recently however, some groups have 
demonstrated the ability to do resistance testing with viral loads less than 1000 copies /ml of 
plasma with a significant success rate below 50 copies/ml of plasma (Gonzalez-Serna et al., 
2014; Santoro et al., 2014). 
1.8.2 New trends in drug resistance assays 
Besides standard phenotypic and genotypic assays, other assays are used for viral 
fitness tests. They include allele-specific PCR assays, ultra-deep and single genome sequencing. 
These assays are used to investigate minority variants with mutations that are hard to detect by 
standard approaches (Hirsch et al., 2008).  
1.8.2.1  Deep sequencing 
Population based Sanger sequencing has been the standard method that has been used 
in DNA sequencing over the past decades but in recent times next generation or deep sequencing 
is revolutionizing the field of genomics including clinical virology (Gibson et al., 2014; 
Quinones-Mateu et al., 2014). 
During Sanger sequencing, the DNA template is only read once, thus increasing the 
chances of errors within the growing nucleotide sequence and also making it difficult to 
differentiate single nucleotide polymorphisms from resistant mutations (Chabria et al., 2014). 
Other limitations of Sanger sequencing includes inability to read minority strains less than 20% 
of viral quasi species (Chabria et al., 2014). It is known that minority variants gain fitness in the 
presence of drugs and can become dominant and therefore, knowledge of such variants is 
important for clinical practice (Chabria et al., 2014). 
Deep sequencing employs next generation sequencing (NGS) strategies that allow 
multiple reading of a single nucleotide in the DNA sequence and thus increase the precision (Fox 
et al., 2014). In the clinical virology settings, when it comes to dealing with minority variants in 
DRMs, deep sequencing techniques, allow for reading of sequences of minority variants as low 
as 0.5-1% in the viral quasi species (Gibson et al., 2014; Quinones-Mateu et al., 2014).  In deep 
sequencing the average number of times a nucleotide is read is referred to as coverage (Sims et 
al., 2014).  Various platforms have been developed for deep sequencing using specific methods 
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however; they all employ the use of reverse transcription of viral RNA and PCR in order to 
generate amplicons for sequencing. Multiple primers ad adapters are used in order to capture all 
the sequences. Examples of NGS platforms currently in use include Roche, Illumina ad Ion 
Torrent (Chabria et al., 2014). Deep sequencing however has some drawbacks including the use 
of different primer pairs that can result in a distortion in the composition of the viral quasi 
species as primer efficiency could vary (Chabria et al., 2014; Jabara et al., 2011) and the 
occurrence of PCR recombinants that result in false strain identification (Chabria et al., 2014; 
Jabara et al., 2011; Kozal et al., 2011).  
1.9 Comparing HIV proviral DNA and RNA for mutations 
During HIV treatment, the selective pressure on the virus quasispecies results in 
selection of resistant mutations (Nikolenko et al., 2011). The mutations are generally measured 
in the viral RNA, which is mainly extracellular. However while mutations occurring in 
intracellular DNA may be similar to the RNA forms, discordance has been shown to exist 
between them as well (Banks et al., 2012). In resource poor countries however, DNA analysis for 
mutation may be cheaper to undertake in comparison to RNA (Banks et al., 2012). Some studies 
have shown that proviral DNA may differ in mutations compared to RNA. One reason for 
possible disparities is the difference in turnover rates (Banks et al., 2012; Delaugerre et al., 
2012). In one study done in Zimbabwe, discordance between viral RNA and DNA drug 
resistance mutations were reported for PIs, NRTIs and NNRTIs (Banks et al., 2012). On the 
other hand, a high concordance between viral RNA and DNA has been reported in several 
studies (Ferrer et al., 2013; Mayers et al., 1998). 
1.10 Therapeutic goals and treatment outcomes during HIV 
management 
The primary goal of current HIV treatment is to reduce viral load of patients to below 
detectable levels (Okulicz et al., 2014) and restore immune function (Okulicz et al., 2014) 
although efforts are being made to completely eradicate the virus (de Mendoza et al., 2014) or 
attain cure based on prevention of reservoir development or viral endogenization (Ananworanich 
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et al., 2015; Colson et al., 2014). Also treatment and prevention of opportunistic infections and 
improvement of overall quality of life are important aims of the management of HIV/AIDS 
patients (Dybul et al., 2002).  
Although the mainstay of clinical management of HIV is antiretroviral therapy, a 
critical issue has been the optimal time to initiate therapy (Ananworanich et al., 2015; Okulicz et 
al., 2014). Some studies have demonstrated that a short course antiretroviral therapy soon after 
infection may significantly slow disease progression (Ananworanich et al., 2015; Saez-Cirion et 
al., 2013). However there are questions about the benefits of early treatment in the face of 
increasing drug resistance (Maartens et al., 2014). Generally, patients are initiated on ARVs 
when their CD4+ T-cell counts are below 350 cells/µl, however patients with CD4+ T-cell counts 
over 350 cells/µl who show signs of complications of AIDS are started on ARVs (Maartens et 
al., 2014). In spite of the limited scope of trials in early initiation of therapy, the consensus on 
initiation of ARVs is inclined to early initiation of therapy where possible as this has been shown 
to improve and sustain viral load reduction, as well as optimize immune recovery 
(Ananworanich et al., 2015; Okulicz et al., 2014). 
1.10.1 Disease monitoring in HIV  
Monitoring of HIV-1 infection and disease progression is an important part of 
management especially in the current era of ARV. Monitoring disease progression determines 
decision-making, especially the timing of initiation of ARVs or opportunistic infection 
prophylaxis and also when to alter therapy (Laurent et al., 2011). There are several markers that 
have been used over the years to monitor HIV and disease progression but the most widely used 
are plasma viral load and CD4+ T-cell counts (Mellors et al., 1995; Mellors et al., 1997a). 
Besides viral load and CD4+ T-cell counts, there are other surrogate markers for HIV disease 
progression and these include hemoglobin (Ioannidis et al., 2001a), serum albumin, total 
lymphocyte count, liver enzymes (Venkataraman, 2013) and in recent times intracellular viral 
DNA levels (Williams et al., 2014). 
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1.10.2 Response to antiviral drug therapy 
Although drug therapy has significantly revolutionized clinical management of 
HIV/AIDS, the response to therapy can vary in practice (Maartens et al., 2014). A good 
understanding of response to drug therapy and its implications is important for optimal clinical 
management. Given that the goal of therapy is to restore immune response and reduce viral load 
to below detection levels, response to therapy is divided into immune response and virological 
response as well as clinical response (Phillips et al., 2001). While response to drug therapy has 
been associated with time of initiation and baseline CD4+ T-cell counts, no significant 
association has been made between virus subtype and response to therapy (Phillips et al., 2001). 
After initiation of ART, viral load usually reduces to below detection limits for most 
assays. This usually occurs within 3 months of treatment initiation (Maartens et al., 2014). In 
contrast to virological response, immunological response lags behind and is usually achieved 
within 6 months of therapy (Maartens et al., 2014). While virological response is usually 
followed by immunological response during therapy, some proportions of treated patients have a 
discordant response to treatment. In one study, 56% of treated patients had a good virological 
and immunological response, 19% of patients had good virological response with poor 
immunological response and 14.8% had a good immunological response with poor virological 
response (Maartens et al., 2014; Tuboi et al., 2007). 
1.11 Determinants of disease progression 
Determinants of disease progression in HIV-1 infection have been an area of intense 
research due to its importance in clinical practice (Singh and Spector, 2009). Being able to 
predict disease progression can help clinicians tailor management regimes to suit individual 
cases in the hope for successful outcomes of therapy. Factors that determine disease progression 
include those due to viral characteristics, host genetic polymorphisms (Ioannidis et al., 2001b; 
Singh and Spector, 2009) and host immune characteristics (Hogan and Hammer, 2001). The viral 
load prior to therapy has been identified as a key determinant in disease progression (Mellors et 
al., 1997b). The viral load usually assessed is the viral load in plasma. However, it has recently 
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been determined that intracellular viral load may be an important and independent determinant of 
disease progression (Demetriou et al., 2010; Kostrikis et al., 2002b).  
1.12 Transmitted drug resistant mutations and disease progression 
Transmitted drug resistant mutations and disease progression in HIV-1 infection 
remains an area not completely clarified. Some studies have indicated that ART resistance is not 
a major determinant of disease progression and that continued adherence to HAART could still 
be protective in the face of drug resistant mutations (Lucas, 2005; Lucas et al., 2004; Recsky et 
al., 2004). However others studies have indicated a clear correlation between number of resistant 
mutations and virological outcomes (Ledergerber et al., 2004), which presupposes that, 
transmitted drug resistance may increase the risk of virologic failure (Daar and Richman, 2005). 
In 2005, a multi-resistant strain was identified in a New Yorker who progressed rapidly to AIDs, 
however, the prevalence of this strain was found to be low (Blick et al., 2007). Thus far, the role 
of drug resistance on disease progression requires a lot more research in order to clarify its 
relevance clinically. 
In Africa, TDRM have been reported (Price et al., 2011b; WHO, 2012) however, not 
much has been studied on its effect on disease progression. Since Africa bears the brunt of the 
world’s HIV-1 burden, it would be worth determining the effect of resistant mutations on disease 
progression, as it would duly inform clinical practice in the wake of the increasing development 
of mutants. 
1.13 HIV-1 intracellular DNA load and disease progression 
Plasma HIV-1 viral load has been shown to be one of the most important and 
independent determinants of HIV-1 disease progression (Mellors et al., 1995; Mellors et al., 
1996). While the clinically determined viral load is RNA, the form of the virus in the nucleus of 
the cell is DNA (Craigie and Bushman, 2012; Demetriou et al., 2010). HIV-1 IC DNA load is a 
marker associated with the viral reservoir and with the spread of the virus (Parisi et al., 2012). 
Studies in patients with primary HIV-1 infection and advanced HIV-1 disease have demonstrated 
that early levels of HIV-1 IC DNA load prior to initiation of highly active anti-retroviral therapy 
(HAART) in peripheral blood mononuclear cells (PBMC) and in CD4+T -cells have a predictive 
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value for long-term virological outcome and for disease progression, independently of CD4+ T-
cell counts and plasma viral RNA load (Russell et al., 2001; Saitoh et al., 2002; Verhofstede et 
al., 1994). Recently, Williams et al showed that HIV-1 intracellular viral DNA may even be a 
better predictor of disease progression than plasma RNA viral load (Williams et al., 2014). 
Thus far, the factors that determine HIV-1 IC DNA levels are not well understood. In a 
recent study conducted in a cohort of newly diagnosed Europeans with HIV infection, it was 
found that the resistant viral strains did not have any correlation with HIV-1 intracellular viral 
DNA load prior to initiation of treatment as compared to non-resistant viral strains (Demetriou et 
al., 2010). 
1.14 Therapy failure with HAART   
The WHO defines treatment failure by plasma viral load and CD4+ T-cell count 
decline (Hirnschall et al., 2013). According to the WHO, HIV viral load monitoring is the 
preferred approach for assessing response to treatment and treatment failure (Hirnschall et al., 
2013). Two parameters are defined with respect to changes in viral load following initiation of 
therapy. Viral suppression refers to a reduction in viral load below detection for the assay, 
usually below 50 copies cells/ml of plasma however, virologic failure is said to have occurred 
when viral load persistently remains above 1000 copies cells/ml of plasma after 6 months of 
ART (WHO, 2013a). While immunological response and clinical outcomes may be used for 
complementing viral load and monitoring ART success, they have a poor sensitivity and positive 
predictive value for identifying virologic failure in adults and children (Hirnschall et al., 2013). 
Where it is impossible to measure viral load during ART, it is also recommended that 
immunological and clinical responses should be used to assess success of therapy (Laurent et al., 
2011; WHO, 2013a). WHO defines immunological failure as CD4+ T-cell counts falling to 
baseline or below or persistent CD4+ T-cell counts below 100 cells/µl of blood (WHO, 2013a) 
and clinical failure represent a new or recurrent event as a result of severs immunological 
dysfunction after 6 months of therapy (WHO, 2013a). 
During treatment with HAART, some patients responding to treatment with 
undetectable viral loads experience a period of low-level detectable viremia, followed by 
suppression of viral replication (Miller et al., 2004). These transient increases in viral load, are 
           Introduction  
24 
 
referred to as blips (Fidler et al., 2014; Miller et al., 2004). Between 10 to 20 percent of patients 
on HAART experience blips (Fidler et al., 2014; Ibrahim et al., 2012) although up to 90 percent 
has been reported in one study (Nettles et al., 2005). The mechanism of virological blips is not 
clearly understood, however, it has been suggested that changes in immune activation and 
reservoir by stimuli like infections may account for it (Jones and Perelson, 2007). Virological 
blips have been attributed to random biological and statistical variations around mean viral levels 
(Nettles et al., 2005) and not poor adherence to medication (Miller et al., 2004). Virological blips 
are however not predictive for virologic failure (Fidler et al., 2014; Ibrahim et al., 2012; Nettles 
et al., 2005). 
1.15 Overview of HIV in Burkina-Faso 
HIV was first diagnosed in Burkina Faso in 1986 (WHO, 2005). The HIV prevalence 
in Burkina Faso varies widely with high rates in urban centers. A study conducted in urban 
Burkina Faso (Bobo-Dioulasso) reported a prevalence of 5.2% in 2004 (Lagarde et al., 2004). 
However the general prevalence of HIV in adults between the ages of 15 and 49 years is 
generally low, estimated at 1.1% (UNAIDS, 2013b). The predominant strains of HIV in Burkina 
Faso are CRF02_AG and CRF06_cpx although several strains are present (Tebit et al., 2006; 
Tebit et al., 2009).  
Up-scale of HAART was initiated in Burkina Faso in 2003 and this has resulted in an 
increase of individuals on treatment alongside with the development of drug resistant mutations 
in treated and drug naïve patients (Somda et al., 2012; Tebit et al., 2008; Tebit et al., 2009). One 
important contribution to resistance mutation development is the use of nevirapine in the 
prevention of mother to child transmission (Tebit et al., 2006; Tebit et al., 2008).  According to 
Tebit et al, the prevalence of resistance mutations in patients failing therapy was 40% to PIs, 
76% NNRTIs and 85% to NRTIs (Tebit et al., 2008). Several studies have assessed the 
prevalence of DRMs among urban populations in Burkina Faso. Among pregnant women, a 
moderate (5-15%) rate of drug resistance mutations was reported (Somda et al., 2012). Also, 
Tebit et al reported a TDRM rate of 12.5% in a study in Ouagadougou (Tebit et al., 2009). In 
rural Burkina Faso, where the present study was conducted, there has been no study reporting 
TDRM mutations and how it correlates with markers of disease progression. 
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1.15.1 Rationale of the study 
The improvement in survival of HIV infected individuals due to the introduction of 
HAART has been a major milestone in the global HIV pandemic. However, new challenges have 
arisen by virtue of the lifelong nature of therapy and the potential for treatment failure due to 
development of drug resistant strains of the virus. Also, there is the need for development of 
more sensitive markers for predicting disease progression in the clinics.  
Plasma HIV RNA load and CD4+ T-cell counts are important determinants of disease 
progression clinically. However in recent times, HIV-1 IC DNA has been shown to be an 
important independent predictor of disease progression (Kostrikis et al., 2002a). The use of HIV-
1 IC DNA could provide an alternative for viral RNA measurements and also can be assessed in 
the case of undetectable RNA levels.  
Although most of the global burden of HIV is in sub-Saharan Africa, studies on 
TDRMs and its implications on HIV-1 IC DNA have only been carried out in developed 
countries. In this study, we assessed the effect of TDRMs on HIV-1 IC DNA levels and the 
utility of HIV-1 IC DNA as a predictor of disease progression in a group HIV infected patients 
from Nouna Burkina Faso in sub-Saharan Africa. 
1.15.2 General objectives 
Using samples from HIV-1 infected patients from Nouna Burkina-Faso, West Africa, 
this study assessed the following: 
1. The predominant DRMs in the protease (PR) and reverse transcriptase 
(RT) region of HIV-1 pol from RNA and DNA templates of treated 
and drug naïve HIV-1 infected patients starting ART.  
2. How TDRMs affect HIV-1 IC DNA levels in HIV-1 infected drug 
naïve patients.  
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3. The correlation between baseline HIV-1 IC DNA levels of infected 
patients and established primary markers of disease progression such 
as plasma RNA viral load, and CD4+ T-cell count as well as other 
indicators associated with disease progression. 
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2 Materials and Methods 
2.1  Materials  
2.1.1 Media and buffers 
Table 1: List of prepared media and buffers used in this study 
 
 
 
 
 
 
 
 
 
 
 
PCRs and Extractions
Tris-EDTA buffer
TaqMan qPCR buffer A
100% glycerol, 2.5% bromphenol blue and 2.5% 
xylene cyanol
with HCl
500 mM KCI, 100 mM Tris-HCI, 0.1 mM EDTA, 
600 nM Passive Reference 1 (Rox dye), pH 8.3 at 
room temperature (solution was autoclaved) 
LB-ampicillin or kanamycin aga
50x TAE buffer 
10x DNA loading buffer 
13 % agar in LB medium
100 µg/ml ampicillin or kanamycin
2 M Tris, 1 M NaAc, 0.1 M EDTA
LB agar 
LB medium 
Bacterial culture Constinuents
1 % peptone, 0.5 % yeast extract, 171 mM NaCl
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2.1.2 Commercial reagents kits and instruments 
Table 2: List of commercial kits and consumables used in this study 
Commercial kit or consumable Supplying company   
Viral DNA extraction kit  
QIAmp viral DNA mini kit, Qiagen, Hilden, 
Germany 
Viral RNA extraction kit  
QIAmp viral RNA mini kit, Qiagen, Hilden, 
Germany 
SS III One Step HIFI RT-PCR amplification 
kit  
Life Technologies, Darmstadt, Germany 
Platinum PCR SuperMix Life Technologies, Darmstadt, Germany 
Taq DNA Polymerase with Standard Taq 
Buffer PCR Kit 
Life Technologies, Darmstadt, Germany 
Phusion high fidelity DNA polymerase New England BioLabs, Frankfurt, Germany 
Verbatim high fidelity DNA polymerase 
enzyme  
Life Technologies, Darmstadt, Germany 
Qiaquick PCR purification kit 
 Qiagen, Hilden, Germany 
Nucleospin Extract II kit, Macherey-Nagel, Düren, 
Germany 
Nucleospin Gel and PCR Clean-up kit  Macherey-Nagel, Düren, Germany 
NucleoBond MaxiPrep Kit  Macherey-Nagel, Düren, Germany 
TaqMan PCR Core Reagent with AmpliTaq 
Gold DNA polymerase  
Life Technologies, Darmstadt, Germany 
    
TOPO® TA Cloning® Kit  Life Technologies, Darmstadt, Germany 
DNA LoBind eppendorf tubes 1.5 ml Eppendorf AG, Hambug, Germany 
    
Agencourt AMPure XP PCR purification 
system  
Beckman Coulter, Inc., Beverly, Massachusetts, 
USA 
Quant-iT Picogreen dsDNA reagent and kits  Invitrogen, Life Technologies 
Nextera XT DNA Library Preparation Kit for 
the MiSeq® System 
Illumina, Inc., San Diego, CA,  USA 
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2.1.3 Reagents and chemicals 
Table 3: List of reagents and chemicals used in this study 
Reagents and Chemicals Supplying company 
Agarose Carl Roth, Karlsruhe, Germany  
Ethanol (99%) Sigma-Aldrich, Steinheim, Germany 
Pure glycerol (100%) AppliChem GmbH, Darmstadt, Germany 
Deoxyribonucleoside triphosphate mix 
(dNTP mix)  
Fermentas, Thermo Scientific, Schwerte, 
Germany  
Ampicillin Carl Roth, Karlsruhe, Germany  
Midori Green Advanced DNA stain  
NIPPON Genetics Europe GmbH, Düren, 
Germany  
Kanamycin  Carl Roth, Karlsruhe, Germany 
RNASE Away Life Technologies, Darmstadt, Germany 
DNAZAP Life Technologies, Darmstadt, Germany 
GeneRuler 1kb Plus DNA ladder mix  
Fermentas, Thermo Scientific, Schwerte, 
Germany  
100 bp DNA Ladder New England BioLabs, Frankfurt, Germany 
Nuclease free water  Life Technologies, Darmstadt, Germany 
MiSeq Reagent Kits v2 Illumina, Inc., San Diego, CA, USA 
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2.1.4 Primers and molecular-beacons 
Table 4: List of oligonucleotide primers and molecular-beacons used in this study 
 
Name                 
Target 
region  
Position 
length of 
amplified 
region     
Reference
PCR primers
1832 ( F1 )            pol              1832–1856    1751 Kousiappa et al., 2009
3583 (R1)             pol                3555–3583                                               Kousiappa et al., 2009
2078 (F2)    pol                        2078–2109  1461 Kousiappa et al., 2009
3539 (R2)              pol                3510-3539                                           Kousiappa et al., 2009
BFp1 (F1)             pol                 2324–2347    491 Tebit D.M et al., 2006
BFp4b (R1)          pol               2790–2815      Tebit D.M et al., 2006
BFp3 (F2)            pol               2388–2407   406 Tebit D.M et al., 2006
BFp4c (R2)            pol              2761–2794 Tebit D.M et al., 2006
RT1 (F)                pol                2480-2509   1054 Kanokporn 2009
RT-Rev-Stu1 (R) pol               
                                                  3479-3534                                               1423 Kanokporn 2009
Pol1 (F1)                pol               2111-2132 Kanokporn 2009
Prot-for-EcoRI (F)  pol                2223-2259 1269 Kanokporn 2009
RT4- Rev            pol                3453-3483 Kanokporn 2009
RT3- For              pol                2514-2547   964 Kanokporn 2009
NewF1 pol               2132-2152 1429 This work
NewR1 pol               3537-3561 This work
NewF2 pol               2146-2165 1304 This work
NewR2 pol               3428-3450 This work
Sequence  5 ́-3 ́                                                                                    
CAGCATGYCAGGGAGTRGGRGGACC                                
GGYTCTTGRTAAATTTGATATGTCCATTG                           
TCCCAGAAGTCTTGAGTTCTCTTATT                            
ATGATAGGGGGAATTGGAGG                                               
TTATTGAGTTCTCTGAAATCTACTAATTTTCTCC        
AGGCTAATTTTTTAGGGAARATYTGGCCTTCC                    
CTGTATTTCTGCTAYTAAGTCTTTTGATGG                          
AGACACAGGAGCAGATGATACAGT                                    
TCAAGGGAAGGCCAGGGAATTT                                          
GAGGGACAAGGAATTCTACCCTCCTTTAGCTTCC
CTCAAA
CTTTTAGAATTTCCCTGTTCTCTGCCAATTC                        
AGTAGGACCTACACCTGTCAACATAATTGG                      
TTTCTGCTACTAGGCCTTTTGCTGGGTCATAA-                                                                                                         
TAGACTCCATGTACAGGTTCTTTT                                        
CCGGAACCATCAGCCCCACC
ACTCTGCTTCCTCAGTCAGTGGT
AATATGTTGACTCAGATTGGTTGTACTTTAAAT             
TCCCCCAGAGCAGACCGGAAC
TCCATTGGTCTTGCCCTTGTTTCTG
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Table 4 continued. 
 
F1 and R1 represent forward and reverse primers respectively of the first round PCR reaction and F2 and R2 represent forward and reverse primers respectively 
of the second round PCR reaction. 
  
Name                 
Target 
region  
Position 
2136 (F)            pol               2136–2162                                                
2216 (F)               pol                 2216–2232                                               
2454 (F)              pol                 2454–2475                                                
2610 (R)             pol                 2593–2610                                                
2650 (R)               pol                2621–2650                                                
2734 (R)       pol                 2703–2734                                            
3003 (F)               pol                GGATGGAAAGGATCACC                                                 3003–3019                                               
3019 (R)               pol                GGTGATCCTTTCCATCC                                                             3003–3019                                              
3462 (R)            pol                 CTGCCARTTCTARYTCTGCTTC                                                                             3441–3462         
CYTTTGGGCCATCCATTC                                                         
AATGCTTTTATTTTYTCTTCTGTCAATGGC                             Kousiappa et al. 2009
Kousiappa et al. 2009
Kousiappa et al. 2009
Kousiappa et al. 2009
Kousiappa et al. 2009
Reference
Kousiappa et al. 2009
Kousiappa et al. 2009
Sequence  5 ́-3 ́                                                                                    
Sequencing primers
 YCAGARCAGACCAGAGCCAACAGCCCC                             
AGGAGCMGAWAGACARG                                                     
GGAMAWAARGCTATAGGTACAG                                       Kousiappa et al. 2009
Kousiappa et al. 2009
GCAAATAYTGGAGTATTRTATGGATTTTCAG                      
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Table 4 continued. 
 
The reporters; FAM and TET stand for fluorescein and Tetrachloro-69-carbofluorescein respectively. The quencher Dabcyl stands for 4-(49-dimethylamino 
phenylazo) benzoic acid. Underlined sequences within the molecular-beacons represent the target recognition sequences within HIV and CCR5. The underlined 
sequences at the 5 ́ and 3 ends represent complementary sequences forming the hairpin. ́ 
  
Name                 
Target 
region  
Position 
MB684  LTR 684–705  
623 For LTR 623–646 
788 Rev                 LTR 765–788  
LK155   CCR5 623–641 
LK46  For         CCR5 478–501 
LK47.new Rev       CCR5 690–713
M13 (F) 
M13 (R)
T3
T7
FAM-
CCGCTGCAAGCCGAGTCCTGCGTCGAGACAGCG
G-Dabcyl 
AAATCTCTAGCAGTGGCGCCCGAA                                        
TCTCTCCTTCTAGCCTCCGCTAGT                                            
TET-GCGCCTATGACAAGCAGCGGCAGGAGGCGC-
Dabcyl                 
GCTGTGTTTGCGTCTCTCCCAGGA                                             
GTAAAACGACGGCCAG
CAGGAAACAGCTATGAC
ATTAACCCTCACTAAAGGGA
TAATACGACTCACTATAGGG
CCR5 quantification molecular-beacons and primers
TOPO TA sequencing primers
Demetriou et al. 2010
Demetriou et al. 2010
Kostrikis et al., unpublished data
Kostrikis et al., unpublished data 
Kostrikis et al., unpublished data
http://tools.lifetechnologies.com/con
tent/sfs/manuals/topotaseq_man.pdf
Reference
Demetriou et al. 2010
HIV-1 quantification molecular-beacons and primers
Sequence  5 ́-3 ́                                                                                    
CACAGCCCTGTGCCTCTTCTTCTCA                                          
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2.1.5 Machines and instruments 
Table 5: List of machines and instruments used in this study 
Machines and Instrumets Supplying company   
Incubators Infors, Einsbach GmbH, Germany 
NanoPhotometer P300  Implen, München, Germany  
Laminar flow Labotect GmbH, Göttingen, Germany 
Gel Running Chambers Minigel-Twin Biometra, Göttingen, Germany 
Tabletop ultracentrifuge TL-100  Beckman Coulter, Fullerton, CA, USA 
Biofuge fresco microcentrifuge  Heraeus, Kleinostheim, Germany 
Centrifuges J2HC or J2HS with rotors JA-10, 
JA-17 and JA-20 
Eppendorf Deutschland, Hamburg, Germany  
PTC-200 PCR Thermo cycler  GMI, Ramsey, MN, USA 
    
Spectrophotometer DU 640 Beckman Coulter, Fullerton, CA, USA 
Computer Monitor and CPU Manufactures   
ABI 7500 real-time PCR system Thermo Scientific, Darmstadt, Germany 
Tabletop ultracentrifuge TL-100 Beckman Coulter, Fullerton, CA, USA 
Abbott RealTime HIV-1 m2000rt viral load 
assay equipment with automated nucleic acid 
extraction station 
Abbott Molecular Inc., Des Plaines, IL, USA   
FLUOstar OPTIMA SP002 BMG  BMG LABTECH, Ortenberg, Germany 
Illumina MiSeq™ Illumina, Inc., San Diego, CA, USA 
 
2.2 Study population 
The study population consisted of 86 HIV-1 infected drug naïve patients originating 
from Nouna Burkina Faso who were mostly followed up either for a period of 48 weeks or 72 
weeks. Eligible patients were identified when HIV infected patients came to the Nouna district 
hospital in Nouna Burkina Faso, for HIV counseling and care. This study was made possible 
through an established collaboration between the Virology Unit of the Department of Infectious 
Diseases of the University Hospital, University of Heidelberg and the Centre de Recherche en 
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Sante de Nouna (CRSN) in Burkina Faso. Blood samples as well as all other clinical and socio-
demographic data were collected within a period of six years. The blood samples were separated 
into plasma and buffy coats. The patients were then followed up and blood samples were 
consecutively collected from January 2009 to August 2010 in Nouna. The longitudinal patient 
samples were collected at 2, 4, 12, 24, 36 and 48 weeks after patients had been put on HAART. 
In a few instances patients were followed up at 68 and 72 weeks post HAART and had their 
blood samples collected. Patients followed over time were on a first line HAART regimen of two 
NRTI (3TC, d4T or AZT, d4T) and 1NNRTI (NVP or EFV).  
2.3 Study design and sample size 
This consisted of two parts, a cross-sectional part, consisting of 86 HIV-1 infected 
drug naïve patients attending the Nouna district hospital in Nouna Burkina Faso whose paired 
templates of DNA and RNA were genotyped and sequenced for the presence of DRMs in the 
protease-reverse transcriptase ((PR/RT) region. This was followed by resolving differences in 
resistance mutations and nucleotides changes within patient cDNA and DNA sequences of the 
same patient with deep sequencing (details are summarized in figure 9). The HIV-1 IC DNA 
levels of all the drug naïve patients were also quantified using a molecular-beacon-real-time 
qPCR assay. The second part was a longitudinal study consisting of 8 patients whose plasma 
samples were genotyped and again sequenced for the presence of DRMs in the PR/RT region of 
HIV-1 over time. The follow-up for DRMs over time was done because these patients did not 
attain virologic suppression at 24 weeks of therapy (see section 2.3.1 for details on sample 
groupings).  
 The CD4+ T-cell counts and plasma viral load of patients prior to initiation of HAART 
and at all-time points during the follow-up period were determined in Burkina Faso, West Africa 
and undetermined plasma viral loads were determined in Heidelberg Germany. 
         Materials and Methods  
35 
 
  
Figure 9: Flow chart on genotyping and sequencing of HIV-1 infected samples from Nouna Burkina Faso. 
2.3.1 Sample groupings and characteristics 
Various groups of HIV-1 infected samples were genotyped for the presence of DRMs. 
The first group of samples was paired samples of viral RNA and DNA extracted from plasma 
and buffy coats of 86 drug naïve patient samples and used as starting templates for drug 
resistance genotyping and HIV subtyping. HIV-1 genotyping and sequencing were used to 
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determine the presence of transmitted drug resistance mutations (TDRMs) and to determine 
similarities existing between RNA and DNA template pairs of the same patient. Three patient 
samples were eliminated from the analysis because the sequences were too heterogeneous and 
could not be read. The remaining 83 pairs were used in the analysis. The workflow for the entire 
genotyping and sequencing process is shown in figure 9. 
The second group consisted of 8 selected patient plasma samples followed 
longitudinally over time from the drug naïve stage. These patients had high plasma viral loads (≥ 
1000 copies per ml of plasma) at 24 and/or 48 weeks of antiretroviral therapy (ART). Patients 
with plasma viral loads depicting viral blips due to for example non-adherence to therapy were 
excluded from this group. The additional criteria for the selection of these 8 samples was that the 
patients had plasma samples available for at least two of the following time points 24, 48, 64 and 
72 weeks post ART and a plasma viral load of ≥1000 copies per ml of plasma. The later criterion 
was to enable amplification of a PCR product that could be sequenced. The genotyping and 
sequencing process was the same as indicated in figure 9 except that samples were longitudinal 
samples collected over time. Drug resistance patterns were assessed.  
The third group was made up of retrospective genotyping and sequencing of 5 patient 
plasma samples over all other remaining time points (4, 12 and 36 weeks post ART). These 
patients were selected from the second group above. The criterion for the selection was based on 
the evidence that the patient had major DRMs in RT. This mutation(s) should have either 
persisted at all time points or an additional mutation(s) developing over the course of infection 
from one time point to the other or a mixture of both of the aforementioned scenarios occurring 
simultaneously.  
The fourth and final group comprised of selected drug naïve paired patient samples 
whose RNA and DNA were extracted from plasma and buffy coats respectively and used as 
starting templates in deep sequencing. These deep sequenced samples had two main 
characteristics. Firstly mutations found in the PR/RT region of paired RNA and DNA templates 
from the same patient using traditional Sanger sequencing were differing and secondly aligned 
nucleotide sequence pairs derived from Sanger sequenced paired RNA and DNA as stating 
templates had more than 10 changes. 
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2.4 Ethical clearance 
Ethical clearance was obtained from the Centre de Recherche en Santé de Nouna 
(CRSN), Nouna Burkina Faso and the Virology Unit of the Department of Infectious Diseases of 
the University Hospital, Heidelberg (refer to appendix I and II for samples of the ethical 
clearances). All ethical considerations were strictly adhered to. 
2.5 Informed consent 
Patients who agreed to be part of the study filled informed consent forms before being 
recruited into the study.  
2.6 Questionnaires and clinical data on patients 
Each patient had their clinical and socio-demographic data recorded via laboratory 
diagnosis and interactive sessions respectively. Clinical data obtained included the patient’s HIV 
status, co-infection with Hepatitis B and C (HBV and HCV), presence or absence of secondary 
bacterial or parasitic infections such as candidiasis, tuberculosis, salmonellosis and 
toxoplasmosis, Hb levels, CDC clinical staging of the HIV-1 infection, the type of anti-retoviral 
treatment, body mass index as indicated by the patient’s weight in kilograms and their height 
squared (Beaudrot et al., 2015). The socio-demographic data consisted of age, gender, marital 
status, level of education, number of children, knowledge of the HIV status and possible 
exposure of sexual partner to HAART. 
2.7 Inclusion and exclusion criteria 
All HIV-1 infected drug naïve patients attending the Nouna district hospital in Nouna 
Burkina Faso and were not on any ARTs were included in the study. All patients registered at the 
Nouna district hospital in Nouna Burkina who were already on ARTs were excluded from the 
study. 
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2.8 Viral load and CD4+ T-cell count determination 
Patient plasma viral load determination was carried out at the Virology Unit of the 
Center Hospital Universitaire Yalgado Ouedraogo (CHUYO) in Ouagadougou with the Abbott 
RealTime HIV-1 assay with the automated m2000 system (Abbott Molecular Inc., Des Plaines, 
IL, USA) and for those samples where viral load was not determined before being shipped to 
Heidelberg, Germany, viral load was determined by the Abbott RealTime HIV-1 assay with the 
automated m2000 system (Abbott Molecular Inc., Des Plaines, IL, USA) at Virology Unit of the 
Department of Infectious Diseases of the University Hospital, Heidelberg. The CD4+ T-cell 
counts of infected patients were determined from whole blood within 6 hours of sample 
collection with a fluorescence activated cell sorter (FACS) count flow cytometer (Becton 
Dickinson and Company, San Jose, USA).  
2.9 Genomic DNA extraction from buffy coats 
Genomic DNA of drug naïve and selected longitudinal samples were extracted from 
140 µl of each patient buffy coat using the QIAmp DNA Blood Mini kit (Qiagen, Hilden, 
Germany) and eluted twice with 50ul elution buffer following the manufacturer’s instructions. 
DNA quality and quantity was checked for all samples by UV spectrophotometry using 
NanoPhotometer P300 (Implen, München, Germany). DNA concentrations of patient samples 
ranged from 40 ng/µl to 195 ng/µl and were enough for PCR reactions. 
2.10 Viral RNA extraction from plasma 
Viral RNA was extracted from 140ul or 500ul (depending on the plasma viral load) of 
each patient plasma sample using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) 
and eluted twice with 40 µl elution buffer following the manufacturer’s instructions. The quality 
and quantity of viral RNA was checked for all samples with UV spectrophotometry using 
NanoPhotometer P300 (Implen, München, Germany). RNA concentrations of patient samples 
ranged from 33ng/ul to 108ng/ul and were also sufficient for PCR reactions. 
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2.11 Reverse transcriptase polymerase chain reaction and nested 
PCR of viral RNA and genomic DNA samples 
HIV-1 sequences encoding approximately 1461bp of gag (p6) and the pol gene 
consisting of the entire PR region of 99 amino acids (aa) and 2/3 of the RT region (between 312 
to 335 aa) as indicated in figure 10 were amplified from each patient sample by both nested 
polymerase chain reaction (PCR) and RT-PCR, using extracted genomic DNA and viral RNA 
respectively. Predominant genotypic DRMs to antiretroviral drugs (Sage et al. 2010) were 
determined by sequencing of purified PCR amplicons within the pol gene of HIV-1 group M 
strains. The PCRs were performed with primers spanning the p6 of HIV-1 gag, PR and p51 of 
the RT region of the HIV-1 pol gene thus from nucleotide position 2078 to 3539 (see table 4 for 
PCR and sequencing primers and their respective HBX2 positions as well as alternative primers 
used for sequencing and figure 10, for a schematic diagram of the region amplified). The outer 
primers were1832 (F1) and 3583 (R1) corresponding to the HBX2 positions 1832-3583 within 
the HV-1 pol region. The inner primers were 2078 (F2) and 3539 (R2) also corresponding to the 
HBX2 positions 2078- 3539 within the HV-1 pol region (Kousiappa et al., 2009). 
Viral RNA samples were reverse transcribed with the SuperScript III One-Step RT-
PCR System (Life Technologies, Darmstadt, Germany) by following the manufacturer’s 
protocol. The first round RT-PCR amplification mix for HIV-1 gag-pol region was prepared in 
0.5ml PCR Eppendorf tubes (Eppendorf, North America) as follows; 15 µl of 33- 108 ng/µl l of 
viral RNA template, 25 µl of 2x RT-PCR reaction mix, 2 µl of 10 µM/µl outer primer (F1), 2 µl 
of 10 µM/µl outer primer (R1), 1 µl of 5 units SuperScript III RT/ Platinum Taq high fidelity 
enzyme mix and nuclease free water (Life technologies, Darmstadt, Germany) added to make a 
total unit volume of 50 µl. The thermocycling conditions was as follows; one cycle at 52°C for 1 
h, 1 cycle at 94°C for 2 min, 40 cycles at 94°C for 15 s, 52°C for 30 s, 68°C for 2 min, one cycle 
at 68°C for 5 min and 4 °C at infinity (Kousiappa et al., 2009).  
The first round PCR reaction mix for the genomic DNA included approximately 60–
100 ng of patient DNA with 2 µl of 10 µM/µl each forward and reverse outer primers F1 and R1 
(table 4) and 43µl of 1.1X Platinum PCR SuperMix (Life Technologies, Darmstadt, Germany) in 
a 50 µl unit volume. The thermocycling conditions were as follows, one cycle at 94°C for 2 min, 
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45 cycles at 94°C for 20 s, 52°C for 30 s, 72°C for 2 min, and one cycle at 72°C for 10 min 
(Kousiappa et al., 2009). 
The second round PCR reactions of the cDNA and the genomic DNA included 60–100 
ng or 3 µl of amplified patient DNA with 2 µl of 10 µM/µl each forward and reverse inner 
primers F2 and R2 (table 4) and 43µl of 1.1X Platinum PCR SuperMix (Life Technologies, 
Darmstadt, Germany) in a 50 µl unit volume. The thermocycling conditions were as follows, one 
cycle at 94°C for 2 min, 45 cycles at 94°C for 20 s, 52°C for 30 s, 72°C for 2 min, and one cycle 
at 72°C for 10 min (Kousiappa et al., 2009). The Eppendorf Master Cycler (Eppendorf, 
Hamburg, Germany) or the PTC-200 PCR Thermo cycler (GMI, Ramsey, MN, USA) was used 
for all the PCR amplifications. 
 
 
Figure 10: A schematic diagram highlighting the PR/RT of HIV-1 pol from the M group. 
This drawing shows the region genotyped among HIV-1 infected patients and assessed for the presence of 
HIV-1 genotypic drug resistance.(A) Shows the entire HIV genome architecture (as can be seen from the 
GenBank accession number K03455) and the corresponding HXB2 regions shown on the rulers above and 
beneath represent demarcations for each genetic region of the viral genome. The rulers above and beneath 
the viral genome also have segments of 100 base pairs from which the length of each of the regions in the viral 
genome can be estimated. The gag (p6) and pol (PR and p51 RT) regions amplified in all patient derived RNA 
and DNA samples are shaded in grey. (B) This shows the region genotyped in the nested PCR and RT-PCR 
reactions for all patients. The first round PCR primers corresponded to the HXB2 positions1832 and 3583 
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and these were also used as primer names for both the forward (FI: 1832) and reverse (R1: 3583) primers in 
the PCR mix. The second round PCR primers also corresponded to the HXB2 positions 2078 and 3539 and 
these were also the primer names for both the forward (F2: 2078) and reverse (R2: 3539) primers in the PCR 
mix (Demetriou et al., 2010). 
2.11.1 PCR optimizations 
 Ribonucleic acid and DNA PCR reactions for the HIV-1 pol region were set-up with 
in-house protocols as shown in appendix III at 50°C annealing temperatures for both RNA and 
DNA reactions. PCR conditions for the HIV-1 pol region were optimized for cDNA synthesis 
and first round PCR initially with SuperScript™ III One-Step RT-PCR System with Platinum® 
taq polymerase High Fidelity enzyme (Life Technologies, Invitrogen) and components were 
pipetted as indicated in appendix III. Template RNA concentrations were increased by 5 µl for 
each trial as shown in appendix III. Primer sequences were as indicated in the table 4. A nested 
PCR reaction with the verbatim high fidelity DNA polymerase enzyme (Thermo Scientific, 
Darmstadt, Germany) was set-up as indicated in appendix III. The PCR primer sequences for the 
second round reaction are given in table 4 above. The PCR consisted of 40 cycles with 1°C 
increments in annealing temperature of up to 60°C. Upon gel electrophoresis, no PCR band was 
realized although viral load of samples used was ≥ 500,000 copies/ml of plasma. Nested PCR for 
DNA samples were carried out with the same primers pairs and first and second round PCRs 
were done as shown in appendix III, but there were also no PCR bands found on agarose gels. 
Note that only one condition was changed at a time for each round of optimization.  
Upon recommendations from a more experienced lab member who also worked on a 
similar project, primers were changed to the following combinations: cDNA and first round 
synthesis; 2.5 µl of 10 µM/µl each of Pol1 forward and RT-rev-stu1 reverse primers and the 
second round nested PCR reaction contained the same amounts of primer concentrations for 
Prot-for-EcoR1 forward primer and RT4 reverse primer as given in table 4. Nested PCR 
conditions were the same as shown in appendix III. No bands were seen on agarose gel 
photographs. PCR reagents were changed to the phusion high fidelity DNA polymerase (New 
England BioLabs, Frankfurt, Germany) and the same PCR conditions were repeated with the 
same primers and primer concentrations as mentioned above with 10 µl of 5x Phusion high 
fidelity or GC rich buffer but again no bands were seen after taking gel photographs. 
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Polymerase chain reactions were again tried with various primer combinations as 
shown in appendix III using the phusion high fidelity DNA polymerase (New England BioLabs, 
Frankfurt, Germany), the same PCR cycling conditions as described in the paragraph above. This 
procedure also yielded no results. 
Three plasma samples were selected and tried on the ViroSeq HIV-1 Genotyping Kit 
(Abbott GmbH & Company, Wiesbaden, Germany) at the Diagnostic section of the University 
hospital, Heidelberg Germany following the manufacturer’s protocol and amplification was 
sucessful. The experiment therefore proved that patient RNA samples were still viable for PCR 
reactions. In order to preserve patient samples for the actual experiments, 10 plasma samples 
from HIV infected patients from the diagnostic unit of the Heidelberg University Hospital were 
obtained and RNA extractions were done with the   ViroSeq HIV-1 RNA extraction Kit (Abbott 
GmbH & Company, Wiesbaden, Germany) and the QIAamp Viral RNA Mini Kit (Qiagen, 
Hilden, Germany). PCR was again repeated with the  ViroSeq HIV-1 Genotyping Kit which had 
its own primer sets (Abbott GmbH & Company, Wiesbaden, Germany) and the SuperScript™ III 
One-Step RT-PCR System with Platinum® Taq polymerase High Fidelity enzyme (Life 
Technologies, Invitrogen) and the  Phusion High Fidelity DNA Polymerase PCR kit (New 
England BioLabs, Frankfurt, Germany). The ViroSeq protocol worked but the SuperScript RT-
PCR System with the Phusion PCR protocols did not work.  The annealing temperature was at 
55°C for 45 minutes during the cDNA synthesis and at 55°C for 30s for both first and second 
round DNA synthesis. The ViroSeq primers could not be used with my PCR protocol because the 
primer sequences and concentrations were unknown. 
 As a proof of concept, further proceeded by using previously designed primers sets 
that specifically amplify a 400bp region spanning the 5’ end of HIV-1 RT to amplify the Burkina 
Faso samples (Tebit et al., 2006). These primers were tried again on 5 pairs of RNA samples 
extracted with the ViroSeq HIV-1 RNA extraction Kit (Abbott GmbH & Company, Wiesbaden, 
Germany) and the QIAamp Viral RNA Mini Kit. PCRs were performed with the combination of 
the SuperScript RT-PCR System with the Phusion PCR protocols using the same conditions as 
described in the previous paragraph and all 5 pairs of samples were amplified. This suggested 
that the PCR primers used previously were not working and had to be changed. The primers were 
BFp1 for and BFp4b rev were first round primers and BFp3 for and BFp4c rev were second 
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round primers (table 4). Although these set of primers worked well, they could not be used to 
amplify the expected region for the purpose of this study. 
New sets of HIV-1 pol primers were designed with the help of Stefan Seitz from the 
Molecular Virology Department of the UniversitätKlinikum, at the Otto Meyerhof Centre in the 
Heidelberg University Hospital. We designed HIV-1 sequences encoding approximately 1300bp 
of gag (p6), PR and about 255 aa in RT. These primers were designed based on consensus 
sequences of an HIV-1 CRF02_AG subtype isolated in 2006 with the GenBank accession 
number AB231895. These primer pairs were namely New F1 and New R1 used in the first round 
PCR reaction and New F2 and New R2 used in the second round PCR reaction. These primers 
were used together with the SuperScript RT-PCR System and Phusion PCR protocols, which 
gave non-specific bands including the band of interest on agarose gel. Gradual 1°C increments of 
annealing temperatures and 30s increments on annealing times did not resolve the problem. 
Activation of PCR reactions at 95°C for 5 min to denature pre-annealed primers, before addition 
of the polymerase also did not resolve the problem. 
Since the protocol described above did not work efficiently, new PCR protocols were 
adapted from Kousiappa et al 2009. The protocol did work along with its published primers 
(table 4) and with minor modifications as described in section 2.11. The amplified region was 
about 1460bp of the HIV-1 pol region.  
2.12 Agarose gel electrophoresis and DNA quantification   
Ten microliters of amplified products were loaded onto ethidium bromide or 0.05% 
midori green (NIPPON Genetics Europe GmbH, Düren, Germany) stained 1.0 % agarose gels in 
1 × TAE buffer (Brody et al, 2004; Sambrook et al, 2001). A 1kb plus molecular weight marker 
(Fermentas, Thermo Scientific, Schwerte, Germany) was always loaded on gels along with PCR 
products, to confirm expected molecular weight of the amplification products which were run at 
90 volts for 45minutes. Gel products were then visualized under a spectrophotometer or a 
transilluminator (Beckman Coulter, Fullerton, CA, USA). If a single distinct band of the 
expected molecular weight was seen in lanes containing patient amplicons, then PCR 
purifications were carried out on the remaining 40 µl of amplified PCR products. On the other 
hand, for instances where non-specific bands were seen along with the expected bands, the 
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remaining 40 µl of amplified PCR products were run again on 1% agarose gels and the expected 
bands were excised from the gel and used in a gel purification assay. DNA concentrations of 
purified products were afterwards quantified by UV absorbance spectrophotometry using the 
NanoPhotometer® P 300 (Implen, München, Germany). 
2.13 Purification and sequencing of amplified PCR products 
Amplified products generated from the second round PCRs were purified using the 
NucleoSpin Extract II PCR clean-up and gel extraction kit (Macherey- Nagel GmbH and Co.KG, 
Dueren, Germany) following the manufacturers protocol. Minor alterations were made to the 
protocol to increase DNA yield. These included centrifuging PCR amplicons for 1 minute at 
11,000rpm and eluting DNA only after heating DNA filled columns having elution buffer 
between 5-8 minutes at 700C. Elution was done twice with 20 µl elution buffer to concentrate 
DNA. DNA concentrations were quantified by UV absorbance spectrophotometry using the 
NanoPhotometer® P 300 (Implen, München, Germany). 
2.14 Sanger sequencing of PCR amplified DNA and cDNA samples 
All purified PCR amplicons of DNA and cDNA were sequenced commercially from 
GATC Biotech (Konstanz, Germany) with the ABI 3130 genetic analyzer (Applied Biosystems, 
Foster City, CA). Briefly, purified second round PCR products containing 1461bps of HIV-1 PR 
and RT were bi-directionally sequenced using the sequencing HIV-1 pol primers annealing at 
HBX2 positions 2454 and 3019 respectively. In PCR amplicons where sequencing could not be 
achieved with the aforementioned primers, pairs of the following alternate gag-pol primers were 
used for sequencing 2136, 2216, 2610, 2650, 2734, 3003, 3462, and 3539 (table 4 and appendix 
VIII). The primer names also represent their annealing positions on the HIV-1 HBX2 template 
DNA sequencing reactions were analyzed with the BigDye Terminator Cycle Sequencing kit 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s recommendations. 
Samples exhibiting partial or extensive viral diversity by direct sequencing were re-sequenced 
twice and if they still remained heterogeneous, the other sequence pair which in all cases was 
successfully sequenced was checked to make sure that they did not contain DRMs or unique 
HIV-1 subtypes before being eliminated from the sequencing analysis. 
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2.15 Determination of drug resistance mutations among HIV 
infected samples over time 
Preceding sequence editing, patient derived HIV-1 PR/RT paired sequences of DNA 
and cDNA, encoding approximately 1461bp of gag (p6) and the pol gene consisting of the entire 
PR and 2/3 of the RT region obtained, were aligned to HIV reference sequences from the HIV 
sequence database (http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) using Bioedit 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html). 
In order to identify mutations known to confer resistance to PR/RT inhibitors, the 
PR/RT sequence of each patient sample was analyzed with the Stanford HIV drug-resistance 
algorithm (Rhee et al., 2003). The Stanford HIV drug-resistance algorithm compares the query 
sequence to consensus subtype B reference sequences of HIV that have shown resistance to 
ARTs. The result differences determined between the query sequence and the consensus subtype 
B reference sequences are then used as an input for the assessment DRMs from the database. 
Genotypic drug resistance was defined as the presence of at least one DRM affecting the drug  of 
any class of ARD as given by the Stanford HIV Drug Resistance database (Shafer, 2006) and the 
International AIDS Society (Avila-Rios et al.)-USA database(Johnson.VA et al., 2013). 
Analyses of the possible impact of DRMs on therapeutic response among drug naive 
patients and selected patients followed over time were assessed using the drug resistance penalty 
score within the Stanford HIV drug-resistance database. This score assigns a mutation penalty to 
DRMs conferring resistance to any particular class of ARDs. The penalty scores for mutations 
within PR or RT conferring resistance to a particular PR or RT inhibitor were then summed up 
for this class of ARV and placed under one of five categories of drug resistance estimates 
defined by the Stanford HIV drug-resistance database. The estimates and their interpretations are 
as follows; 
a. A range of 0 to 9 meant the virus was susceptible to the anti-HIV drug and presents no 
evidence of mutation. 
b. A 10 to 14 range denoted potential low-level resistance to the ARV suggesting that the 
virus might have been exposed to the ARV at one point in time. 
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c. An estimate of 15 to 29 was indicative of low-level resistance depicting a reduced in-
vitro drug susceptibility of these virus isolates. Patients infected with viruses in this 
category, are said to portray suboptimal virologic response to ARVs.  
d. A 30 to 59 range showed an intermediate drug resistance level which was greater than 
low-level resistance but lower than high-level resistance 
e. A level >60 depicted the high-level resistance and patients infected with viruses in this 
group, portray virologic failure to ARVs. 
2.15.1 Analysis of HIV-1 drug resistance mutations over time 
Eight patient plasma samples with high plasma viral load values at 24 weeks into 
therapy were selected and RNA was extracted from these samples. A cDNA synthesis was then 
performed and samples were then purified and commercially sequenced by Sanger sequencing. 
Resultant sequences generated from these patient samples were then aligned with wildtype 
reference sequences and edited using sequence chromatographs. DRMs were then determined by 
feeding edited sequences into the Stanford HIV Drug Resistance Database 
(http://hivdb.stanford.edu). In a few instances other expert list like the IAS-USA DRM panel 
(Johnson.VA et al., 2013) was consulted. 
 DRMs were determined for eight patients followed over the time points 24, 48, 64 and 
72 weeks post ART. Since the plasma viral load is important in determining the probability with 
which a given HIV infected plasma sample could be amplified, the plasma viral load of each of 
the eight patient samples available at each time point was ≥1000 copies per ml of plasma (also 
the level generally considered as optimum for amplification of viral cDNA). 
2.16 HIV-1 subtyping by phylogenetic tree analysis 
Patient HIV-1 subtypes were determined from cDNA and DNA templates from the 
Stanford HIV Drug Resistance Database (Shafer, 2006) and then by phylogenetic tree analysis. 
The Molecular Evolution Genetic Analysis (MEGA) software version 6.0 was used to align 
DNA and cDNA sequences from drug naïve patients’ samples, calculate distances, and construct 
phylogenetic trees (Tamura et al., 2007). All patient DNA and cDNA sequences encoding the 
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PR/RT region of HIV-1 pol viral genome were aligned against corresponding reference 
sequences of genetically characterized HIV-1 strains obtained from the Los Alamos database 
(Leitner.T et al., 2005) using the default setting on the MEGA software version 6.0 (Tamura et 
al., 2013). The Kimura two-parameter distance estimation approach with a transition/ 
transversion ratio of 2.0 was used to calculate pairwise distance matrices. Phylogenetic trees 
were then constructed by the neighbor-joining method of the CLUSTAL X programme in the 
MEGA software version 6.0. The consistency of the phylogenetic clustering was tested using 
bootstrap analysis with 1,000 replicates (Felsenstein, 1985). Bootstrap values above 70 were 
considered as enough for subtype designation and subtype designation was re-confirmed with 
subtypes as generated from Stanford HIV Drug Resistance Database output (Shafer, 2006). 
2.17 Comparison of RNA- and DNA-associated pol sequences 
HIV-1 pol nucleotide sequences derived from plasma viral RNA and DNA and 
covering the PR/RT region were compared to determine similarities existing between the two 
templates. These sequences were analyzed in the positions known to confer resistance to  ARDs 
within the PR and RT regions of HIV-1, in order to establish whether genotypic drug resistance 
testing on the two types of sequences showed marked differences or remained the same. 
2.18 Deep sequencing of drug naïve patient plasma samples 
Polymerase chain reaction amplicons spanning the PR/RT of the HIV-1 pol region 
were generated from thirteen drug naïve paired patients RNA and DNA templates by RT-PCR 
and direct PCR respectively. Amplicon generation, gel electrophoresis, purification and 
quantification protocols used were the same as already described in sections 2.11-2.13. The 
primer sets used were also the same. The thirteen patients either had differences in DRMs within 
paired samples of their viral DNA and RNA derived sequences or ten or more differences within 
aligned nucleotide sequence pairs of RNA and DNA templates or had both differences in DRMs 
and aligned nucleotide sequence pairs of RNA and DNA templates. 
Polymerase chain reaction products of all thirteen patients were then sent to the 
Institute of Immunology and Genetics, a commercial deep sequencing facility in Kaiserslautern, 
Germany where we purified the PCR products using the Agencourt AMPure XP PCR 
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purification system (Beckman Coulter, Inc., Beverly, Massachusetts, USA), which makes use of 
paramagnetic beads. The DNA was quantified with Quant-iT Picogreen dsDNA reagent and kits 
(Invitrogen, Life Technologies) using FLUOstar OPTIMA SP002 (BMG LABTECH, Ortenberg, 
Germany). The Picogreen kit includes a plasmid standard whose concentrations were used in 
determining the concentrations of the unknown PCR amplicons. After the quantifications, PCR 
amplicons were diluted and 1 ng DNA from each sample was used in generating DNA libraries. 
The Nextera DNA library preparation kit was used for generating DNA libraries by following the 
manufacturer’s protocol (Illumina, Inc., San Diego, CA, USA). Shortly, DNA amplicons were 
fragmented into approximately 250bp at 55°C for 5 minutes in a process termed tagmentation. 
Unique index primers and adapters were then added in a short cycle PCR (12 cycles), a process 
termed barcoding. The process of fragmenting DNA and tagging them with index primers and 
adapters is termed Nextera tagmentation. After tagmentation, the PCR products were again 
purified, followed by normalization of the DNA library. The library for each DNA sample were 
all pooled and sequenced in the Illumina Miseq sequencer (Illumina, Inc., San Diego, CA, USA) 
overnight. Each new read contained both the DNA fragment sequence and the unique barcode. 
Sequencing was completed overnight and sequence data was demultiplexed using an 
in-house bioinformatics pipeline, which sorted out identical sequences, by barcodes. The number 
of reads per sample was around 200,000 and the coverage per nucleotide position was between 
10,000 - 20,000 times. Sequence data was then loaded into the HIV Grade Database (Obermeier 
et al., 2012) for alignments to reference HIV subtype B sequences, generation of consensus 
sequences for each patient sample and identification of DRMs and differences within paired 
nucleotide sequences of RNA and DNA templates. Minority variants in up to 1% of the viral 
quasispecies were determined. 
2.19 Quantification of intracellular HIV-1 DNA load in drug-naïve 
patients samples by molecular-beacon-based real-time PCR  
A molecular-beacon-based real-time PCR assay which had been improved to 
specifically quantify HIV-1 IC DNA that have completed both first and second template 
switches (STS) also called the HIV-1 STS DNA or strong stop DNA was used to quantify HIV-1 
IC DNA levels in all drug naïve patient DNA samples. This assay was adapted from a 
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combination of protocols from Demetriou et al., 2010 and Kostrikis et al., 2002. The general 
procedure for quantifying single sequences with nucleotide-specific molecular beacons and real-
time PCR was used in the assay (Tyagi and Kramer, 1996). Primers used in the real-time PCR 
assays spanned regions from the end of HIV-1 U5 in the LTR region to the region before the gag 
sequence (figure 11). The primers spanned a 165-nucleotide region starting from positions 623 to 
788 in the HXB2 HIV sequence. The target recognition sequence of the molecular-beacon and 
the PCR primers were designed by an exhaustive alignment process of all HIV-1 sequences 
available within the HIV sequence database (Demetriou et al., 2010) to bind to HIV-1 group M 
conserved regions. Table 4 show the primers and the target recognition sequence of the 
molecular-beacon. The HIV-1 real time PCR assay was optimized for in-house detection of all 
HIV-1 IC DNA forms that had undergone both first and second DNA template switches, 
including integrated and unintegrated DNA forms within drug naïve patient DNA samples. 
  
 
Figure 11: Schematic diagram of the HIV-1 IC DNA region quantified from all drug naïve DNA samples.  
(A) Indicates the entire HIV-1 genome architecture showing all gene locations and gene lengths. (B) 
Illustrates the magnified image of the LTR and p24 region of gag thereby detailing the exact region within the 
viral genome, which was targeted in the quantification of HIV-1 IC DNA forms. 
 
                 A 
 
B  
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2.19.1 PCR amplification of HIV-1 intracellular and CCR5 DNA standards 
 Patient derived HIV-1 and CCR5 DNA were PCR amplified to generate PCR 
amplicons for plasmid production. These plasmids were then used as external standards in the 
real-time qPCR amplification of HIV-1 infected drug naïve patients DNA samples. The PCR 
products were generated with HIV-1 and CCR5 DNA amplification primers as indicated in table 
4 above. The PCR amplification reaction conditions per 50 µl reaction mix and thermocycling 
conditions for both HIV-1 and CCR5 DNA were as shown in appendix IV. Electrophoresis of 
PCR amplicons were performed at 100 volts on 2% agarose gels stained with ethidium bromide. 
The expected PCR bands were 165 and 237 nucleotides for HIV-1 and CCR5 DNA (see 
appendix V) were then excised from gel and purified with the NucleoSpin Extract II PCR clean-
up and gel extraction kit (Macherey- Nagel GmbH and Co.KG, Dueren, Germany) by following 
the manufacturers protocol. Amplicons were then used for cloning. 
2.19.2 Cloning and transformation of HIV-1 and CCR5 plasmids into E.coli 
Polymerase chain reaction amplicons of HIV-1 and CCR5 DNA were cloned into a 
pCR 4-TOPO vector obtained from the TOPO TA cloning kit (Invitrogen, Karlsruhe, Germany). 
The cloning reaction was set up according to the manufacturer’s instructions as shown in 
appendix VI for HIV-1 IC DNA and CCR5 DNA. The pCR 4-TOPO plasmid vector (Invitrogen, 
Karlsruhe, Germany) was designed linearized with single 3 ́ deoxythymidine (T) overhangs. On 
the other hand, the Taq DNA polymerase within the PCR reaction mix has a non-template-
dependent terminal transferase activity that adds a single deoxyadenosine (A) to the 3 ́ ends of 
PCR products. This allows efficient ligation of PCR inserts with the linearized TOPO vector in 
the cloning reaction (http://redrecombineering.ncifcrf.gov/Protocols.html). 
 Transformation was carried out by adding 4 µl each of TOPO cloning reaction mix to 
two 50 µl vials of competent E. coli cells which had been thawed on ice and mixed gently. The 
mixtures were incubated on ice for 30 minutes and afterwards heat shocked at 42 °C in a water 
bath for 30s. The mixtures were then immediately cooled on ice for 2 minutes and cultured in 1 
ml antibiotic-free LB medium for an hour in a 37°C incubator. Afterwards different 
concentrations of the mixture (20-50 µl) were streaked on pre-warmed LB-agar plates containing 
         Materials and Methods  
51 
 
50 µg/ml of selection antibiotics. The plates were subsequently incubated overnight at 37°C. 
Single colonies of eight to ten suspected to have the plasmid inserts of each sample, were 
selected and sub-cultured in 6 ml of LB medium containing 50 µg/ml of selection antibiotics 
overnight at 37°C overnight. Plasmid DNA was then extracted from 6 ml of these sub-cultures 
containing single or pure bacteria colonies using the QIAprep Spin MiniPrep kit (QIAGEN, 
Hilden, Germany) and extracted DNA were confirmed for expected HIV-1 or CCR5 DNA 
plasmid insert via sequencing with the TOPO TA sequencing primers (table 4) at the GATC 
Biotech (Konstanz, Germany). This was then followed with a second overnight sub-culture of 
0.5ml pure colonies containing the required insert, at 37°C overnight in 400 ml of LB medium 
containing selection antibiotics.  DNA extraction of cultures containing the plasmid insert were 
performed using QIAprep Spin MaxiPrep kit (QIAGEN, Hilden, Germany) to generate large 
volumes of the plasmids to serve as external standards in the real-time qPCR reactions. Plasmid 
DNA was suspended in Tris-EDTA (TE) buffer (components of the buffer are indicated in table 
1) and stored at -20°C. Table 6 and 7 show the plasmid DNA inserts for HIV-1 and CCR5 
sequence lengths (165 nucleotides and 237 nucleotides respectively) and the HBX2 locations of 
both inserts.  
Table 6: Query sequence of patient HIV-1 intracellular DNA inserted into a topo vector 
 
Table 7: Sequence of patient CCR5 amplicon inserted into a topo vector 
 
Generated from http://www.hiv.lanl.gov/content/sequence/QUICK_ALIGNv2/QuickAlign.html 
 
Patient Derived HIV IC DNA 
Sequence inserted Into Topo
TCTCTCCTTCTAGCCTCCGCTAGtCAAAAATTTCTTGGCGTACTCACCGG 
TCGCCGCTCTCGCCTCTTGCTGTGTGCACCTCAGCAAGCCGAGTCCTGCG 
TCGAGAGAACTTCTCTGGAACTTTCGCTTTCGAGTCCTTATTAACTTTCA 
CTTTCGGGTCCCTGTTCGGGCGCCACTGCTAGAGATTT
Query Length: 165
HXB2 Location: genome: 623←788 reverse complement
Patient Derived HIV IC DNA 
Sequence inserted Into Topo
TCTCTCCTTCTAGCCTCCGCTAGtCAAAAATTTCTTGGCGTACTCACCGG 
TCGCCGCTCTCGCCTCTTGCTGTGTGCACCTCAGCAAGCCGAGTCCTGCG 
TCGAGAGAACTTCTCTGGAACTTTCGCTTTCGAGTCCTTATTAACTTTCA 
CTTTCGGGTCCCTGTTCGGGCGCCACTGCTAGAGATTT
Query Length: 165
HXB2 Location: genome: 623←788 reverse complement
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2.19.3 Plasmid quantifications and dilutions 
Both the TOPO vector with either the HIV-1 or CCR5 plasmid DNA each consisted of 
3956bp in size. The DNA concentrations of the plasmid HIV-1 and CCR5 DNA were 2268 ng/ul 
and 2638 ng/ul respectively. Plasmid DNA concentrations were quantified with the 
NanoPhotometer® P 300 (Implen, München, Germany).  The DNA copy number per unit 
volume for each standard was calculated using the respective DNA concentrations measured. 
Tenfold serial dilutions of the HIV-1 and CCR5 plasmid DNA with a dynamic range of 101- 106 
and 103- 107 DNA copies respectively, were freshly prepared and used for real-time qPCR. Low 
copy number DNA was maintained by using low DNA binding Eppendorf tubes for the 
dilutions, to ensure the highest recovery of DNA over time. Low CCR5 DNA copy numbers 
(101-102) could not be amplified. 
2.19.4 Generation of HIV-1 and CCR5 standard curves with real-time PCR  
Each real-time qPCR standard was carried out in triplicates in a 96 well plate. For the 
HIV-1 DNA standard, Each 50 µl real-time PCR mix consisted of 0.5 to 5.0µg of genomic DNA, 
0.5 µl of 10 µM/µl HIV-1 MB684 molecular beacon, 2.5 µl of 10 µM/µl forward and reverse 
primers each, 10 mM dATP, 10 mM dCTP, 10 mM dGTP, 20 mM dTUP, 0.5 µl of 5 U/µl of 
AmpliTaq Gold DNA polymerase (Life Technologies, Darmstadt, Germany), 7 µl of 25mM 
MgCl2, 5 µl of 10X TaqMan qPCR Buffer A (table 1 gives the constituents of the buffer).  PCR 
grade water was added to the mix to make it up to 50µl per unit volume. The thermocycling 
conditions were set as follows; one cycle of denaturation (95°C for 10 minutes), followed by 40 
cycles of amplification (denaturation at 95°C for 15 s, annealing and data collection at 62°C for 1 
min, and polymerization at 72°C for 30 s in an ABI 7500 real-time spectrofluorometric thermal 
cycler (Thermo Scientific, Darmstadt, Germany). The molecular beacon had the FAM reporter 
and the quencher dabcyl. The target recognition sequence and primers are given in table 4. 
The CCR5 DNA standard was generated for each 50 µl real-time PCR mix with the 
same reaction conditions as specified for the HIV-1 DNA qPCR with a further addition of the 
0.50 µl of 1 U/µl of AmpErase Uracil-N-glycosylase to prevent amplification of dU- 
contaminating PCR products. The primers and the CCR5 molecular beacon containing the target 
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recognition sequence are listed in table 4.  Also the thermocycling was carried out as follows; 
One incubation cycle for the Uracil-N-glycosylase (50°C for 2 minutes) and one cycle of 
denaturation at 95°C for 10 minutes, followed by 40 cycles of amplification as follows 
denaturation at 95°C for 15 s, annealing at 60°C for 1 min in an ABI 7500 real-time 
spectrofluorometric thermal cycler (Thermo Scientific, Darmstadt, Germany). Data was collected 
at all amplification stages and there was no polymerization cycle. Fluorescence emission was 
subsequently recorded at 521nm during the data-collection stage of each qPCR cycle.  
HIV-1 and CCR5 standard curves were generated by constructing a scatter plot of 
known CCR5 and HIV-1 copies against the cycle threshold of each dilution point (Microsoft 
excel software 2010). The slope and co-efficient of determination R2 of each of the two standard 
curves was calculated based on the equation of a straight line (CT=mx+b), where m and b 
represents the slope and intercept of the straight line respectively, x represents the independent 
variable and CT the dependent variable. The PCR efficiency, E, of the experimentally derived 
standards was computed from the equation, E = (10-1/slope-1).  
2.19.5 Assessment of target specific binding to the HIV DNA template 
 The specific binding of HIV-1 DNA primers and molecular-beacons to the HIV-1 
DNA template from the patient DNA samples was determined by using 10ul µl of 96 ng/µl of a 
non-template control (NTC) human HIV negative sample diluted in 90 ul of TE buffer and 
serially like the HIV-1 plasmid DNA standard. In this assay three experimental set-ups were 
made. The first consisted of qPCR mixes having the NTC and the HIV plasmid DNA template in 
the same qPCR mix per unit reaction. The dilution factor for both the HIV plasmid DNA and the 
NTC were the same. The qPCR mixes and thermocycling conditions were performed in the same 
manner as in the HIV plasmid DNA standard generation (section 2.19.4). Six dilutions points 
were setup with a dynamic range from 101 to 106 of HIV-1 DNA copies and for each dilution 
point, an NTC of the same dilution was added. The dilution points were set-up in triplicates. The 
second set-up consisted of the HIV-1 plasmid DNA only with a dynamic range from 101 to 106 
also done in triplicates. The third reaction comprised of the human HIV negative control only, 
having again a dynamic range from a 1 in 10 dilution point to a 1 in 1000000 dilution point for 
each triplicate reaction. The three qPCR set-ups were run simultaneously on a 96 well plate. 
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2.19.6 Quantification of HIV-1 intracellular DNA levels in drug naïve patients   
DNA samples  
Quantification of HIV-1 IC DNA of all drug naïve genomic DNA samples extracted 
from buffy coats was achieved with two molecular-beacon-based real-time qPCR assays. PCRs 
were carried out in triplicate in 96 well plates for the absolute quantification of CCR5 DNA 
copies and HIV-1 IC DNA copies for each patient sample, as described above.  For each 96 well 
plate run, HIV-1 and human CCR5 DNA standard curves were also run alongside in triplicate 
using six serial dilution points as described above. Each 50 µl qPCR mix and thermocycling 
conditions were done as described in generating the standards. Each experimental qPCR output 
was assessed based on its own standard curve results. The co-efficient of determination (R2) of 
each standard curve was determined by the slope and the intercept. For each patient DNA 
sample, the threshold cycles obtained from either the HIV-1 IC DNA or CCR5 qPCR were used 
to determine the HIV-1 IC DNA copies or the human CCR5 copy number. The HIV-1 IC DNA 
load was then defined as the number of HIV-1 IC DNA copies per one million cells. Cell 
numbers for each patient sample were obtained from the human CCR5 qPCR because it is 
already known that the CCR5 gene, exist as two copies in a cell. 
2.20 Optimizations of absolute real-time quantitative PCR reactions 
2.20.1 Optimizations of HIV-1 intracellular DNA quantification protocol 
In order to quantify HIV-1 IC DNA from genomic DNA samples of infected drug 
naïve patients, an absolute qPCR reaction protocol employing the use of molecular beacons was 
optimized to specifically quantify HIV-1 IC DNA that has completed both first and second 
template switches. 
2.20.1.1 Quantification of HIV-1 intracellular DNA with the platinum qPCR SuperMix 
Standards were prepared with pCHIV transformed into E.coli, cultured and plasmid 
purified from pure cultures. Known plasmid concentrations of 106-101 pCHIV DNA copies were 
amplified with the platinum qPCR SuperMix at an annealing and data collection temperature of 
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55°C. The resultant amplifications (106-105) copies were non-specific and the other standard 
points gave no amplification. 
 A patient derived HIV-1 DNA plasmid was generated from PCR amplicons using the 
HIV-1 DNA primers, which were also used in the quantification of HIV-1 IC DNA. The qPCR 
reactions were performed with the platinum qPCR SuperMix-UDG (Life Technologies, 
Darmstadt, Germany) in the ABI 7500 real-time spectrofluorometric thermal cycler (Thermo 
Scientific, Darmstadt, Germany). Each reaction mix consisted of a total volume of 25 µl, 
containing 5 µl of extracted genomic DNA, 1 µl of 20 pmol/µl each of forward and reverse 
primer, 12.5 µl of 1X Platinum quantitative qPCR Supermix-UDG (Invitrogen, Carlsbad, CA, 
USA), 1 µl of 6 pmol/µl of the HIV DNA molecular-beacon (MB684) and 4.5 µl of nuclease free 
water. The cycling conditions were as follows: one incubation cycle at 50°C for 2 minutes, 
followed by one cycle of denaturation at 95°C for 10 min and 50 cycles of amplification 
consisting of a denaturation at 95°C for 15 s, annealing and data collection at 55°C for 30 s 
(annealing temperature was increased by 1°C at a time until an annealing temperature of 62°C 
was reached and annealing time was also increased to 1 min), polymerization was set at 72°C for 
30 s. Specific amplifications were seen for 106-103 HIV-1 DNA copies at an annealing 
temperature of 60°C for 1minute and the other two standard points gave non-specific 
amplification. 
2.20.1.2 Quantification of HIV-1 intracellular DNA with AmpliTaq Gold DNA polymerase 
Patient derived HIV-1 DNA plasmid was used again as a standard for the absolute 
quantification of HIV-1 DNA copies using a molecular-beacons designed to hybridize with the 
HIV-1 templates in the M group (Demetriou et al., 2010). The dynamic range of the standard 
was 106-101 HIV-1 DNA copies. The 50 µl reaction mix per unit was prepared for the qPCR 
with AmpliTaq Gold DNA Polymerase (Life Technologies, Darmstadt, Germany). All reactions 
were carried out in triplicates in 96 well plates and sealed with qPCR plate sealers. In the initial 
set of reactions, each 50 µl mix included 10 µl of genomic DNA, 0.5 µl of 10 µM/µl HIV-1 
MB684, 2.5 µl of 10 µM/µl forward and reverse primers each, 0.5 µl of 25 mM dNTPs, 7 µl of 
25mM MgCl2, 5 µl of 10X TaqMan qPCR Buffer A (table 1 gives the constituents of the buffer).  
Nuclease free water was added to the mix to add up to 50µl volume. The thermocycling 
conditions were set as follows; one cycle of denaturation (95°C for 10 min), followed by 40 
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cycles of amplification (denaturation at 95°C for 15 s, annealing and data collection was set at 
55°C for 1 min and increased gradually by 1°C in each experimental set-up to 62°C but the 
annealing time was kept constant. Extension was set at 72°C for 30. The ABI 7500 real-time 
spectrofluorometric thermal cycler (Thermo Scientific, Darmstadt, Germany) was used for all the 
HIV-1 DNA quantification reactions. Five dilution points (106-102 HIV-1 DNA copies) were 
quantified and the co-efficient of determination achieved was 0.95 which was lower than the co-
efficient (0.99) achieved by Demetriou et al. 2010 and Kostrikis et al. 2002 and also the PCR 
efficiency achieved was above 100%.   
In order to improve the qPCR efficiency and also quantify 10 copies of HIV-1 DNA, 
efficiently, the dNTPs was changed to single dNTPs and qPCR mix was prepared as already 
described in section 2.19.4 with the same thermocycling conditions. The annealing temperature 
was adjusted as well from 60°C to 62°C and the best results were obtained at the 62°C annealing 
temperature. All HIV-1 DNA dilution points (106-101 copies) were efficiently quantified with 
these conditions. 
2.20.2 Optimizations of human CCR5 DNA quantification protocol 
To quantify the numbers of cell input in the HIV-1 DNA, a molecular-beacon-based 
qPCR, which uses primers flanking the positions 478-623 bp of the human CCR5 gene, was 
used. A patient derived plasmid CCR5 DNA was used as the standard. 
2.20.2.1 CCR5 DNA amplification with the platinum qPCR SuperMix 
 The standard was initially amplified with platinum qPCR SuperMix-UDG (Life 
Technologies, Darmstadt, Germany).  For the real-time PCR reaction, each 25 µl reaction 
mixture contained 5 µl of extracted genomic DNA, 1 µl of 20 pmol/µl each of forward and 
reverse primer respectively, 12.5 µl of 1X Platinum quantitative qPCR SuperMix-UDG 
(Invitrogen, Carlsbad, CA, USA) and nuclease free water added to make the 25 µl volumes. The 
molecular-beacon (LK155) used in the 25 µl reaction mix was 13 pmol/µl. The cycling 
conditions were the same as in the HIV-1 IC DNA reaction and performed in ABI 7500 real-time 
spectrofluorometric thermal cycler (Thermo Scientific, Darmstadt, Germany). Data was collected 
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at 55 °C for 30s and in the repeat experiment data was collected at 55 °C for 1 min. Annealing 
temperature was increased by 1°C at a time, keeping all other conditions constant until an 
annealing temperature of 62°C was reached. The FAM and JOE fluorescence emission 
wavelengths 518 nm and 548 nm respectively were used instead of the TET filter (emission 
wavelength 538 nm) which is the reporter dye for the CCR5 molecular-beacon. The reason was 
that the ABI 7500 real-time spectrofluorometric thermal cycler does not have the TET filter. 
Amplification at 50 cycles gave non-specific bands. Quantitative PCR was again tried in the ABI 
480 real-time spectrofluorometric light cycler (Thermo Scientific, Darmstadt, Germany). The 
higher standard points from 106-104 CCR5 copies had non-specific amplification with varied 
CTs within each standard point and the lower standard points (103-101 copies) showed no 
amplification. Experiments were repeated twice and results were the same. Standards were 
afterwards prepared from 108-103 CCR5 copies and specific amplification was detected for 108-
107 CCR5 copies only. 
2.20.2.2 CCR5 DNA amplification with AmpliTaq gold DNA polymerase 
The CCR5 plasmid standards (108-103 CCR5 copies) were again amplified with the 
AmpliTaq Gold DNA Polymerase (Life Technologies, Darmstadt, Germany). The 50 µl reaction 
mix was performed as described in section 2.19.4 and thermal cycling conditions were also the 
same with no incubation cycle for the Uracil-N-glycosylase because the reaction mix did not 
contain this enzyme. The qPCR was run in the ABI 7500 real-time spectrofluorometric thermal 
cycler and also in the ABI 480 real-time spectrofluorometric light cycler (Thermo Scientific, 
Darmstadt, Germany). At the 62°C annealing temperature, three standard points were 
specifically amplified from 108-106 CCR5 copies.  Amplification products were run on 2% 
agarose gels at each run to detect the presence of specific and non-specific bands. Keeping qPCR 
reaction mix and reaction conditions the same the experiments were repeated using the ABI 7900 
HT real-time spectrofluorometric thermal cycler (Thermo Scientific, Darmstadt, Germany) 
which has the TET reporter. Data was collected at 62°C annealing temperature. Amplification 
products obtained were non-specific at all data points. A 0.50 µl of 1 U/µl of AmpErase Uracil-
N-glycosylase and the additional 50°C incubation step was added and data again collected at the 
annealing temperature and again non- specific amplifications were obtained.  
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The next round of amplifications were carried out at an annealing temperature of 60°C 
for 1 min in the ABI 7900 HT real-time spectrofluorometric thermal cycler (Thermo Scientific, 
Darmstadt, Germany) and data collection was performed at all thermal cycling points. There was 
no polymerization step added. These conditions eventually gave specific amplifications of 108-
103 CCR5 copies and this was used to quantify and the external standards were also used to 
measure the unknown CCR5 DNA copies of patients. 
2.21 Statistical analysis  
The Stanford HIV drug resistance algorithm was used to determine TDRM having an 
effect on HIV drug susceptibility for a particular class of ARVs. TDRMs to RT and PR 
inhibitors were displayed in percentages. The prevalence of transmitted resistance was 
determined with the Wilson score interval at 95% confidence interval (CI). A bar chart was used 
to display the distribution of HIV-1 IC DNA or HIV-1 STS DNA load among HIV-1 infected 
drug naïve patients. Descriptive statistics of median and interquartile ranges (IQR) were used for 
displaying HIV-1 IC DNA load/106 cells, plasma viral RNA load/ml of plasma, CD4+ T-cell 
count/ml of blood and other relevant clinical parameters among infected patients. Pearson’s 
correlation coefficient at 95% CI was used to evaluate the associations between HIV-1 IC DNA 
levels, plasma HIV-1 viral RNA levels and CD4+ T-cell counts. The Mann-Whitney test at 95% 
CI, was used to compare HIV-1 IC DNA load, plasma HIV-1 viral RNA load, CD4+ T-cell 
counts and all other clinical parameters among drug resistant and drug sensitive patients. A one-
way ANOVA was used to demonstrate the association between age of patients and HIV-1 IC 
DNA load. Consequently the HIV-1 IC DNA levels among predominant HIV-1 subtypes 
depicted by analysis done with the Kruskal-Wallis test and the Bartlett's test for equal variances 
were also displayed. All statistical analysis were done with Microsoft excel 2010 or with the 
GraphPad Prism version 6.00 (Graph Pad Inc., San Diego, California, USA) softwares. 
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3 Results 
3.1 HIV-1 infected patient demographics and clinical parameters 
 This section describes the characteristics of all drug naïve patients from Nouna 
Burkina Faso recruited for this study. The drug naïve HIV-1 infected patients consisted of  61 
(71%) females, 24 (28%) males and 1(1%) with unknown gender. The median ages of females 
34 (30–41) and males 42 (34.25–48.00) were significantly different (p=0.0076). The median 
log10 plasma viral load and the CD4
+ T-cell count for all drug naïve patients were 5.757 copies 
per ml of plasma and 5.301 cells per ml of blood respectively. The total number of patients with 
records on the presence or absence of secondary bacterial infections was 60 and the remaining 26 
had no records on their infection status. Among the 60 patients with infection history, 34 
harboured secondary bacterial infections and the remaining 26 had no bacterial infections. None 
of the patients had secondary parasitic infections. Sixty-one patients had data on HBV co-
infection status and the remaining 25 had no records. Among these 61 patients, those harbouring 
HBV as a co-infection with HIV-1 were six and those without HBV co-infection were 55. Fifty- 
five males and females had records on their Hb levels while the remaining 31 patients had no 
history on Hb levels. The median Hb levels for males and females were 11.7g/dl and 10.25g/dl 
respectively. With respect to the Centers for Disease Control and Prevention (CDC) classification 
system for HIV infection, 57 patients had their respective clinical staging categories recorded 
and per the record, a majority of patients 56 were within CDC category B and 1 patient was 
within the CDC category A. The remaining 29 patients had no records on their clinical staging 
status. Table 8 describes demographics and clinical characteristics of HIV-1 infected patients in 
this study.  
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Table 8: Baseline characteristic details of drug naïve patients attending the Nouna District hospital in Nouna 
Burkina Faso 
The Mann Whitney t-test for unpaired data was used to estimate the median and IQR. Abbreviations IQR represent 
Interquartile Range; CDC represents the Centers for Disease Control and Prevention 
 Drug NaïvePatients 
Number of patients (n=86, median age in years, IQR) 35 (30–43) 
Females {n=61 (71 %), median age in years, IQR}  34 (30–41)  
Males {n= 24 (28%), median age in years, IQR}  42 (34–48)  
Unknown gender (n, %)                                                          1 (1) 
Median log10 transformed plasma RNA load in copies per ml of plasma 
(n=86, median, IQR) 
5.76 (4.99 - 6.16) 
Median log10 transformed CD4
+
 T-cell count in cells per ml  (n=86, 
median, IQR) 
 
5.30 (5.08 -5.45) 
Patients’ records on CDC Classification System for HIV Infection CDC-A/B/C (n=57) 
CDC-Category A (n) 1 
CDC-Category B2, B3 (n) 55 
CDC-Category B1 (n) 
Recorded number of patients with infection status (n)  
1 
60 
Presence of Secondary bacterial or parasitic infection (n) 34 
Absence of Secondary bacterial or parasitic infection (n) 26 
Recorded patients’ HBV co-infection status (n) 
Presence of HBV Co-infection (n) 
61 
6 
Absence of HBV Co-infection (n) 55 
Recorded patients BMI in kg/m
2
 (n=58, median, IQR) 17.72 (20.59-15.76) 
BMI Categories:   
Males Underweight, Below 18.5kg/m2 (n=10, median, IQR) 15.87 (14.74-17.41) 
Females Underweight Below 18.5kg/m2  (n=22, median, IQR) 16.18 (14.54-17.28) 
Males Normal Weight, 18.5–24.9kg/m2 (n=4, median, IQR) 22.51 (20.90-23.86) 
Females Normal Weight, 18.5–24.9kg/m2 (n=20, median, IQR)  20.57 (20.36-21.80) 
Overweight Female, 25–29.9kg/m2 (n=1, actual BMI) 26.17 
Obese Female, 30.0kg/m2 and Above (n=1, actual BMI) 35.16 
Recorded patients Hb in g/dl (n=55, median, IQR) 10.60 (9.70-11.80) 
Hb of Males in g/dl (n=15, median, IQR) 11.70 (10.60-12.60) 
Hb of females in g/dl (n=40, median, IQR) 10.25 (9.63-11.23) 
 
3.2 HIV-1 subtyping of drug naïve patient RNA and DNA 
sequences by phylogenetic tree analysis 
In order to determine the HIV-1 subtypes found among drug naïve patients, edited 
patient sequences were fed into the Stanford HIV Drug Resistance Database 
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(http://hivdb.stanford.edu) for subtype determination. Subtypes were again confirmed using 
phylogenetic trees as shown in figures 12A, 12B, 12C, 12D, 12E and 12F. Phylogenetic trees 
were generated with patient RNA and DNA sequences encoding the PR/RT of HIV-1 pol gene. 
The predominant HIV-1 subtype found among patient sequences was CRF02_AG- like viruses. 
These formed 70% (58/83) of the entire patient sequence pool analyzed, CRF06_cpx -like 
viruses were the second abundant group of viruses 14.5% (12/83), the third was CRF01_AE-like 
7.2% (6/83), the fourth virus subtype was G-like viruses 5% (4/83), the fifth subtype was 02_A1- 
like viruses 2.4% (2/83), the sixth and final was subtype D- like viruses 1.0% (1/83). There were 
no major differences between RNA and DNA virus subtypes of the same patient. 
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Figure 12A: Phylogenetic tree from DNA as starting template. See details on pages 67-68.
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Figure 12B: Enlarged 
phylogenetic tree from 1A 
showing CRF02_AG subtypes 
with DNA as starting template. 
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Figure 12C: Enlarged phylogenetic tree from 1A showing all other subtypes apart from CRF02_AG, with DNA as starting template. 
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Figure 12D: Phylogenetic tree from RNA as starting template. See details on pages 67-68. 
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Figure 12E: Enlarged phylogenetic tree from 
1D showing CRF02_AG subtypes with RNA 
as starting template. 
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Figure 12F: Enlarged 
phylogenetic tree from 
1D showing all other 
subtypes apart from 
CRF02_AG, with RNA 
as starting template. 
Figure 122: Neighbor-
joining phylogenetic tree 
comprising of the PR/RT 
region of HIV-1 
sequences from drug 
naïve patients residing in 
Nouna Burkina Faso.  
The trees were generated 
from eighty three viral 
RNA and DNA template 
pairs isolated from the 
same patient. (A) 
Phylogenetic trees from 
DNA as starting 
template. (B) Enlarged 
phylogenetic tree from 
1A showing CRF02_AG 
subtypes. (C) Enlarged 
phylogenetic tree from 
1A showing all other 
subtypes apart from 
CRF02_AG.  
 
                                                                        Results  
68 
 
 (D) Phylogenetic tree from RNA as starting template. (E) Enlarged phylogenetic tree from 1D showing CRF02_AG subtypes. (F) Enlarged phylogenetic 
tree from 1D showing all other subtypes apart from CRF02_AG. Representative reference sequences of HIV-1 subtypes (A–K) and CRF02_AG, 
CRF01_AE and CRF06_cpx indicated as dark shaded circles were included from the National Center for Biotechnology Information (NCBI) database 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) via a megablast for highly similar HIV-1 sequences to the query sequence. Inverted triangles representing 
patient HIV-1 query sequences clustered to various references, which were used to determine the respective subtypes of the query sequences. The 
divergence existing between any two sequences was determined by the sum of the horizontal branch length, using the scale at the lower left. The straight 
lines on the right end of the trees indicate the subtype/CRF clustering. CRF02 AG was the predominant virus subtype in both DNA and cDNA trees. 
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3.3 Genotyping of viral sequences from drug naïve and follow-up 
patients  
3.3.1 Transmitted drug resistance mutations among drug naïve patients and      
further comparisons of viral RNA and DNA templates from the same 
patient  
Genomic RNA and DNA were extracted from plasma and buffy coat samples of 86 
HIV-1 infected drug naïve Burkinabés and used in drug resistance genotyping for the detection 
of TDRMs in the PR/RT region of HIV-1. Among the drug naïve patients, sequence alignment, 
editing and DRM analysis for mutations conferring resistance to HIV-1 was done for 83 paired 
patient derived HIV-1 RNA/DNA sequences out of a total number of 86 sequence pairs. The 
remaining three paired patient sequences were eliminated from the analysis because the sequence 
chromatographs could not be read. 
Seventy-five patients harboured the drug susceptible strain of the virus and these had a 
Wilson’s score mean of 0.91 (91%) and a Wilson's score confidence interval (CI) range of (0.81-
0.95) at 95% CI. The remaining eight patients harboured TDRM that are known to affect drug 
susceptibility (as shown in figure 13B) with a Wilson’s score mean of 0.09 (9%) and a CI range 
of 0.05- 0.17 at 95% CI. The drug resistance categories (see table 9 and appendix VII) were 
determined from the overall drug resistance score for a particular class of ARVs as given by the 
Stanford HIV drug resistance database (Rhee et al. 2003). Patients with no TDRM affecting drug 
susceptibility for a particular class of ARVs were 75 (90.4%) and those that had TDRM affecting 
drug susceptibility for a particular class of ARVs were 8 (9.6%) (figure 13B). Other minor and 
accessory resistance mutations were also seen but these had no effect on overall drug 
susceptibility and therefore nothing was recorded for the drug resistance mutations per resistance 
score category as shown again in table 9 and appendix VII. Among patients harbouring DRM 
that affected drug susceptibility, 7 (87.5%) had mutations affecting the susceptibility to reverse 
transcriptase inhibitors (RTIs) while 1 (12.5%) had a mutation affecting the susceptibility to 
protease inhibitors (PIs) as indicated in figure 13C. Consequently, among those harbouring RTI 
mutations, 6(86%) had DRMs to NNRTIs and only 1 (14%) had mutations affecting NRTI 
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susceptibility (see figure 13D). The general DRM profile per resistance score as seen in figure 
13E, showed mainly low-level resistance to NNRTIs 4 (50%) followed by intermediate/high 
level resistance to NNRTIs 2 (25%), low-level resistance to NRTIs 1 (12.5%) and low-level 
resistance to PIs 1 (12.5%). 
The major DRMs among drug naïve patients were mainly mutations to NNRTIs and 
NRTIs. Table 9 and appendix VII show the details of the DRM found among patient derived 
HIV-1 sequences. Table 9 gives the summary of mainly the mutations that are known to affect 
drug susceptibility and appendix VII gives details of DRM found within all 83 individual drug 
naïve patients. PI associated mutations and polymorphisms were L10V/I/F/L, K20I/R/V, L89M/I, 
V11I, K43T, A71T, T74S, K33F, and I93M. The K20I polymorphism was found in 81(98%) of 
all 83 patients and the K20R mutation was found in the remaining 2 (2%). Major NNRTI 
mutations included K103N and Y181C, these were found in 4 (5%) out of 83 patients. Minor 
NNRTI mutations, V108I, V179I, V90I, E138A, V106I and K238K/R were found in 20 (24%) 
out of all the 83 patients. A major NRTI mutation L210W was found in 1 (1%) of all 83 patients. 
Minor NRTI mutations found in 4 (5%) out of the 83 patients were mainly T69N, E44D, 
V118I/V and K219N mutations. 
Furthermore, similarities between viral RNA and DNA sequences in PR/RT regions 
conferring resistance to HIV-1 were also assessed among drug naïve patients. A high similarity 
78(94%) existed between RNA and DNA templates of the same patient among drug naïve patients 
and differences between templates were few 5 (6%) as shown in figure 13A. Appendix VII gives a 
detailed profile on how the similarities and differences in figure 13A were achieved. In table 9 
and appendix VII, all yellow coloured regions in the tables indicate same mutations found in 
RNA and DNA templates of the respective patients and orange coloured regions indicate patients 
whose RNA and DNA templates differed by the presence of one or more mutations in RNA or 
DNA or vice versa. Within the orange coloured regions, the light blue segments highlight the 
differences in mutations. An example is the patient with lab ID SRIN48 in table 9. This patient 
had the K219N mutation in DNA and not in RNA. 
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Table 9: Summary of drug resistance profile of HIV-1 infected drug naïve patients from Nouna Burkina Faso 
 
 
DR represents drug resistance; LR represents level resistance Type of template: RNA; Region analyzed: PR 1-99 codons and RT (2/3) 1-335 codons. Primary 
resistance mutations are bolded, primary resistance mutations in other expert list are bolded and underlined and minor and accessory resistance mutations are 
italicized. 
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Table  9 continued. 
SRIN69 515487 428 RNA
DNA
SRIN81 590908 323 RNA
DNA
SRIN106 3589550 176 RNA
DNA
SRIN120 1400866 504 RNA
DNA
SRIN123 976517 301 RNA
DNA
SRIN124 225569 467 RNA
DNA
SRIN125 1126782 33 RNA
DNA
Lab ID
CD4+T -cell 
counts (cells/ul)
Type of  
Template
 Viral RNA 
load copies/ml Low-LR High/ Intermediate -LR
CRF02_AG - Like L10LV no mutation
K20I
L210LW AZT, D4T
CRF02_AG - Like L10V no mutation
 K20I
L210LW AZT, D4T
CRF02_AG - Like   K20I, T74S NFV 
K238KR 
CRF02_AG - Like  K20I, T74S NFV 
K238R 
CRF02_AG - Like K20I no mutation
V108I NVP
V90I
CRF02_AG - Like K20I no mutation NVP
V108I 
V90I
CRF02_AG  - Like K20I no mutation
V11I
L10I
K103N NVP, EFV
CRF02_AG  - Like K20I no mutation
V11I
L10I
K103KN NVP, EFV
CRF02_AG  - Like K20I no mutation
E138A RVP
CRF02_AG  - Like K20I no mutation
E138A RVP
CRF02_AG  - Like K20I no mutation
CRF02_AG  - Like K20I no mutation
CRF02_AG  - Like K20I no mutation
CRF02_AG  - Like K20I no mutation
Subtype PR-RT
Drug Resistance Interpretations Per Resistance Scores
NNRTI 
Mutations
NRTI  
Mutations
PI 
Mutations
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Figure 13: Summary of HIV-1 genotyping profile of the PR/RT region of the HIV-1 pol gene of drug naive patients from Nouna Burkina Faso 
(A) A pie chart demonstrating similarities and/or differences between RNA/DNA templates in regions conferring resistance to RTIs and PIs. (B) 
Comparison of patients with or without TDRM in PR/RT. (C) Among patients harbouring DRM that affect drug susceptibility, as indicated in B, 7 
(87.5%) had mutations affecting the susceptibility of RTIs while 1 (12.5%) had mutations affecting the susceptibility of PIs. (D) Profile of RTI 
mutations only among patients with TDRM. High prevalence of mutations to NNRTI mutations n= 6 (86%) and low prevalence of NRTI mutations n=1 
(14%). (E) DRM categories per resistance scores in patient derived PR/RT viruses. 
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3.4 Nucleotide and amino acid changes within HIV-1 RNA and 
DNA paired sequences of the same patient 
Among the drug naïve patients, paired sequences from the PR/RT of the HIV-1 pol 
region, obtained from RNA and DNA starting templates of the same patients were aligned to 
each other to determine any nucleotide differences present within these paired sequences. The 
sequences were made up of the entire HIV-1 protease (1-99 amino acids) and 2/3 of RT. The 
numbers of positions having nucleotide differences were noted and subsequent codons from both 
templates specifying an amino acid were written. 
Nucleotide differences were synonymous when they did not change the resultant 
amino acid. For instance, a base substitution occurring at position 942 in the paired nucleotide 
sequence of patient SRIN15 from C (in RNA) to A (in DNA) changed the codon ACC (in RNA) 
to ACA (in DNA). The resulting amino acid in both cases was lysine, which is denoted by K, and 
therefore the change was synonymous. In instances where the amino acid changed from for 
example lysine (ACC) in RNA, to threonine (ACG) in DNA, the change was described as non-
synonymous because the nucleotide difference resulted in changing the amino acid. A change 
was described as either synonymous or non-synonymous when a degenerate code occurred at a 
position that allowed possibilities of both a synonymous and a non-synonymous change to occur 
at the same position. Every ambiguity nucleotide (also termed the degenerate code) either in the 
viral DNA or RNA or both, were given a value of one, the total number of ambiguities was 
determined by adding up the number of ambiguities in a given sequence and the resultant value 
was divided by two and added to already obtained values under the sections synonymous and 
non-synonymous. Table 10 summarizes the results of the nucleotide changes found among all 
drug naive paired RNA/DNA templates. Templates with more than 10 nucleotide changes were 
deep sequenced as a way of confirming the results obtained. Paired templates having no 
nucleotide differences were not included. 
Forty one percent of the patients had nucleotide differences in paired viral templates, 
while 59% had no nucleotide differences and there was no significant difference (p=0.60) 
between the number of synonymous changes (n=170) and the number of non-synonymous 
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nucleotide changes (n=198) (table 11). Among patients who had nucleotide differences, 38% of 
them had at least ten nucleotide differences within paired viral templates. 
Table 10: Summary of RNA/DNA paired nucleotide sequence alignments from drug naïve patients 
 
Patient sequences with nucleotide changes of ≥10 are highlighted in grey. 
  
Patient No of postions with Chracteristics of change based  on amino acid
Lab ID  nucleotide changes Synonymous Non- synonymous
Srin 14 day 0 2 2 0
Srin 16 day 0 23 7 16
Srin 31 day 0 26 18 8
Srin 38 day 0 53 29 23
Srin 39 day 0 23 5 17
Srin 47 day 0 5 3 2
Srin 48 day 0 2 1 1
Srin 52 day 0 1 1 0
Srin 55 day 0 3 3 0
Srin 56 day 0 6 3 3
Srin 60 day 0 8 4 4
Srin 63 day 0 3 3 0
Srin 66 day 0 5 5 0
Srin 69 day 0 7 3 4
Srin 70 day 0 1 1 0
Srin 71 day 0 3 2 1
Srin 72 day 0 2 1 1
Srin 74 day 0 1 1 0
Srin 75 day 0 2 1 0
Srin 77 day 0 1 1 0
Srin 80 day 0 7 1 6
Srin 81 day 0 2 0 2
Srin 82 day 0 2 2 0
Srin 83 day 0 1 1 0
Srin 84 day 0 2 0 0
Srin 85 day 0 2 1 1
Srin 86 day 0 14 5 9
Srin 87 day 0 2 0 2
SRIN93 day 0 10 1 9
SRIN94 day 0 10 2 8
SRIN95 day 0 12 2 10
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Table 11: Summary of nucleotide substitution analysis for all drug naïve patient derived viral sequences via 
Sanger sequencing 
 
3.4.1 Patterns of HIV-1 drug resistance mutations among patients followed 
over time  
Follow-up plasma samples from all patients 24 weeks post HAART with high plasma 
viral load > 1000 copies per ml of plasma were genotyped and sequenced for HIV-1 DRM 
analysis. Patients were put on a first line regime of 2 NRTI (3TC, d4T or AZT, d4T) and 
1NNRTI (NVP or EFV). A total of eight patients were followed-up. Six out of the eight patients 
had DRMs affecting drug susceptibility for a particular class of ARVs as described earlier for 
drug naïve patients in section 3.3.1. The remaining two patients had no resistance mutations 
affecting drug susceptibility. These six patients harboured DRMs that affected the susceptibility 
to RTIs. Furthermore, the six patients had mainly major DRMs to NNRTIs and three out of these 
six patients again had additional major DRMs to NRTIs (table 12).  
As indicated in table 12 the patient SRIN31, had a major DRM K103N developing to 
NNRTI within 48 weeks of therapy, causing high-level resistance to NVP and EFV. This 
mutation was still present at 72 weeks post ART. Patient SRIN48 on the other hand, harboured 
the major TDRM to NNRTIs, the Y181C mutation and the NRTI accessory TAM, K219N, at the 
drug naïve stage. The accessory TAM disappeared after 2 weeks of therapy but the Y181C 
mutation persisted. At 12 weeks into therapy, a major NRTI mutation M184V emerged in 
addition to the Y181C mutation and at 36 weeks into therapy, multiple mutations to NNRTIs 
(V108I and H221HY) emerged in addition to the already existing ones. All these mutations 
disappeared at 64 weeks into therapy leaving the accessory resistance mutation V108I which 
causes low-level resistance to NNRTIs. Furthermore, patient SRIN72 had the V179I mutation, 
which was no longer present at 48 weeks into therapy. Consequently, patient SRIN98 had a 
Type Number Median (IQR) Maximum 
170 2(1-5) 30
198 2(0-8.5) 30
Number of 
paired templates
Paired templates
Number of patients 
with changes in 
RNA and DNA 
sequence pairs
Number of patients 
with no changes in 
RNA and DNA 
n=34
n=49
Synonymous
Non-synonymous
Nucleotide substitutions
Mann–Whitney U test
p= 0.60
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major DRM to NNRTIs, thus the K103N that causes high-level resistance to NVP and EFV. This 
mutation developed at 24 weeks into therapy. At 36 weeks into therapy an additional DRM to 
NRTI, the M184V developed with the K103N mutation. The former disappeared and the NNRTI 
mutation E138Q that is known to cause high-level resistance to NVP and EFV and low level 
resistance to RPV appeared in addition to the K103N mutation at 48 weeks into therapy. Patient 
SRIN103 developed multiple major DRMs G190A, and M230L to NNRTI and M184V to NRTIs 
within 24 weeks into therapy. These cause high-level resistance to 3TC, FTC, EFV, NVP and 
RPV and intermediate level resistance to ETR and also low-level resistance to ABC. At 36 
weeks into therapy the M230L mutation disappeared leaving the G190A and the M184V 
mutations. Subsequently, patient SRIN106 developed the major NNRTI DRM K103N in 
addition to the NNRTI polymorphism V90I at 24 weeks of therapy and this mutation persisted at 
48 weeks into therapy in addition to the reappearance of the V108I mutation. The V108I and the 
V90I polymorphism persisted from the drug naïve stage until 12 weeks into therapy when the 
V108I mutation disappeared.  Patient SRIN117 had no DRM that affected drug susceptibility. 
Finally patient SRIN120 had the major NNRTI mutation K103N at the drug naïve stage and 
within 24 weeks of therapy, this patient had the NRTI mutation M184V emerging in addition to 
the NNRTI mutation K103N. Both major DRMs K103N and M184V were still present at 48 
weeks of therapy together with minor PI mutations and polymorphisms that were present at the 
drug naïve stage. The specific scenarios above indicate that major DRMs developed during the 
course of HIV infection usually persist a while and may either disappear or lead to multi drug 
DRMs. Also in some instances high viral loads seen in patients undergoing HAART may be due 
to other reasons (for example non- compliance) either than resistance mutations as seen in 
patients SRIN72 and SRIN117.  
 
                 Results  
78 
 
Table 12: Drug resistance profile in plasma samples of HIV-1 infected patients over time 
 
 
DR represents drug resistance; LR represents level resistance Type of template: RNA; Region analyzed: PR 1-99 
codons and RT (2/3) 1-335 codons. Primary resistance mutations are bolded, primary resistance mutations in other 
expert list are bolded and underlined and minor and accessory resistance mutations are italicized. CD4
+
 T-cell 
counts were measured in cells/ul. ND means not determined. 
Low-LR Intermediate-LR  High level-LR
SRIN31 98000 271 CRF02_AG - Like 0
K20I no mutation
2000 ND CRF02_AG - Like 2  K20I no mutation
ND  564 CRF02_AG - Like 4 K20I no mutation
< 40 450 CRF02_AG - Like 12 K20I no mutation
39000 462 CRF02_AG - Like 48  K20I K103N no mutation NVP, EFV
L10V
2600 ND CRF02_AG - Like 72 K103N no mutation NVP, EFV
SRIN48 2400000 147 CRF06_cpx - Like 0 K43T
K201
Y181C K219N EFV,ETR NVP,RPV
9200 ND CRF06_cpx - Like 2 K20I
K43T
Y181C EFV,ETR,RPV NVP
1900 498 CRF06_cpx - Like 12 K20I
K43T
Y181C M184V ABC EFV,ETR,RPV NVP,3TC,FTC
22000 344 CRF06_cpx - Like 36 K20I
K43T
V108I, 
Y181C, 
H221HY
M184V ABC EFV,ETR,RPV NVP,3TC,FTC
6400 310 CRF06_cpx - Like 64 V108I NVP
SRIN72 97000 333 G - Like 0  K20I
V179I
8800 436 G - Like 48  K20I
SRIN98 10000000 63 CRF02_AG - Like 0 K20I no mutation
L10V
1900 498 CRF02_AG - Like 12 K20I no mutation
L10V
40000 217 CRF02_AG - Like 24 K103N NVP, EFV
CRF02_AG - Like 36 K20I
L10V
K103N M184V ABC 3TC,FTC,EFV,NVP
650000 85 CRF02_AG - Like 48 K103N RPV NVP, EFV
E138Q
SRIN103 183000 397  CRF01_AE- like 0 L10V no mutation
V179I
8000 ND  CRF01_AE- like 2 L10V
V179I
900 682  CRF01_AE- like 4 L10V
V179I
15000 608  CRF01_AE- like 12 L10V
K20R
150000 701  CRF01_AE- like 24 L10V G190A M184V ABC ETR 3TC,FTC,EFV,NVP,RPV
M230L
V179I
220000 681  CRF01_AE- like 36 L10V
G190A M184V
ABC, 
ETR, RPV
EFV 3TC,FTC,NVP
V179I
NRTI 
Mutations
Drug Resistance Interpretations Per Resistance Scores
Lab ID
 Viral RNA load 
copies/ml 
CD4
+
T -cell 
counts 
Subtype PR-RT
Weeks of 
follow-up
PI 
Mutations
NNRTI 
Mutation
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Table 12 continued.  
 
 
DR represents drug resistance; LR represents level resistance Type of template: RNA; Region analyzed: PR 1-99 
codons and RT (2/3) 1-335 codons. Primary resistance mutations are bolded, primary resistance mutations in other 
expert list are bolded and underlined and minor and accessory resistance mutations are italicized. CD4
+
 T-cell 
counts were measured in cells/ul. ND means not determined. 
Low-LR Intermediate-LR  High level-LR
SRIN106 3600000 176 CRF02_AG - Like 0 K20I no mutation
V108I NVP
V90I
35000 ND CRF02_AG - Like 2 K20I no mutation
V108I NVP
V90I
ND 353 CRF02_AG - Like 4 K20I no mutation
V108I NVP
V90I
19000 386 CRF02_AG - Like 12 K20I no mutation
V108I NVP
V90I
59000 309 CRF02_AG - Like 24 K20I no mutation
V90I
K103N NVP, EFV
163000 ND CRF02_AG - Like 48 V108I no mutation
V90I
K103N NVP, EFV
SRIN117 90000 341 CRF02_AG  - Like 0 K20I no mutation
8000 409 CRF02_AG  - Like 24 no mutation
SRIN120 1400000 504 CRF02_AG  - Like 0 K20I no mutation
V11I
L10I
K103N NVP, EFV
5000 589 CRF02_AG  - Like 4 K20I no mutation
V11I
L10I
13000 704 CRF02_AG  - Like 24 K20I K103N M184V ABC 3TC,FTC,EFV
V11I
18000 ND CRF02_AG  - Like 36 K20I K103N M184V ABC 3TC,FTC,EFV
V11I
ND ND CRF02_AG  - Like 48 K20I K103N M184V ABC 3TC,FTC,EFV,NVP
V11I
Drug Resistance Interpretations Per Resistance Scores
Lab ID
 Viral RNA load 
copies/ml 
CD4
+
T -cell 
counts 
Subtype PR-RT
Weeks of 
follow-up
PI 
Mutations
NNRTI 
Mutation
NRTI 
Mutations
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3.5 Deep sequencing of thirteen drug naïve patient templates 
Thirteen patients derived HIV-1 RNA and DNA templates from HIV-1 infected drug 
naïve patients were deep sequenced via a process called Nextera tagmentation using PCR 
amplicons. These patients were selected based on the fact that after Sanger sequence analysis, 
they either had differences in DRMs between individual RNA and DNA pairs or had ten or more 
differences in RNA and DNA nucleotide pairs that needed to be confirmed by a more robust 
method. 
3.5.1 Transmitted drug resistance mutations profile of all thirteen drug naïve 
patient paired RNA and DNA templates from deep sequencing 
compared to Sanger sequencing. 
In deep sequencing, mutational frequencies were given for TDRMs from 1 to 100% 
frequency cut-offs (Table 13). Minority variants were classified as TDRMs detected at a 
frequency of 1% to less than 20% of the viral quasispecies (Colson et al., 2014). The minority 
variants represented TDRMs, which could not be detected via Sanger sequencing but were 
detected in deep sequencing. Sanger sequencing only detected mutations occurring in deep 
sequencing, at a frequency of 20% or higher, while deep sequencing detected mutations at all 
frequencies from 1 to 100%. In deep sequencing, the coverage per nucleotide position for each 
patient sample was between 20,000-10,000 reads and the number of reads for each patient RNA 
or DNA template was approximately 200,000 reads unlike in Sanger sequencing where the 
templates were read only once as described by (Chabria et al., 2014). Of the thirteen paired 
patient templates, ten harboured TDRMs to PIs and RTIs at frequencies defined as minority 
variants whereas in the previous Sanger sequencing these mutations were not seen.  The 
additional mutations detected in only deep sequencing as minority variants and not in Sanger 
sequencing were D30N, I47V and G73S to PIs and mutations to RTIs included K103N, T69D, 
M230I, M184I, E138K, K101E, V179I, V90I and F22FL (Table 13). Above the frequency of 
20%, all DRMs detected by deep sequencing were also detected by Sanger sequencing. 
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Deep sequenced viral RNA and DNA templates were compared for concordance or 
discordance in terms of detecting DRMs within paired sequences by frequency, as shown in table 
13. We defined concordance as the identification of a mutation in both paired viral RNA and 
DNA templates at a frequency of 20% and above (also the range for Sanger sequencing) or 
below 20% for the minority viral population in deep sequencing. Discordance on the other hand 
was defined as the inability of identifying a mutation at a frequency of 20% and above or below 
20% in either viral RNA or DNA templates. The detection limit for all mutations considered was 
a frequency of 1-100%. What defined discordance was the ability of the mutation being picked 
up in one template and not in the other. Since Sanger sequencing only detects mutations at a 
frequency of 20% or higher, we decided to assess how DNA and RNA detection compared with 
each other above 20%. We observed a high level of concordance (95%) between DNA and RNA 
pairs for mutation frequencies 20% and above. Discordance observed in this group was only 5%. 
Also we assessed the same concept of discordance or concordance in paired RNA and DNA 
sequences in the minority viral population at a frequency below 20%, in contrast to mutation 
frequencies 20% and above, there was a high rate of discordance (74%) in paired RNA and DNA 
samples in the minority viral population with a percentage concordance of 26%. 
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Table 13: Detection of drug resistance mutations from thirteen drug naïve patient RNA/DNA template pairs 
via frequency cut-offs in deep sequencing  
  
Freqency cut-offs of DRMs from 1% to less than 20% of the viral quasispecies represent minority variants while  
frequency cut-offs from 20% to 100% represent majority variants, which are also detected by Sanger or bulk 
HIV-1 target region Type of DRM
SRIN16-RNA SRIN16-DNA
PR K20I 100 100
PR L89M 99 99
RT V189I 42
SRIN31-RNA SRIN31-DNA
PR K20I 100 100
PR D30N 1
PR M46I 2 3
PR L89I 3
PR L10V 37 33
PR L89M 96 99
RT V189I 5
RT M230I 6
SRIN33-RNA SRIN33-DNA
PR I47V 3
PR V11I 4
PR K20I 100 100
PR L10V 65 100
PR L89M 99 99
SRIN38-RNA SRIN38-DNA
PR L89M 78 100
PR K20I 100 100
RT M184I 1
SRIN39-RNA SRIN39-DNA
PR M46I 11
PR V82I 100 100
PR L89I 2
PR L89M 97 99
PR K20I 100 100
RT M230I 15
SRIN48-RNA SRIN48-DNA
PR K43T 99 100
PR K20I 100 99
PR L89M 99 100
RT K219N 2 27
RT K103N 1
RT Y181C 63 57
SRIN56-RNA SRIN56-DNA
PR K20R 2
PR L89I 34 17
PR L10V 73 35
PR K20I 99 97
PR L89M 65 83
RT E138K 2
RT V179I 9 9
RT K101E 4
RT M184I 4
RT M230I 8
Frequencies of DRM in patient template (%)
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sequencing. Empty cubicles represent DRMs in less than 1% frequency cut-off  of the virus population. Here 
frequency values are not shown.  
 
Table 13 continued. 
 
 
HIV-1 target region Type of DRM
SRIN58-RNA SRIN58-DNA
PR I47V 2
PR L89I 18 5
PR K20I 100 100
PR V11I 16 6
PR L10V 74 74
PR L89M 81 95
RT V90I 10 6
RT F227L 1
SRIN78-RNA SRIN78-DNA
PR V11I 1
PR K20I 99 100
PR L89M 27
RT D67N 1
RT M230I 1
SRIN86-RNA SRIN86-DNA
PR L10V 2 2
PR L10I 97 98
PR K20I 99 99
PR L89M 99 100
SRIN93-RNA SRIN93-DNA
PR G73S 1
PR K20I 100 100
PR L10V 35 8
PR L89M 99 99
RT M184I 2
RT M230I 2
SRIN94-RNA SRIN94-DNA
PR K20R 89 96
PR L89I 18 15
PR L10V 89 100
PR L10I 11
PR K20I 32 12
PR L89M 81 84
RT V90I 88 100
SRIN95-RNA SRIN95-DNA
PR V11I 1
PR K20I 98 99
PR L10I 98 99
PR L89M 99 99
RT T69D 1
RT V90I 26 6
RT E138K 2
Frequencies of DRM in patient template (%)
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3.5.2 Comparison of RNA and DNA templates of thirteen selected samples 
using bulk or Sanger and deep sequencing data at the 20 percent cut-off 
Bulk sequencing detected differences in mutations among RNA and DNA templates of five 
patients, which were later, confirmed by deep sequencing. These patient templates were part of 
the thirteen paired patient samples that were deep sequenced. Deep sequencing results confirmed 
the differences in resistance mutations seen in bulk sequencing as indicated in table 14. One 
mutation, the K219N mutation, seen in DNA and not in RNA templates of patient derived HIV-1 
sequences in Sanger sequencing was also confirmed in deep sequencing. In Sanger sequencing, 
two minor mutations and two polymorphisms were found in RNA that were not present in DNA. 
These were the PI mutation L89I and the RTI mutation V90I and the PI polymorphisms K20I 
and L10V respectively. The same pattern was also seen in deep sequencing thereby showing that 
at a frequency of 20%, mutation profiles of both deep and Sanger sequencing are the same. 
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Table 14: Differences and similarities in mutations between RNA and DNA templates of thirteen selected 
drug naïve patients using Sanger and deep sequencing data at a 20 percent frequency cut-off. 
 
Brown coloured sections with grey colours within represent the five patient templates that showed one or more 
different mutations in RNA or DNA templates in Sanger and deep sequencing. Green and yellows coloured sections 
represent sequences, which had the same mutations in RNA and DNA templates. 
 
 
 
 
 
Deep Sequencing 20% Variants
SRIN16 RNA K20I no mutation K20I no mutation
DNA K20I no mutation K20I no mutation
SRIN31 RNA K20I no mutation K20I
DNA K20I no mutation K20I
SRIN33 RNA L10V no mutation L10V no mutation
K20I K20I
DNA L10V no mutation L10V no mutation
K20I K20I
SRIN38 RNA K20I no mutation K20I no mutation
DNA K20I no mutation K20I no mutation
SRIN39 RNA V82I no mutation V82I no mutation
K20I K20I
DNA V82I no mutation V82I no mutation
K20I K20I
SRIN48 RNA K43T K43T
K201 K201
Y181C Y181C
DNA K43T K43T
K201 K201
Y181C Y181C
K219N K219N
Sanger Sequencing
PI Mutations
NNRTI 
Mutations
NRTI 
Mutations
PI Mutations
NNRTI 
Mutations
NRTI 
Mutations
Lab ID
Type of  
Template
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Table 14 continued 
SRIN56 RNA K20I no mutation K20I no mutation
L10V L10V
L89I L89I
DNA K20I no mutation K20I no mutation
L10V L10V
no mutation no mutation
SRIN58 RNA K20I no mutation K20I no mutation
L10V L10V
DNA K20I K20I
L10V no mutation L10V no mutation
SRIN78 RNA no mutation no mutation
DNA no mutation no mutation
SRIN86 RNA L10I no mutation L10I no mutation
K20I K20I
DNA L10I no mutation L10I no mutation
K20I K20I
SRIN93 RNA  K20I V90I  K20I V90I
L10V L10V
DNA K20I V90I K20I V90I
no mutation no mutation
SRIN94 RNA  K20I  K20I
L10V L10V
V90I V90I
DNA no mutation no mutation
L10V L10V
V90I V90I
SRIN95 RNA  K20I K20I
L10I L10I
V90I V90I
DNA  K20I  K20I
L10I L10I
no mutation no mutation
NRTI 
Mutations
Lab ID
Type of  
Template
PI Mutations
NNRTI 
Mutations
NRTI 
Mutations
PI Mutations
NNRTI 
Mutations
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3.5.3 Patterns of synonymous and non-synonymous nucleotide differences 
compared among individual subjects from the thirteen HIV-1 infected 
drug naïve patients, at various sensitivity cut-offs in deep and bulk 
sequencing 
Heterogeneity in RNA/DNA sequence pairs were assessed by aligning nucleotide 
sequence pairs of RNA/DNA in each of the 13 patient sequences for deep sequencing sensitivity 
cut-offs of 1, 2, 5, 10 and 20% and also in Sanger or bulk sequencing sensitivity cut-off which is 
usually 20%. In all deep sequencing sensitivity cut-offs, more non-synonymous nucleotide 
changes were recorded for twelve patients (SRIN16, 31, 38, 39, 48, 56, 58, 78, 86, 93, 94 and 95) 
except one (SRIN 33), who had more synonymous nucleotide changes than non-synonymous 
changes (figure 14A, 14B, 14C and 14D). In the case of bulk or Sanger sequencing, eight 
patients (SRIN16, 33, 39, 78, 86, 93, 94 and 95) had more non-synonymous nucleotide changes 
then synonymous changes, two (SRIN31, 38), had more synonymous nucleotide changes and the 
remaining three patients, (SRIN48, 56, 58), had equal number of synonymous and non-
synonymous changes (figure 14E).  
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Figure 14: Bar charts depicting synonymous and non-synonymous nucleotide differences in RNA and DNA 
templates of individual patients from the list of thirteen drug naive patient sequences as seen in both deep and 
bulk or Sanger sequencing of amplified PCR products.  
In deep sequencing the cut-offs include 1, 2, 5, 10 and 20% and in Sanger or bulk sequencing the cut-off is 
approximately 20%. Synonymous nucleotide changes are indicated as blue bars and non-synonymous 
nucleotide changes are shown as red bars.  
3.5.4 Statistical evaluation of the pattern of synonymous and non-
synonymous nucleotide differences compared among various cut-offs in 
deep and bulk sequencing 
Nucleotide differences examined within each paired sequence of viral RNA and DNA 
of the thirteen drug naïve patient samples indicated that, at the one percent cut-off in deep 
sequencing, synonymous and non-synonymous nucleotide changes were significantly different 
(p=0.0003), with approximately two-fold increase in the number of nucleotide changes seen 
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between the synonymous and the non-synonymous groups. The same pattern of fold increase 
was observed in the five percent (p=0.0003), ten percent (p=0.0004) and twenty percent 
(p=0.0003) cut-offs. On the contrary, the difference between synonymous and the non-
synonymous nucleotide differences seen in bulk or Sanger sequencing did not reach statistical 
significance (p=0.23) although more non-synonymous nucleotide differences were present in 
bulk sequencing of paired viral RNA and DNA sequences as compared to synonymous 
nucleotide differences. The non-synonymous group had more nucleotide differences than the 
synonymous group in all cut-offs in deep sequencing and also in bulk or Sanger sequencing 
(figure 15). Statistical significance was attained between all synonymous and non-synonymous 
differences for all deep sequencing cut-offs with more non-synonymous differences seen in each 
instance.  This indicates that The heterogeneity seen within RNA/DNA template pairs, most 
likely lead to more divergence in the amino acid sequence of the protein structure. The results 
indicate that synonymous differences that generally conserve the protein structure were less 
frequently seen in deep sequencing. Also minority mutations existed that could not be 
determined with bulk sequencing. 
Table 15 also gives the summary of nucleotide differences as observed in all thirteen 
patient samples. It indicates the number of synonymous and non-synonymous differences in each 
cut–off and shows the median and the IQR for each cut-off. The number of nucleotide 
differences in bulk sequencing either synonymous (132 nucleotide differences) or non-
synonymous (173 nucleotide differences) was higher than differences observed in all the other 
cut-offs in deep sequencing although the synonymous and non-synonymous differences when 
compared within patient RNA/DNA pairs were not statistically significant. Noticeably non-
synonymous nucleotide differences at the 20% cut-off in deep (170 nucleotide differences) and 
bulk sequencing (173 nucleotide differences) were similar, with median and IQRs of 12 (9.5-
13.5) and 10 (8-20) respectively. However, with respect to synonymous changes the values were 
quite different. In the 20% cut-off in deep sequencing, 81 nucleotide differences were seen, 
while in bulk sequencing 132 nucleotide differences were present. The mean and IQRs of 
synonymous differences for the 20% cut-off in deep and bulk sequencing were 4 (1.5-7) and 6 
(2-19) respectively. There was nearly two times more synonymous differences seen in bulk 
sequencing at a cut-off of 20% as compared to the same sensitivity cut-off in deep sequencing 
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indicating that, there was more heterogeneity in bulk sequenced samples at the 20% cut-off 
compared to deep sequencing probably due to the high degree of sensitivity in deep sequencing 
although these changes are ones that maintain protein structure since they do not lead to a change 
in the amino acid sequence. One reason for the heterogeneity seen in bulk sequencing data may 
be because it is read only once while deep sequenced data is read many times. 
 
Figure 15: Column plots depicting differences in synonymous and non-synonymous nucleotide differences 
among the thirteen drug naïve HIV-1 infected patients.  
One percent cut-off in deep sequencing represents codons occurring at a frequency of 1 to 100% within each 
patient derived viral sequence. Five percent cut-off represents codons at a frequency of 5 to 100% of patient 
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derived viral sequences. Ten and 20% cut-offs denote codons from 10 to 100% and from 20 to 100% 
respectively within each patient derived viral sequence. Bulk or Sanger sequencing represents patient derived 
viral sequences occurring at a frequency of approximately 20 to 100% of patient derived viral sequences 
(Chabria et al., 2014). P values of synonymous and non-synonymous nucleotide changes between the same 
cut-offs are indicated on the graph. A one-way ANOVA showed that values of synonymous and non-
synonymous nucleotide changes were different (p< 0.001). 
Table 15: Summary of nucleotide substitution analysis for thirteen drug naïve patient derived viral sequences 
via deep and bulk sequencing  
 
3.6 Quantification of HIV-1 intracellular DNA of drug naïve patient 
samples using patient derived HIV-1 and CCR5 plasmid 
standards  
Total HIV-1 IC DNA that has completed the first and second template switches also 
called HIV-1 STS DNA were measured from DNA samples of drug naïve patients using a real-
time PCR assay. This was done to investigate any correlations existing between HIV-1 IC DNA 
levels of infected patients and primary markers of disease progression, mainly plasma RNA viral 
load, and CD4+ T –cell count as well as correlations with other surrogate markers of disease 
progression. 
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3.6.1 Real-time PCR assay characteristics of HIV-1 intracellular DNA and 
CCR5 plasmid standards  
           Patient derived target HIV-1 IC DNA also called HIV-1 STS DNA and CCR5 
PCR amplicons were successfully cloned into topo plasmids. The plasmids were further used to 
generate HIV-1 IC DNA and CCR5 DNA standards for the quantifications of all drug naïve 
patients DNA. HIV-1 IC DNA and CCR5 DNA inserts were 165 and 237 nucleotides in length. 
There was a 99% identity of the patient derived CCR5 DNA insert to human CCR5 reference 
sequences in the National Center for Biotechnology Information (NCBI) Database 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi).  The HIV-1 IC DNA insert starts from the end of 
U5 to just before the gag sequence as shown in figure 16. 
Figures 17A and 17B are the standard curves generated from the real- time PCR assays 
showing the quantifications of the HIV-1 IC DNA and CCR5 copies respectively. The specificity 
of the HIV-1 IC DNA assay was determined by accurately detecting 10 HIV-1 IC DNA copies 
with a qPCR dynamic range of 1x101 to 1x106 DNA copies. The sensitivity for CCR5 was 
determined by detecting 1000 CCR5 DNA copies accurately with a dynamic range of 1x103 to 
1x108 DNA copies.  The slopes of the standard curves were -3.3 cycles/log10 DNA templates for 
the HIV-1 IC DNA assay and that for the CCR5 assay was -3.4 cycles/log10 DNA templates. 
These slopes corresponded to PCR efficiencies of greater than 99.99% for both HIV-1 IC DNA 
and CCR5 assays. The optimum temperatures for the annealing and data collection of the HIV-1 
IC DNA and CCR5 assays were optimized to 62°C and 60°C respectively. 
The ability of the HIV-1 IC DNA assay to detect the M group HIV-1 strains was 
demonstrated by the assay’s potential to quantify the HIV-1 IC DNA of all HIV-1 drug naïve 
patients DNA samples from Nouna Burkina Faso with HIV-1 genetic subtypes G, 02A1 and 
recombinants CRF01_AE, CRF02_AG and CRF06_cpx (Demetriou et al., 2010).  
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Figure 16: Schematic representation of the patient derived HIV-1 STS DNA insert sequence, within the HIV-
1 Genome.  
The red mark shows the location of the sequence within the HIV-1 genome. The figure shows that the target 
starts from the end of U5 to just before the gag sequence with a sequence length of 165 nucleotides. The gene 
map was obtained from the HIV Los Alamos database (http://www.hiv.lanl.gov/cgi-
bin/QUICK_ALIGNv2/convent.cgi). 
 
       A                                                                          B 
 
Figure 17: Standard curves used for the HIV-1 IC DNA and CCR5 DNA quantifications.  
(A) A scatter plot representing HIV-1 STS DNA plasmid standard curve (B) A scatter plot 
representing human CCR5 DNA plasmid standard curve. Both curves had a co-efficient of 
determination r2 > 0.99 and were both generated from molecular beacon real-time PCRs. 
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3.6.2 Specificity of binding of HIV-1 IC DNA primers and molecular-beacons 
to the target template  
The assay specificity of the forward and reverse primer sets and the target specific molecular-
beacon to the HIV-1 IC DNA was tested against HIV negative human DNA using a molecular-
beacon-real-time qPCR approach. The real-time qPCR showed no detectable HIV-1 IC DNA in 
the HIV-1 negative human DNA under the regular HIV-1 IC DNA qPCR conditions of 40 
cycles. Figures 18A and 18B demonstrates the standard curves obtained from the HIV-1 DNA 
standard mixed with the HIV negative human DNA and the HIV-1 IC DNA standard only. In 
both cases the PCR efficiencies were >99%. The HIV negative human DNA only real-time 
qPCR assay gave no cycle threshold value after 40 qPCR amplification cycles.  
 
         A                                                                            B 
 
Figure 18: A scatter plot representing the specificity of binding of HIV-1 STS DNA primers and beacons to 
the plasmid standard in the presence of an HIV negative human DNA control.  
(A) HIV-1 STS DNA plasmid standard only. (B) HIV-1 STS DNA plasmid standard mixed with the HIV 
negative human DNA or non-template control (NTC).  Tenfold serial dilutions of the purified plasmid and 
NTC of known concentrations were used as templates to generate the standard curves for the qPCR assay. 
HIV negative human DNA of known concentrations corresponding to 10
6
 HIV DNA copies contained 96 ng of 
DNA and five more dilution points were obtained. The last dilution point corresponding to 10 HIV DNA 
copies contained 9.6 x 10
-4 
ng of HIV negative human DNA. 
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3.7 Distribution of HIV-1 IC DNA load among HIV -1 drug naïve 
patients 
The HIV-1 IC DNA load and CCR5 copy numbers were determined for all 86 HIV-1 
infected drug naïve patient DNA samples from Nouna Burkina Faso. The HIV-1 IC DNA load 
for each patient was expressed as per 1 million buffy coat cells. The number of cells in the input 
DNA used for the quantification of HIV-1 IC DNA was determined from the CCR5 copy 
number, which is known to exist as two copies in a cell (Samson et al., 1996).   
According to Figure 19, all patient HIV-1 IC DNA load per 1 million cells were 
mainly between 100 to 1,000 copies/106 cells 50 (58%) followed by 1,000 to 10,000 copies/106 
cells 22 (26%). The median log10 transformed HIV-1 IC DNA copies/ 10
6 cells was 2.645 
copies/ 106 cells (IQR 2.259-3.055). 
 
 
Figure 19: A skewed curve showing HIV-1 STS DNA load among HIV -1 infected drug naïve patients from 
Nouna Burkina Faso.  
The HIV-1 STS DNA load of patients was mainly between 100 and 1,000 copies/10
6
 cells. The HIV-1 STS 
DNA load was calculated as HIV-1 STS DNA copies per 1million buffy coat cells. The total number of patient 
samples analyzed was 86 and the median log10 transformed HIV-1 IC DNA load was 2.645 (IQR 2.2596 – 
3.055).   
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3.8 Correlation of HIV-1 intracellular DNA load on known markers 
of disease progression  
This section describes the correlation of HIV-1 IC DNA load and plasma viral load, 
CD4+ T -cell counts and CDC clinical staging, based on CD4+ T -cell counts of drug naive 
patients. 
3.8.1 HIV-1 intracellular DNA load correlated with plasma viral load and 
CD4
+
 T-cell counts 
A potential correlation between HIV-1 IC DNA load and plasma viral load and that 
between HIV-1 IC DNA load and CD4+ T -cell counts were assessed among all drug naïve 
patients as shown in figures 20A and 20B. In figure 20A there was no correlation between HIV-1 
IC DNA load and plasma viral load (r2=0.0032; p=0.6077). Also in figure 20B there was no 
significant correlation between HIV-1 IC DNA load and CD4+ T-cell count (r2=0.0172; 
p=0.2292). The individual patient values used in the correlation are shown in table 16. 
 
 
Figure 20: Correlations of HIV-1 STS DNA load against plasma viral load and CD4
+
 T –cells among HIV-1 
infected drug naive patients from Nouna Burkina Faso.  
(A) Correlation of plasma viral load/ml of plasma against HIV-1 STS DNA load/10
6
 cells, (B) Correlation of 
CD4
+
T -cells/ml of blood against HIV-1 STS DNA load/10
6
 cells. At 95% confidence interval, there was no 
correlation between HIV-1 STS DNA and plasma viral load and HIV-1 STS DNA and CD4
+
 T-cell counts 
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Table 16: HIV-1 STS DNA, CD4
+
 T-cell counts and plasma viral load values of drug naïve patients used for 
correlations 
 
 
 
 
Lab ID HIV DNA Copies/ 10^6 Cells
SRIN14 373.96
SRIN15 59.47
SRIN16 1703.59
SRIN25 2662.58
SRIN30 112.14
SRIN31 99.10
SRIN32 759.81
SRIN33 204.31
SRIN34 322.99
SRIN37 794.99
SRIN38 1142.02
SRIN39 66.23
SRIN41 1964.83
SRIN47 567.88
SRIN48 766.43
SRIN51 129.96
SRIN52 348.33
SRIN55 48.01
SRIN56 4107.70
SRIN57 110.11
SRIN58 414.57
SRIN59 940.93
SRIN60 199.34
SRIN61 702.55
SRIN62 989.57
SRIN63 130.27
SRIN64 306.21
SRIN65 171.00
SRIN66 1103.67
SRIN67 470.74
SRIN68 2158.53
SRIN69 46.95
SRIN70 223.52
SRIN71 365.78
SRIN72 445.47
SRIN73 856.60
SRIN74 206.62
SRIN75 263.20
SRIN76 1210.15
SRIN77 154.99
SRIN78 23216.97
SRIN79 19.22
SRIN80 86.45
SRIN81 1091.12
SRIN82 963.52
SRIN83 80.76
CD4 count/ml of blood Viral load/ml of plasma
202000 939988
7000 971579
10000 707181
152000 54837
163000 89125
271000 98426
177000 430515
180000 3399058
3000 2801732
172000 707210
248000 223957
262000 115615
144000 2314931
66000 743697
147000 2416935
122000 722623
153000 194086
227000 93865
81000 1593082
198000 653455
231000 256724
230000 1229920
226000 121581
284000 749061
180000 2005003
316000 86731
193000 677363
32000 145511
140000 227199
293000 1195067
411000 2201354
418000 515487
13000 46747
256000 325435
333000 95911
157000 1818940
7000 40625
247000 13291
177000 51695
123000 45750
269000 24482
256000 11678
152000 23449
323000 590908
140000 569328
279000 43140
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Table 16 continued 
 
Lab ID HIV DNA Copies/ 10^6 Cells
SRIN84 1531.37
SRIN85 187.71
SRIN86 249.71
SRIN87 437.89
SRIN88 185.29
SRIN89 101.39
SRIN90 255.56
SRIN91 425.18
SRIN92 117.75
SRIN93 1456.33
SRIN94 61.46
SRIN95 310.80
SRIN96 129.41
SRIN97 209.51
SRIN98 1431.20
SRIN99 936.53
SRIN100 475.62
SRIN101 572.97
SRIN102 2096.61
SRIN103 3679.25
SRIN105 265.99
SRIN106 701.95
SRIN107 321.07
SRIN108 71.18
SRIN109 1134.23
SRIN110 661.71
SRIN111 529.86
SRIN112 1717.59
SRIN113 472.80
SRIN114 35.59
SRIN116 58.90
SRIN117 410.15
SRIN118 12586.42
SRIN119 1529.91
SRIN120 4701.27
SRIN121 811.20
SRIN122 1330.56
SRIN123 7585.02
SRIN124 1792.91
SRIN125 3856.28
CD4 count/ml of blood Viral load/ml of plasma
156000 15793
215000 1434896
146000 2233224
65000 4040062
45000 574163
54000 677363
236000 1379797
66000 977237
282000 561916
643000 10000000
116000 10000000
7000 10000000
90000 1892979
106000 1581674
63000 10000000
322000 10000000
292000 71380
408000 339531
88000 3790705
397000 182608
218000 98211
176000 3589550
406000 290269
232000 27833
313000 405359
44000 1420627
212000 236592
213000 1373030
11000 1803350
349000 21777
508000 262060
341000 90498
279000 2579
364000 272998
504000 1400866
281000 224037
170000 1531228
301000 976517
467000 225569
33000 1126782
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3.9 Correlation of HIV-1 intracellular DNA load with plasma viral 
load and CD4
+
 T-cell counts based on CDC clinical Stage B of 
the disease 
The relationship between HIV-1 IC DNA load, plasma viral load and CD4+ T-cell 
counts was assessed among HIV-1 infected drug naïve patients based on the Centers for Disease 
Control and Prevention (CDC) clinical Stage B of the disease as depicted in figures 21A and 
21B. Correlations were considered based on CDC clinical disease stage because it was important 
to find out if HIV-1 IC DNA had any effect on disease staging. Clinical stage B was correlated 
with HIV-1 IC DNA levels at baseline because almost all the patients with clinical stating status 
recorded were in clinical stage B (n=56) except one patient who was in clinical stage A (table 8) 
There was no correlation between HIV-1 IC DNA load and plasma viral load (r2=0.0020; 
p=0.7429) and between HIV-1 IC DNA load and CD4+ T-cell counts (r2=0.0119; p=0.4242). 
   
 
Figure 21: HIV-1 STS DNA load based on CDC Staging of disease against plasma viral load and CD4
+
 T- 
cells among drug naïve patients.  
(A) An XY correlation between plasma viral load/ml of plasma and HIV-1 STS DNA load/106 
cells based on CDC clinical Stage B (B) An XY correlation between CD4+ T-cell counts/ml of 
blood against HIV-1 STS DNA load/106 cells. 
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3.10 Assessing disease progression after six months of therapy based 
on HIV-1 intracellular DNA levels 
3.10.1 Comparison of HIV-1 IC DNA levels in patients with virologic failure 
at twenty four weeks of therapy 
In assessing disease progression based on baseline HIV-1 DNA levels, follow-up 
patients were grouped into those who achieved virologic suppression under HAART and those 
who had virologic failure. Virologic failure was defined as viral RNA levels of ≥ 1,000 copies/ 
ml of plasma detected in follow-up patient samples after 24 weeks or 6 months of HAART and 
virologic suppression was defined as the attainment of viral RNA levels of  < 1,000 copies/ ml of 
plasma detected in follow-up patient samples after 24 weeks or 6 months under HAART 
(Dionisio et al., 2001). The baseline HIV-1 IC DNA load of patients who experienced virologic 
failure at twenty-four weeks of therapy (n=5) was compared to that of those who experienced 
virologic suppression (n=55). There was a significantly higher baseline HIV-1 IC DNA load 
among patients who experienced virologic failure than those who did not (p=0.045).  The 
corresponding median levels were 3.16 log10 copies/10
6 cells (IQR 2.75- 3.62) and 2.63 log10 
copies/106 cells (IQR, 2.12 -3.04) respectively (figure 22). 
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Figure 22: HIV-1 STS DNA levels of patients experiencing virologic failure and those with no virologic 
failure, 24 weeks post HAART. Comparisons of plasma viral levels of infected patients with and without 
virologic failure 
The plasma viral load and CD4+ T-cell counts of patients experiencing virologic failure 
and those in whom viral suppression was achieved were compared at the drug naïve stage and at 
24 weeks of therapy. At the drug naïve stage, the results showed no difference in viral load and 
CD4+ T-cell counts between patients who experienced virologic suppression post therapy and 
those who had virologic failure (figure 23C and 23D). The median viral load levels/ ml of 
plasma among those who had virologic failure and those who did not were 6.15 log10 (5.14-6.83) 
and 5.82 log10 (4.97-6.16) respectively. The median CD4
+ T-cell counts were 5.53 log10 (5.08-
5.65) and 5.26 log10 (5.09-5.43) respectively between the two groups of patients. However, at 24 
weeks into therapy, there was a strong difference in plasma viral load (approximately 2.5 log10 
difference, p<0.001) observed among patients who achieved virologic suppression and those 
who did not (figure 23A). The median viral load levels were 4.11 log10 (IQR 3.41-5.02) and 1.60 
log10 (IQR 1.60-1.99) respectively. On the contrary, there was no significant difference observed 
in CD4+ T-cell counts among these patients (figure 23B). The median CD4+ T-cell count at 24 
weeks of therapy was 5.53 log10 (5.37-5.60) and 5.61 log10 (5.48-5.85) among patients who 
experienced virologic suppression and those who had virologic failure respectively. 
          Results  
104 
 
 
Figure 23: Plasma viral load and CD4
+
 T-cell counts comparisons among patients experiencing virologic 
failure and those who achieved virologic suppression after 24 weeks on HAART.  
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3.11 Influence of other factors associated with HIV-1 disease 
progression on HIV-1 intracellular DNA load 
This section describes the influence of other factors associated with disease 
progression such as the presence or absence of hepatitis B (HBV) co-infection, number of DRMs 
that have an impact on drug susceptibility, predominant HIV-1 subtypes, age Hb levels and the 
presence or absence of secondary bacterial or parasitic infections (opportunistic infections) on 
HIV-1 IC DNA load.   
3.11.1 Hepatitis B co-infection 
 In figure 24A, there is a trend towards a higher HIV-1 IC DNA load among drug 
naïve patients with HBV co-infection as compared to those without HBV co-infection but this 
difference did not reach statistical significance (p= 0.1496). As illustrated in figure 24B and 24C, 
there was no difference in baseline CD4+ T-cell counts (p= 0.6806) and plasma viral load levels 
(p= 0.3638) in drug naïve patients with HBV co-infection and those without HBV co-infection.  
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Figure 24: Hepatitis B co-infections among drug naïve patients.  
Boxes and whiskers of (A) HIV-1 STS DNA load levels (p= 0.1496), (B) CD4
+
 T-cell counts (p= 0.6806) and 
(C) Plasma viral load (p= 0.3638) among drug naïve patients with HBV co-infection and those without HBV 
co-infection. 
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3.11.2 Age, predominant HIV-1 subtypes, number of mutations and 
hemoglobin levels 
Figure 25A shows an analysis that assessed the relationship between HIV-1 IC DNA levels and 
the age of drug naïve patients in years. There was no correlation between HIV-1 IC DNA load 
and the age of patients (r2= 0.0224; p= 0.1692). Using the Kruskal-Wallis test, differences in 
HIV-1 IC DNA levels among drug naïve patients having predominant HIV-1 subtypes namely 
CRF02_AG, CRF06_cpx and CRF01_AE were analyzed and there was no significant difference 
(p=0.8162) seen between all subtypes compared (Figure 25B). We proceeded to determine the 
variances of HIV-1 IC DNA levels between subtypes using the Bartlett's test for equal variances 
as shown in table 17 and demonstrated that, the spread of HIV-1 IC DNA levels between HIV-1 
subtypes analyzed are unequal (p<0.0001). There was no relationship (r2= 0.1056; p= 0.4323) 
between HIV-1 IC DNA and number of mutations affecting drug susceptibility as shown in 
figure 25C.  
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Figure 25: HIV-1 STS DNA load compared with age of patients, virus subtype and number of DRMs.  
(A) A correlation of HIV-1 STS DNA load against age of drug naïve patients, (B) A box and whisker plot of 
HIV-1 STS DNA load with the predominant HIV-1 subtypes and (C) A correlation of HIV-1 STS DNA load 
to number of mutations affecting drug susceptibility. 
 Table 17: The Bartlett's test for equal variances among predominant HIV-1 subtypes 
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3.12 Comparison of HIV-1 intracellular DNA load, plasma viral 
load and CD4
+
 T-cell counts of susceptible and resistant HIV-1 
strains among drug naïve patients 
These consisted of drug naïve patients harbouring drug sensitive strains (n=75) or drug resistant 
strains (n=8) of HIV-1. In figures 26A, 26B and 26C, there were no significant differences in 
terms of HIV-1 IC DNA load (p=0.2633), viral load (p=0.3585) and CD4+ T-cell counts 
(p=0.0723) among drug resistant and drug sensitive strains of HIV-1 infected drug naïve 
patients. 
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Figure 26: Vertical scatter plots of HIV-1 STS DNA load, plasma viral load and CD4
+
 T-cell counts of drug 
resistant and drug sensitive strains of HIV-1 infected drug naive patients from Nouna Burkina Faso.  
The numbers of patient samples analyzed were 83. (A) HIV-1 STS DNA load in drug resistant and drug 
sensitive strains. The median log10 transformed HIV-1 STS DNA/10
6
 cells and IQR in resistant and sensitive 
strains were 2.961 (IQR 2.298- 3.515) and 2.618 (IQR 2.233- 3.058) respectively, (B) Plasma viral load in drug 
resistant and drug sensitive strains. The median log10 transformed viral load and IQR in resistant and 
sensitive strains were 5.881 (IQR 5.445- 6.324) and 5.634 (IQR 4.982- 6.185) respectively and (C) CD4
+
 T-cell 
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counts in drug resistant and drug sensitive strains. The median log10 transformed CD4
+
 T-cell counts and IQR 
in resistant and sensitive strains were 5.489 (IQR 5.187- 6.5.593) and 5.297 (IQR 4.954- 5.446) respectively.  
3.12.1 Categorization of HIV-1 intracellular DNA load plasma with plasma 
viral load and CD4
+
T -cells among HIV-1 drug resistant and drug 
sensitive patients by CDC clinical staging  
A total number of 57(98%) drug naïve patients had their CDC clinical staging recorded 
and among these patients, 56 were within the clinical stage B and only 1(2%) patient was within 
the clinical stage A category. This section of the analysis was done with only clinical stage B 
patients as a dominant group to determine whether clinical staging of HIV-1 influences baseline 
HIV-1 IC DNA levels, CD4+ T-cell counts and plasma viral load among drug resistant and drug 
susceptible strains of HIV. These patients were divided into two groups namely the drug resistant 
group and the drug sensitive group. A column plot was then used to assess the two groups with 
respect to their HIV-1 IC DNA copies/106 cells, plasma viral load/ml of plasma and CD4+ T-cell 
counts/ml of blood as indicated in figures 27A, 27B and 27C respectively. The median HIV-1 IC 
DNA values among resistant and sensitive strains were 2.885 (IQR 1.948- 3.040 log10 copies /10
6 
cells) and 2.493 (IQR 2.114- 2.984 log10 copies /10
6 cells) respectively. The median plasma viral 
load copies for resistant and sensitive viruses were 5.712 (IQR 5.1959- 6.177 log10 copies /ml of 
plasma) and 5.815 (IQR 4.982- 6.202 log10 copies /ml of plasma) respectively. Finally the 
median CD4+ T-cell counts/ml of blood among resistant and sensitive virus groups was 5.500 
(IQR 5.157- 5.569 log10 CD4
+ T-cell counts/ml of blood) and 4.501 (IQR 4.214- 4.698 log10 
CD4+ T-cell counts/ml of blood) respectively. According to figure 27C, resistant strains had 
significantly higher CD4+ T-cell counts as when compared to drug sensitive patents (p=0.0003). 
No significant changes were observed in HIV-1 IC DNA loads and plasma viral load of drug 
resistant and drug sensitive strains as shown in figures 27A and 27B. 
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Figure 27: Column plots of HIV-1 STS DNA load against plasma viral load and CD4
+
 T-cell counts of drug 
resistant and drug sensitive strains using CDC clinical stage B patients only.  
(A) HIV-1 STS DNA load of drug resistant and drug sensitive strains (B) Plasma viral load in drug resistant 
and drug sensitive strains (C) CD4
+
 T-cell counts in drug resistant and drug sensitive strains.  
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3.13 Principal component analysis for disease progression among 
drug naïve patients 
Principal component analysis (PCA) is a data reduction method used when one has 
several related variables that measure different aspects of a common component (Vyas and 
Kumaranayake, 2006) in our case disease progression. In PCA, one comes up with a measure 
that holistically describes the different variables forming the component.  It is used to transform 
a set of related data into a set of linearly unrelated components in which the first component 
gives the most variance or the largest variability existing in the data. Patients’ experimental and 
biodata were extracted for the analysis. The indicators used to explain PCA could be continuous 
or categorical (Vyas and Kumaranayake, 2006). PCA was done for nine variables among 82 drug 
naïve patients (table 18). All but one patient had data for all nine variables. This patient was 
eliminated from the analysis. Also four variables that had a number of missing patient 
information were also eliminated. Twenty-five percent of variants in all nine variables assessed 
within each patient explained influence to HIV-1 disease progression as shown by component 1 
in table 18.  Variables that stood out as dominant contributors to HIV-1 disease progression in 
PCA in descending order were the HIV drug resistance status of a patient (either susceptible or 
resistant to HIV-1) and the number of DRMs in the viral genome of an infected patient, CD4+ T-
cell counts and the HIV-1 subtype, HIV-1 IC DNA load and gender, secondary parasitic or 
bacterial infection status of an infected patient, plasma viral load and age (table 18). The values 
contributing to diseases progression according to PCA are in the range +1 to -1, where 
proportionality increases or value of contribution increases as the variable gets closer to +1 and 
decreases when it approaches -1. 
Table 18: Variable contribution to disease progression 
 
Variable Component 1 (25%) 
Drug resistance status 0.6
Age -0.1
Gender 0.2
HIV-1 IC DNA copies per 1 million cells 0.2
CD4+T –cell counts 0.3
Number of mutations 0.6
HIV-1 subtype 0.3
Secondary infection status 0.03
Plasma viral load/ml of plasma -0.1
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4 Discussion 
One important area of challenge in the fight against HIV is the development of drug 
resistant mutations and their transmission, which can undermine effective drug treatment 
(Ndembi et al., 2011; Price et al., 2011b). Also, in clinical practice, new methods in monitoring 
disease progress are needed in order to complement the already existing ones to the ends of 
predicting and improving patient outcomes. These challenges are particularly relevant in sub-
Saharan Africa since most of the world’s HIV infected people are located there. 
Using samples from HIV infected patients from Nouna, Burkina Faso in West-Africa, 
this study analyzed HIV-1 DRMs that are found in paired RNA and DNA templates of HIV-1 
infected drug naïve patients and also assessed DRMs that can be found in RNA templates of 
follow-up patients who harboured persistently high plasma viral loads after 24 weeks of 
HAART. The determination of DRMs was performed with Sanger or bulk sequencing and 
selected samples having discrepancies in resistance mutations or in paired nucleotide sequences 
of RNA and DNA were resolved with deep sequencing. Furthermore, results obtained from 
Sanger sequencing were then compared with deep sequencing results. The second part of the 
study focused on HIV-1 IC DNA levels among HIV-1 infected drug naïve individuals 
harbouring resistant or susceptible strains of HIV and discusses how HIV-1 IC DNA correlates 
with known markers of HIV disease progression. Most studies that have assessed HIV-1 IC 
DNA load in terms of its correlation with known markers of disease progression have been 
carried out in non-African populations and the few studies carried out on drug naïve African 
populations are mainly based on DRM surveillance. This study therefore looked jointly at HIV-1 
DRMs and the role of HIV-1 IC DNA levels in relation to the traditional markers of disease 
progression such as viral load and CD4 T-cell counts in predicting disease among HIV-1 infected 
African patients. 
4.1  Patient demographics and clinical characteristics 
A total of 86 HIV infected patients were recruited for this study. There were 61 
females and 24 males making 61% and 28% of the population respectively. In areas where 
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heterosexual transmission of HIV predominates, like in sub-Saharan Africa, it is known that 
there are more females living with HIV infection than males with females making up to 58% of 
all infected cases in the population (Garcia-Calleja et al., 2006; UNAIDS, 2014a).  The male to 
female HIV infection ratio in this study (1:2.5) is in concordance with the general sex ratio of 
HIV in sub-Saharan Africa. However, Burkina Faso represents one of the few sub-Saharan 
African countries with a slight male preponderance in infections (Garcia-Calleja et al., 2006; 
UNAIDS, 2014a). In that regard, the sex ratio observed in this study may represent a local area 
with some characteristics different from the general population in Burkina Faso. The factors that 
may have resulted in a reversal of sex ratio in HIV infections in Nouna is a topic that may need 
to be looked into again in a population based study of infected persons, where the sample size is 
large. HIV infects people of all age groups, however majority of cases occur in adults over 15 
years of age (UNAIDS, 2014a). In this study, the median age of infected persons was 35 years. 
The median age of infected females (34 years) was lower compared to males (42 years) and this 
is in conformity with regional trends reported by UNAIDS, where the median age of infected 
adult females are generally lower as compared to males UNAIDS (2014a) . 
The median log10 transformed plasma viral load observed was 5.757 copies/ml of 
plasma (IQR 4.993 - 6.1640) and the median CD4 T-cell count was 199,986 copies/ ml of blood  
(IQR 120,504- 282,488). These values were higher than those observed among newly infected 
patients recruited for the Europe HIV resistance network study (Demetriou et al., 2010) where  
the median log10 transformed plasma viral load was 4.43 copies/ ml of plasma (IQR 3.87–5.14) 
and the median CD4+ T-cell count was 423 copies/ ml of blood (IQR 255.3–578.5).  The age 
ranges of infected persons in our study were comparable to that of the European study but the 
European study subjects were predominantly males whilst our study was predominated by 
females. 
The CDC has categorized HIV infection into A, B and C based on CD4+ T-cell counts 
and some clinical parameters (Schneider et al., 2008). Almost all the patients in this study were 
in the category B except one patient who was in the A category. It has been demonstrated that, 
levels of CD4+ T-cell counts within which therapy is initiated correlates with the duration of 
CD4+ T-cell recovery during treatment with ART (Okulicz et al., 2014). Furthermore, 
individuals who initiate treatment when CD4+ T-cell count is <350 cells/µl do not reach levels 
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>500 cells/µl even after several years of treatment, although the viral load may reach below 
detection limit (Callegaro et al., 2014). An HIV-CAUSAL study consisting of 8,392 ART-naive 
patients who started ART when CD4+ T-cell count had fallen to <350 cells/µl, demonstrated that 
patients in this category present with a greater risk of acquiring AIDS-defining illness or death 
than those patients initiating ART when CD4+ T-cell counts are between 350 cells/µl and 500 
cells/µl (Cain et al., 2011). In contrast to the aforementioned cohort, seventy-six patients (88%) 
in this study had CD4+ T-cell counts of < 350 cells/µl of blood and ten patients (12%) had CD4+ 
T-cell counts of ≥ 350 cells/µl of blood and no significant difference was observed between 
plasma viral levels of these two CD4+ T-cell count divisions. This observation buttresses the 
point that in resource poor setting it is still a challenge to start ARTs when CD4+ T-cell counts 
are between 350 cells/µl to 500 cells/µl since ARTs are most often inadequate and individuals 
start ARTs rather late as shown by the CD4+ T-cell counts of the drug naïve patients in this 
study. This scenario is in contrast to the situation in developed countries where ARTs are readily 
available and started early to give the patient the maximum benefit from therapy (Menon, 2010). 
Secondary bacterial or parasitic infections were recorded among 57% of the patients. 
The infections were mainly vulvovaginal candidiasis, one of the most common fungal infections 
noted to frequently recur in HIV-infected women (Ray et al., 2011). In a few instances, oral 
candidiasis and salmonellosis were also recorded. Studies have shown that oral candidiasis when 
left untreated in HIV infected patients, may often lead to morbidity. When these lesions are 
treated, the quality of life of the infected patient is maintained (Pienaar et al., 2010).  
HIV co-infection with the hepatitis B virus (HBV) is endemic in sub-Saharan Africans 
(Mphahlele, 2008). There is a 17.4%- 21.3% seroprevalence rate of active HBV infection status 
observed in Burkina Faso (Nacro et al., 2001, Mulders et al., 2004). In Nouna, rural Burkina 
Faso where our study subjects came from and Ouagadougou urban Burkina Faso, the 
seroprevalence of both recent and past HBV infections are high (69.9% and 76.4% respectively) 
as seen in serological tests for HBV core antibodies while the reported seroprevalence for active 
HBV infections as indicated by HBV surface antigen tests are 14.3% and 17.3% respectively. 
The study reporting the seroprevalences of HBV also found an association between HIV and 
HBV core antibody status of infected subjects (Collenberg et al., 2006). In this study, among the 
61 patients whose HBV sero-status were recorded, 6(10%) of the patients were reported to have 
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co-infection with HBV. Our data is however comparable to the general observation that up to 
15% of HIV infected patients within sub-Saharan are estimated to be living with HBV (Hamers 
et al., 2013) but reports a lower HBV infection status than those previously observed in the 
general population in Burkina Faso (Nacro et al., 2001, Mulders et al., 2004) but again 
comparable with active HBV sero-status reported in Nouna (Collenberg et al., 2006). The report 
also agrees with the nationwide retrospective observational cohort study on HIV, HBV and HCV 
co-infection status among infected patients from the China national free ART program, where 
they observed an HBV seroprevalence of 8.7% among infected patients (Zhang et al., 2014). 
Anemia is a common feature of HIV infection and has been correlated with disease 
progression (Sullivan, 2002). Indeed a prompt treatment of anemia in HIV patients has been 
shown to improve prognosis (CDC, 1992). Anemia is defined by the WHO as an Hb of less than 
13.0 g/dl in men and 11.0 g/dl in non-pregnant women. In men, Hb in mild anemia ranges 
between 11-12.9 g/dl and moderate anemia ranges between 8-10.9 g/dl. In women, Hb in mild 
anemia ranges between 10.0-10.9 g/dl while moderate anemia lies between 7-9.9 g/dl (WHO, 
2011). A study in South Africa reports up to 25% prevalence of anemia among HIV patients 
initiating HAART (Takuva et al., 2013). Meidani et al., 2012, reported a prevalence of as high as 
67% anemia in a cohort of HIV patients (Meidani et al., 2012). In Burkina Faso, the prevalence 
of anemia among women of reproductive age is 58.6% (Meda et al., 1996). This prevalence is 
comparable to WHO’s reported prevalence of 48.40% and 57.80% among non-pregnant and 
pregnant women respectively in 2011 (Stevens et al., 2013). In this study, the median Hb level 
was low 10.6 g/dl (IQR 9.7-11.8) indicating a high prevalence of anemia. Nearly all the patients 
fell in the range of mild to moderate anemia except one male who had a normal Hb. The 
prevalence of anemia reported in our study subjects was higher than trends reported in Burkina 
Faso. Such high prevalence of anemia may generally be a reflection of poor prognosis and is 
probably an indication of late initiation of treatment with HAART. 
The mean body mass index (BMI) of women in rural Burkina Faso has been reported 
as 20.5 kg/m2 (Savy et al., 2007). HIV infection has been associated with weight loss (WHO, 
2007). The BMI is therefore an important factor in HIV infected patients. Indeed low BMI at the 
time of diagnosis has been shown to be a strong independent predictor of poor prognosis in HIV 
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infected patients prior to treatment (Maas et al., 1998; van der Sande et al., 2004). The median 
BMI of all subjects in this study was 17.72 kg/m2 reflecting a possible poor prognosis. 
4.2 Transmitted drug resistance mutations in HIV infected patients 
in Nouna, Burkina Faso 
The expanding use of ARVs in HIV treatment globally parallels the increase in DRMs 
and TDRMs. A recent pooled prevalence of HIV drug resistance mutations in Africa was 10.6% 
with wide regional differences (Ssemwanga et al., 2014). Burkina Faso like most African 
countries has seen an increase in HAART in recent times and as expected, drug resistance and 
TDRMs have been reported (Tebit et al., 2006; Tebit et al., 2008). A previous study reported 
prevalence rates of DRMs as high as 40% for PI, 76% for NNRTIs and 85% for NRTIs among 
patients failing therapy in Ouagadougou (Tebit et al.). Prevalence of primary mutations in the 
general population of Burkina Faso was however 12.5% (Tebit et al.). The HAART drugs 
prescribed in Burkina Faso are two NRTIs and one NNRT1. In this study, the entire protease and 
two-thirds of reverse transcriptase in the pol region of HIV-1 were genotyped and sequenced 
because the drugs used for HIV management target these HIV enzymes. These HIV enzymes are 
also the targets of most antiretroviral drugs (Kantor and Katzenstein, 2003).  
In assessing drug resistant mutations, plasma viral RNA or proviral DNA can be used. 
Given that the infective form of the virus (the viral RNA), is found in plasma, it is widely used 
for resistance mutation assessment (Saracino et al., 2008). However the use of proviral DNA for 
resistance mutation assessment may be relatively easier to carry out in resource limited countries, 
though the sequence profile may differ between RNA and DNA. Furthermore, profiles for 
interpreting HIV-1 drug resistance are generally formulated for HIV-1 subtype B, since this is 
the HIV subtype predominantly found in resource rich countries. However, evidence suggests 
that a similar set of resistance mutations are seen in non-B HIV-1 subtypes (Grossman et al., 
2004; Kantor et al., 2005; Soares et al., 2007). Also alterations in amino acid sequences in the PR 
and RT regions of HIV-1 that result from genetic diversity in the viral genome affect drug 
resistance levels (Sanches et al., 2007; Velazquez-Campoy et al., 2001). In HIV-1 subtype B 
viruses, some minor or accessory mutations selected for under treatment with HAART are found 
as natural polymorphisms in HIV-1 non-B subtype viruses. (Holguin et al., 2002; Johnson et al., 
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2011; Kantor and Katzenstein, 2003; Pieniazek et al., 2000). An example is the K20I resistance 
mutation that is a minor or accessory mutation selected for in HIV-1 subtype B viruses but occur 
as a natural polymorphism in HIV-1 non-B subtypes. This mutation cause reduced viral 
susceptibility and may also compensate for defects in viral fitness in subtype B HIV-1 viruses.  
In our study, the K20I polymorphism was found in almost all (98%) viral genomes sequenced. 
The K20I mutation in subtype B viruses have been identified as causing resistance to the 
protease inhibitor nelfinavir (Rhee et al., 2003). Evidence exist that natural polymorphisms to PIs 
in viruses of non-B subtype origin result in hypersusceptibility to PIs and increased viral fitness. 
(Santos et al., 2012).  
In West Africa, the predominant HIV subtype has been reported to be CRF02_AG 
(Hemelaar et al., 2011; Nii-Trebi et al., 2013; Tebit et al., 2006). In our study, we identified 70% 
of the patients as being infected with CRF02_AG, followed by CRF06_cpx -like viruses, 
CRF01_AE-like, G-like and 02_A1-like subtypes in agreement with earlier work done in 
Burkina Faso and the West African sub region (Nii-Trebi et al., 2013; Tebit et al., 2006).  
Sanger sequencing was used to assess the mutations in viral RNA and DNA among our 
patients. This platform detects mutations that occur in  ≥ 20% of the total viral population of 
virus genomes while less frequent mutations < 20% are not detected with this method (Adje et 
al., 2001; Chabria et al., 2014). All patient samples were sequenced for DRMs using Sanger 
sequencing and targeting the pol region of HIV-1. Due to high sequence heterogeneity in 3 
samples, analysis was only reported for 83 patients. The resistance mutations were classified as 
major or minor. Major DRMs on their own confer resistance to an ARV while minor DRMs do 
not (Wensing et al., 2014). A high rate of TDRM exists in drug naïve HIV-1 infected patients in 
Nouna, Burkina Faso 
Among HIV-1 infected drug naïve patients in this study, TDRMs known to affect drug 
susceptibility prior to HAART was found in 9% of the patients. Among patients harbouring 
TDRMs only, most (87.5%) of the mutations affect susceptibility to RTIs and 12.5% to PIs. 
Furthermore, TDRMs affecting the action of NNRTIs formed the bulk (86%) of mutations 
affecting susceptibility to RTIs. Mutations affecting drug susceptibility were thus highest for 
NNRTIs followed by both NRTIs and PIs. Also, many minor mutations were detected that did 
not confer resistance to any antiretroviral drug in particular but could in combination with major 
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DRMs cause resistance. Generally, the frequency of occurrence of TDRMs to specific HIV drugs 
among HIV-1 infected drug naïve sub-Saharan Africans vary significantly between geographical 
regions (Price et al., 2011a; Bartolo et al., 2014; Tshabalala et al., 2011). The WHO reports an 
increasing trend for resistance against NNRTIs (WHO, 2012). A study done in Burkina Faso in 
2006 also showed more resistance mutations affecting NNRTIs compared to PIs and NRTIs in 
drug naïve patients (Vergne et al., 2006) while a Malian study had a higher prevalence of 
mutations conferring resistance to PIs (Derache et al., 2008). In our study, there were more 
resistance mutations to NNRTIs compared to NRTs and PIs which reflects the trends observed 
by the WHO (WHO, 2012). 
The WHO reports an average prevalence of 6.6% (CI 5.1-8.3) for TDRMs. However, 
various prevalence rates have been reported around Africa. In East and Southern Africa, an 
average prevalence of 5% was reported (Price et al., 2011b). Also recent studies in drug naïve 
pregnant women in Zimbabwe reported less than 5% prevalence in resistance mutation 
(Tshabalala et al., 2011). A similar trend of TDRMs was observed in Angola (Bartolo et al., 
2014). Our observation of 9% prevalence is relatively high although a rate of 11.5% has been 
reported in Mali (Derache et al., 2008).  Given the fact that the sample size in this study was 
small, trends of TDRMs have to be studied in a larger group of drug naïve patients. It should also 
be noted drug naïve patients in this study were assumed not to have taken antiretroviral drugs but 
this is not proven and therefore one should also be open to the possibility of some DRMs found 
in this group, being mutations that might have been selected for under prior drug use. Given the 
high prevalence of DRMs in our study, it is worthwhile to recommend that a patient’s HIV 
resistance mutation profile should be known before the initiation of therapy. Resistance 
monitoring should also be incorporated into clinical practice in developing countries, for 
effective clinical management of HIV. 
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4.2.1 Patterns of the emergence of drug resistance mutations and its 
persistence or disappearance among HIV-1 infected patients on 
HAART  
 The current stage in the HIV pandemic poses the dual problem of development of 
DRMs during treatment. We further assessed sequences of follow-up patients who maintained 
their viral load levels at baseline or those who had higher viral load while under HAART. This 
group of patients were assessed under the assumption that they might have developed new or 
additional DRMs and thus escaped therapy. Therapy failure was determined using longitudinal 
plasma RNA load levels of infected patients from baseline to 24 weeks into treatment. We 
selected eight follow-up patients based on the aforementioned assessment and the availability of 
plasma samples with viral load above 1,000 copies/ml of plasma since this enabled us to 
successfully genotype and sequence patients RNA templates. All selected follow-up patients 
were assessed for DRMs development over time.  
Highly active antiretroviral therapy exerts selection pressure on HIV quasispecies in an 
individual and that selects for HIV resistant strains during treatment (Metzner et al., 2009). If 
active HIV replication ensues in the presence of ARDs at a certain threshold, viral populations 
may evolve that select for critical DRMs to antiretroviral regimes administered and may render 
antiretroviral drugs ineffective. This process is termed the genetic barrier to resistance. Genetic 
barrier to resistance could also be defined as the threshold beyond which mutations that reduce 
viral susceptibility to ARDs develop. Factors that influence the genetic barrier to resistance are 
numerous among which are the number of critical mutations needed to cause resistance (it should 
be noted that a single mutation may be enough), the number of preexisting mutations and their 
replicative fitness. Some mutations influence drug susceptibility more than others. There exist 
ARTs with either high genetic barrier to resistance (ARDs of thymidine based origin and boosted 
PI drugs) or low genetic barrier to resistance (triple HAART regimes of NNRTIs and NRTIs 
origin as used by our study subjects). For drugs with high genetic barrier to resistance, a high 
number of DRMs are needed to render ARDs ineffective but drugs with low genetic barrier to 
resistance only require a few mutations to make ARDs ineffective (Eron, 1996; Gallant et al., 
2003; Kempf et al., 2004; Kessler, 2005).   
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The major DRMs detected among the study subjects were those that conferred 
resistance to NNRTIs and NRTIs, reflecting that HAART regimes administered to patients in 
rural Burkina Faso have low genetic barrier to resistance and may only require a single or a few 
mutations to cause resistance to antiretroviral regimes being used. Major NNRTI mutations 
detected in ART naïve patients included K103N and Y181C mutations. These made up a small 
proportion (5%) of our patients. Tebit et al., 2009, reported a similar percentage (6.1%) of 
NNRTI mutations in drug naïve patients in Ouagadougou (Tebit et al., 2009). The neverapine 
related resistance mutations K103N and Y181C have been widely reported in sub-Saharan 
Africans undergoing treatment with NNRTIs because of its wide use in the treatment of mother-
child-transmissions (Tebit et al., 2008) as well as in drug naïve patients starting therapy 
(Akinsete et al., 2004; Tebit et al., 2009). The Y181C and K103N mutations have also been 
reported in drug naïve (Magiorkinis et al., 2008) and treated individuals (Tebit et al., 2009). The 
NNRTI based DRMs found in our study subjects confer broad based resistance to all known 
NNRTIs and since they have a low genetic barrier to resistance, are selected more frequently.  
Of the eight follow-up patients for whom DRMs were analyzed, the K103N was the 
most common major mutation detected after 24 weeks of HAART in 3 (38%) of patients, 48 
weeks in 4 (50%) patients including a patient who developed the mutation at 24 weeks under 
HAART and another who had the mutation already at the drug naive period. In each case, the 
mutation then remained till 48 or 72 weeks depending on the time of the last analysis. The 
predominance of K103N mutation in the patients followed over time is in consonance with work 
done by Tebit et al., 2008, they showed that 44% of major resistance mutations found in HAART 
treated patients in Ouagadougou, Burkina Faso are K103N mutations (Tebit et al., 2008). 
Moreover, the dominance of the K103N mutation seen among drug naïve and follow-up patients 
might be explained by not only the low genetic barrier of resistance in the viral population due to 
the use of NNRTIs but also the added advantage that the mutation does not confer a reduced 
fitness cost and for that matter behaves like the wildtype virus. This advantage helps in 
facilitating the replication and emergence of new viral genomes harbouring the K103N mutation 
both in the presence and in the absence of ARDs. These mutated viral genomes may then be 
present in the viral quasispecies in equal proportions as wildtype viruses.  Another possibility for 
the dominance of the K103N mutation among our patients might be the selection of minority 
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viral populations within the viral quasispecies that harbour this mutation. These mutant viruses 
may  gain the advantage of replicating to levels proportional to wildtype viruses within the 
growing  viral population in the patient (Mackie, 2006). The other major DRMs to NNRTIs 
observed in the follow up patients were the E138Q, G109A, Y181C and M230L mutations. Most 
of these mutations, in contrast to K103N, were infrequent. These infrequent mutations have 
reduced fitness thereby being unable to compete with the K103N mutation in the viral 
population. (Mackie, 2006).  Given that the K103N mutation is by far the most observed, efforts 
to determine its presence before and during treatment is recommended. 
4.2.2 Multiple drug resistance mutations may lead to virologic failure in 
follow-up patients on HAART  
Virologic failure rates under HAART among Africans and Asians have been described 
as varied, ranging from a prevalence of 2.9% to 20.6% (Aghokeng et al., 2014). Other studies in 
certain African countries have seen rates as high as 35% to 50% (Barennes et al., 2014). In urban 
Burkina Faso, the prevalence of DRMs in patients with virologic failure have been studied with 
high prevalences reported per ARV use as follows; NRTIs 85%, NNRTIs 76%, and PIs 40% 
(Tebit et al., 2008). In our study 6 (75%) of the eight follow-up patients on HAART from rural 
Burkina Faso had multiple DRMs to NRTIs and NNRTIs, which could explain virologic failure. 
Several studies have also identified multiple DRMs as a common cause to therapy failure among 
patients on ART (Daar and Richman, 2005; Jiamsakul et al., 2014). The trend observed in our 
study, was similar to trends reported in previous studies conducted among 209 patients with 
virologic failure under HAART in urban Burkina Faso (Tebit et al., 2008). However, the sample 
size was small and therefore the observations need to be interpreted with caution. The two 
remaining follow-up patients 2(25%) with high viral loads (greater than 1,000 copies/ml of 
plasma) suggestive of therapy failure did not have DRMs known to significantly reduce drug 
susceptibility. In one of the two follow-up patients, the reason for virologic failure was the 
interruption of treatment for 14 days. The reason for therapy failure in the other patient was not 
known. It should therefore be noted that virologic failure under treatment could initially be due 
to reasons other than resistance mutations but may lead to future development of DRMs that 
render ARTs ineffective at a later time. Although the patients were indicated to have been on 
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HAART, it is possible that additional factors such as inadequate therapy or non-compliance to 
HAART regimes, drug rationing, frequent treatment interruptions and not only DRMs led to 
persistently high plasma viral RNA levels.  The development of DRMs therefore makes it 
necessary that adequate monitoring of patients is done both for adherence to therapy and 
determination of emergence of resistance mutations. 
Disease progression in HIV patients is dependent on many factors including the 
development of DRMs during treatment. Major TDRMs among drug naïve patients may have led 
to the emergence of multiple drug resistance mutations at latter time points. Major TDRMs are 
pre-existing DRMs that are found in HIV infected drug naïve patients. These mutations reduce 
the susceptibility of ARDs substantially on their own while minor mutations reduce drug 
susceptibility minimally or substantially in combination with major DRMs (Wensing et al., 
2014). In our eight follow-up patients who showed signs of therapy failure indicated by high 
viral loads, two patients had major TDRMs to NNRTIs at baseline while the remaining six 
patients either had minor resistance mutations to RTIs or no mutations at baseline. Of the two 
patients with major DRMs to NNRTIs at baseline, one had the K103N mutation and failed 
HAART within 24 weeks while the other had the Y181C mutation and failed treatment within 12 
weeks. These mutations are known to be selected for among patients under HAART in sub-
Saharan Africa due to the NNRTI based HAART regimes given (Tebit et al., 2008). These two 
patients also developed multi- DRMs at 12 weeks and 24 weeks under HAART.  It has been 
shown that the number of TDRMs at baseline may increase the risk of virologic failure (Daar and 
Richman, 2005; Jiamsakul et al., 2014). The two patients with major TDRMs at baseline failed 
therapy, giving an indication that such patients indeed run the risk of virologic failure although 
our sample size was small. The other six follow-up patients who experienced virologic failure 
but only had minor or no baseline mutations also failed therapy within the same duration of 12 to 
24 weeks as in the case of those patients who had TDRMs. Two of these patients developed 
multi drug resistance mutations within 24 weeks into therapy. This observation indicates that 
patients could experience virologic failure with or without pre-existing baseline mutations and 
that other factors not limited to TDRMs may increase the risk of virologic failure as well, 
therefore proper patient monitoring and education are paramount to disease management.  
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Evidence of major multi- DRMs can be highlighted in four (50%) of the eight follow-
up patients. They had the major NRTI resistance mutation M184V emerging together with other 
major NNRTI DRMs like the K103N, Y181C, E138Q, G109A, and M230L. In two of the four 
patients the M184V mutation appeared at 24 weeks into therapy and persisted with multiple 
NNRTI mutations. In the remaining two patients, one had the mutation at 12 weeks and then it 
disappeared at 64 weeks with all the other multiple mutations while the other had the mutation at 
36 weeks and lost it at 48 weeks while a new mutation to NNRTIs emerged with pre-existing 
NNRTI mutations still present. The M184V mutation confers high-level resistance to 3TC and 
FTC and low level resistance to ABC and ddI (Turner et al., 2003) and has also been associated 
with reduced viral fitness (Turner et al., 2003). It is not clear why the mutation would disappear 
in the patient, however rapid disappearance of M184V mutations has been associated cessation 
of therapy (Mackie 2006; http://www.ncbi.nlm.nih.gov/books/NBK2249/). Stopping therapy will 
remove the pressure selecting for the M184V mutation, which has a fitness disadvantage in the 
absence of the drugs (Mackie 2006; http://www.ncbi.nlm.nih.gov/books/NBK2249/). Data on the 
patient does not indicate a termination of treatment, however it cannot be ruled out. The two 
other patients had minor mutations and within 24 and 48 weeks developed major resistance 
mutations to the action of NVP and EVF, till 72 weeks under HAART. Again although the 
sample size was small, the evidence leads to the fact that DRMs to NNRTI and NRTI based 
HAART are on the rise and HIV treatment plans for sub-Saharan Africa need alternatives drugs 
in combination with RTIs to reduce resistance. 
4.2.3 A high concordance exists between HIV-1 RNA and proviral DNA in 
drug naïve patients in Nouna Burkina Faso 
HIV provirus integrated into the genome serves as viral reservoirs and ensures viral 
persistence even with undetectable viral RNA load during therapy. While a lot of focus has been 
put on assessing viral RNA mutations for clinical decision-making, it is still unclear what the 
benefits of assessing proviral DNA mutations could be (Chew et al., 2005). Potential benefits of 
assessing mutations in viral DNA however exist. First, if the determination of viral DNA 
mutations can predict effectiveness of HAART to a similar extent in a given population as viral 
RNA mutations, the use of DNA can be implemented in less resourced regions due to ease of 
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amplification and the stability of the template (Banks et al., 2012). Also, where RNA viral loads 
are very low, proviral DNA may give some information on potential resistance in the future 
(Banks et al., 2012; Chew et al., 2005).  
Assessing viral DNA as a template for resistance testing is an evolving concept and 
existing data on the topic is quite limited, especially data comparing viral RNA and DNA 
templates of HIV infected African patients in terms of DRMs. However one study has been done 
on in Zimbabwe which indicates the potential usefulness of viral DNA (Banks et al., 2012). 
Studies involving 253 newly-diagnosed HIV infected patients from the Europe HIV resistance 
network compared paired viral RNA and DNA derived PR/RT sequences from each of their 
patients for HIV-1 DRMs that confers resistance to inhibitors of PR and RT and found a high 
concordance between the two templates in regions assessed for DRMs (Demetriou et al., 2010). 
We therefore assessed the level of concordance or discordance between paired RNA and DNA of 
drug naïve patient derived HIV-1 PR/RT sequences for DRMs at regions that conferred 
resistance to PR/RT based ART in each of our patients. On comparing mutations in viral RNA to 
DNA we observed a high level of concordance (94%) and a low level of discordance (6%) 
among drug naïve patients. There were more resistance mutations seen in RNA compared to 
DNA in the discordant group. Regarding the disparities seen in paired viral RNA and DNA 
sequences, studies have shown diverse results. Some studies report a higher number of mutations 
for RNA compared to DNA while others report the opposite (Bon et al., 2007; Saracino et al., 
2008). Again, existing studies on paired HIV-1 RNA and DNA sequence comparisons reveal a 
wide range of results (Bon et al., 2007; Saracino et al., 2008). While some studies show no 
significant differences between the two sequences and suggest DNA as an alternative to RNA 
(Derache et al., 2015; Vicenti et al., 2007), others have demonstrated wide disparities that might 
discourage the use of DNA as an alternative template (Chew et al., 2005; Smith et al., 1993). 
One study reported as high as 87 % discordance in RNA and DNA templates of the same patient, 
in ARV treated individuals (Saracino et al., 2008). Bon et al., 2007, reported a discordant rate of 
26% in drug naïve patients (Bon et al., 2007). There are also further disagreements on whether 
detected DNA mutations can be used in clinical assessments instead of RNA or whether DNA 
should complement RNA in clinical decision-making (Banks et al., 2012; Chew et al., 2005). 
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However, discordant sequence pairs of RNA and DNA in terms of DRMs found in our study was 
low. 
There are several reasons why discordance can occur between viral DNA and RNA. 
While the viral DNA is stably incorporated into the genome and is rarely altered, DNA 
dependent RNA polymerase II that transcribes the viral RNA can induce errors during 
transcription (Abram et al., 2010) and as a result, many mutations can be incorporated in viral 
RNA that would not be present in the viral DNA. This could explain why more mutations may 
be seen in the viral RNA than DNA. On the other hand, while resistant mutations can appear in 
RNA and disappear over time due to the changing environment of the infected patient, the 
mutations could be archived in the form of proviral DNA which can be detected at a later time 
when the RNA population has changed (Banks et al., 2012). Archiving of various resistant 
mutations in DNA over time may result in the viral DNA having more mutations than RNA. 
Finally, the high error-prone reverse transcriptase enzyme can cause mutations in the reverse 
transcribed viral RNA that would be archived in proviral DNA. These mutations may not be 
present in the RNA population depending on the transcription status of the DNA. Therefore, 
depending on the unique circumstance of the patient, some degree of discordance may be seen in 
mutations when comparing RNA and DNA. Some degree of discordance between RNA and 
DNA mutations is therefore expected in HIV infected patients.  
DRMs in viral DNA are a reflection of previous and current resistant mutation states of 
viral RNA. It has been shown that detection of DRMs in viral RNA precedes DNA and as a 
consequence, mutations are detected in DNA latter in relation to RNA, however established 
mutations will eventually be reflected in DNA (Banks et al., 2012). Detection of DRMs in DNA 
should therefore be interpreted with the view that not all the DRMs detected at a given time point 
will be clinically relevant for immediate management decisions as some DRMs in DNA may 
indicate previous resistance states. However DNA DRMs may help in better understanding of 
evolution of the viral quasispecies and could also be used to predict potential resistance in the 
future. Also, DNA DRMs could provide useful clinical information in the absence of facilities 
for viral RNA studies but should be interpreted with caution (Derache et al., 2015). 
In our patients, the high concordance rate between paired RNA and DNA samples in 
terms of HIV-1 DRMs suggests that DNA could be substituted for RNA in making clinical 
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decisions on drug resistance. A larger study would be necessary to determine the general 
likelihood of concordance between DNA and RNA and protocols could be developed to optimize 
interpretation of DNA data to closely reflect the prevailing RNA resistance mutations in a 
patient.  
4.2.4 In-depth analysis of RNA DNA discordance using deep sequencing 
Determination of DRMs using bulk sequencing is limited by the fact that only 
mutations that occur ≥ 20% of the viral quasi species are detected (Chabria et al.). Bulk 
sequencing therefore excludes a significant proportion of the viral population, which can impact 
disease progression. In order to obtain a more in depth assessment of viral populations in patients 
who had discordances in mutations between RNA and DNA or had ≥ 10 nucleotide differences 
in paired RNA and DNA sequences in Sanger sequencing, we resorted to use deep sequencing 
since it detects both mutations that occur in ≥ 20% of the viral population (comparable to Sanger 
sequencing) and mutations in less than 20% of the viral population referred to as minority viral 
populations which Sanger Sequencing does not detect. Deep sequencing therefore allowed 
analysis of viral RNA and DNA sequences at greater depth and therefore could be used to detect 
whether discordance possibly represented minority mutations. 
Our deep sequencing method detected mutations occurring in as low as 1% of the viral 
population. We assessed for discordance in mutations between RNA and DNA in the range 
above 20% frequency. We also compared mutations in RNA and DNA in the range below 20% 
(minority mutations), which is below the range of bulk sequencing detection. These comparisons 
were done in order to determine whether discordances in RNA and DNA mutations vary or not 
and also determine whether mutations found in deep sequencing above the 20% mutation 
frequency reflects that seen in bulk or Sanger sequencing.  
There was a high concordance (95%) for resistance mutations between RNA and DNA 
with deep sequencing in populations ≥ 20%, similar to what was observed in bulk sequencing. 
However there was a high level of discordance (74%) between RNA and DNA in the minority 
population. It is known that mutations are detected earlier in HIV viral RNA while mutations in 
proviral DNA are detected at a later time (Banks et al., 2012; Palmisano et al., 2009). Our data 
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suggests that mutations seen in RNA are also seen in DNA within the majority or dominant viral 
population and this strengthens the argument that DNA mutations picked up by Sanger 
sequencing mostly reflect the RNA mutant population hence either DNA or RNA templates 
could be used in genotyping and sequencing for the determination of DRMs routinely.  
4.2.5 Non Synonymous mutations predominate in the viral populations of 
HIV infected patients in Nouna Burkina Faso 
The nature of mutations in HIV impacts the behavior of the virus. Nucleotide changes 
that do not result in changes in amino acid are referred to as synonymous mutations while those 
that result in a change in the amino acid are non-synonymous mutations (Hunt et al., 2014). Non-
synonymous mutations lead to changes in the primary structure of proteins and therefore could 
impact its function.  In HIV, non-synonymous mutations provide mechanisms for escape of the 
virus by altering epitopes leading to evasion of immune cells and neutralizing antibodies (Zanini 
and Neher, 2013). Traditionally, synonymous mutations however have been considered inert, but 
this view has changed in recent times (Hunt et al., 2014). Synonymous mutations can alter 
transcriptional and translational processes and affect the stability of RNA. In HIV, it has been 
shown that synonymous mutations in the 3 prime region of the pol gene can significantly alter 
viral protein translation and viral replication rates (Nomaguchi et al., 2014). 
In our study, paired sequences of RNA and DNA templates from HIV-1 infected drug 
naive patients were assessed for the presence of synonymous and non-synonymous nucleotide 
differences first by bulk or Sanger sequencing and then changes ≥ 10 were resolved with deep 
sequencing. We observed high levels of synonymous mutation rates as compared to non-
synonymous mutations among patient sequences using the bulk sequencing method. The high 
synonymous mutation rates observed can be explained by the fact that synonymous mutations 
usually have a high fitness cost and will generally be selected for in the viral population (Zanini 
and Neher, 2013). Samples that were confirmed with deep sequencing showed a high non-
synonymous mutation rate as compared to synonymous mutations both in bulk and all deep 
sequencing frequency cut-offs of 1, 2, 5, 10 and 20%. The high non-synonymous mutation rate 
implies that the viruses may be adapting to changing environments in patients in the face of drug 
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therapy and host immune effects. As stated earlier, synonymous mutations are generally selected 
for relative to non-synonymous mutations because synonymous mutations usually have a high 
fitness cost as compared to non- synonymous (Zanini and Neher, 2013). The high non-
synonymous mutation rate among the study population is an indication of viral effort to 
overcome bottlenecks like drug treatment and host immune response and therefore strengthens 
the justification for the introduction of resistance monitoring. 
4.3 The relationship between HIV-1 intracellular DNA and other 
markers of disease progression among HIV-1 infected 
Burkinabés 
In the current clinical management of HIV, plasma viral load and CD4+ T-cell counts 
are used for disease monitoring and they form the basis for decision-making on drug therapy and 
alteration of treatment regimes (Langford et al., 2007). Although viral load and CD4+ T-cell 
counts have been useful clinically, there is still room for development of other disease 
monitoring tools in the face of increasing complexity of drug treatment and resistance mutations. 
Also, the development of new, easily available and cheaper disease monitoring tools can 
complement management of HIV in resource-limited settings. In recent times HIV-1 IC DNA, in 
contrast to plasma RNA of HIV, is becoming of interest to clinicians and researchers as a disease 
monitoring tool in clinical management of HIV. The HIV-1 IC viral DNA also serves as 
reservoir for the virus (Demetriou et al., 2010).  Recent studies have shown intracellular DNA as 
an independent determinant of disease progression (Demetriou et al., 2010) and further 
assessment of this finding is necessary among sub Saharan Africans who may benefit from the 
use of  HIV-1 IC DNA in disease monitoring.  
In this study, we assessed HIV-1 IC DNA levels in HIV patients from Nouna, Burkina 
Faso and determined how they correlated with plasma viral load and CD4+ T-cell counts as well 
as other surrogate markers of disease progression. We also assessed HIV-1 IC DNA loads in 
terms of comparing levels in patients with drug resistant strains and non-resistant strains and 
determined how they compared with established standards of disease monitoring like CD4+ T-
cell counts and plasma viral load. We also analyzed HIV-1 IC DNA loads in terms of patients 
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who experienced virologic failure after 24 weeks of HAART and those who experienced 
virologic suppression within the same time frame. 
4.3.1 HIV-1 intracellular DNA levels ranged between 10 and 10,000 copies 
per one million cells among drug naïve patients. 
HIV-1 IC DNA was measured by a molecular-beacon-based qPCR technique using 
CCR5 gene copies as a reference to calculate the number of cells in buffy coat. The majority of 
the patients (58%) had HIV-1 IC DNA loads between 100 and 1,000 copies/106 cells, 26% had 
HIV-1 IC DNA between 1,000 and 10,000 copies/106 cells, 14% were between 10 and 100 
copies/106 cells while 2% were between 10,000 and 100,000 copies/106 cells and none fell in the 
range of 100,000 to 1,000,000 copies/106 cells.   
HIV-1 IC DNA viral load has been shown to be relatively stable as compared to the 
plasma viral load especially during treatment (Saitoh et al., 2002). There is a paucity of studies 
that have analyzed the level of HIV-1 IC DNA among Africans. In studies done in developed 
countries, Kostrikis et al., 2002, demonstrated in an European cohort a median HIV-1 IC DNA 
level of 2.646 copies/106 PBMCs at baseline (Kostrikis et al., 2002a). Our median HIV-1 IC 
DNA level was in a range 2.645 (IQR 2.260 – 3.055), almost identical to that observed by 
Kostrikis et al., 2002. 
4.3.2 HIV-1 intracellular DNA does not correlate with primary markers of 
disease progression in drug naïve HIV-1 infected Burkinabés. 
In order to assess the utility of HIV-1 IC DNA as a potential substitute to established 
markers of disease progression like CD4+ T-cell counts and plasma viral load, we assessed 
correlations between HIV-1 IC DNA on one hand with plasma viral load and CD4+ T-cell counts 
on the other hand. Our results showed no correlation between cellular viral DNA and CD4+ T-
cell counts or plasma viral load using all patient samples (n=83). The correlation between HIV-1 
IC DNA levels and CD4+ T-cell counts of CDC clinical stage B stratified populations of drug 
naïve patients was also assessed but again no association was observed.  
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Reports on the association between HIV-1 IC DNA loads, plasma viral load and CD4+ 
T-cell counts vary widely. While some studies have reported no significant correlations in drug 
naïve patients, others have reported significant associations especially in treated patients (Buzon 
et al., 2014). Poizot-Martin et al., 2013, reported no correlation between HIV-1 IC DNA and 
plasma viral load as well as HIV-1 IC DNA and CD4+ T-cell counts, in a cohort of HIV-1 
infected patients (Poizot-Martin et al., 2013). This was in agreement with our results. 
Furthermore, in a study conducted by Kostrikis et al., 2002, it was shown that HIV-1 IC DNA 
levels moderately correlated with plasma viral load and weakly correlated with CD4+ T-cell 
counts (Kostrikis et al., 2002a). Watanabe et al., 2011, however reported a negative correlation 
between absolute HIV-1 IC DNA levels and CD4+ T-cell counts but the correlation was not 
observed when relative HIV IC DNA quantifications were used (Watanabe et al., 2011). In this 
study, they defined the assessment of HIV-1 IC DNA load relative to the number of PBMCs as 
the ‘relative amounts’ in contrast to ‘absolute amounts’ when HIV-1 IC DNA was expressed as 
per milliliter of blood (Watanabe et al., 2011). 
Our cross sectional data may also reflect treatment outcomes in our patients since 
quantifications of HIV-1 IC DNA levels in treated patients have been shown not to change 
significantly over time (Cone et al., 1998; Kostrikis et al., 2002b) but may rather be concordant 
with the time of treatment initiation and not the duration of treatment (Watanabe et al., 2011).  
4.3.3 HIV-1 DNA levels are significantly higher in patients who experience 
virologic failure than those who do not. 
Our studies demonstrated a significantly higher (p=0.045) median HIV-1 IC DNA 
level at baseline (median 3.16 log10 copies/10
6 cells, IQR 2.75-3.62) in patients who experienced 
virologic failure after 24 weeks of HAART as compared to their counterparts in whom virologic 
suppression was attained (the median baseline HIV-1 IC DNA was 2.63 log10copies/10
6 cells, 
corresponding to the range IQR, 2.12-3.04 log10copies/10
6 cells). This observation is in 
agreement with studies conducted by Saitoh et al., 2007, who demonstrated that HIV-1 IC DNA 
is lower in HAART treated children with undetectable RNA viral loads compared to those with 
high viral loads (Saitoh et al., 2002) also signifying that HIV-1C DNA load could be used to 
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predict disease progression at baseline before therapy commencement. A study undertaken by 
Parisi et al., 2012, demonstrated that low baseline levels of HIV-1 IC DNA load leads to 
undetectable levels of the cellular DNA load and plasma viral load levels during therapy (Parisi 
et al., 2012). Williams et al., 2014, stated from their studies that, cellular HIV-1 DNA is a better 
predictor of disease outcome than plasma viral load and could even help to identify individuals 
who can safely interrupt therapy (Williams et al., 2014). Our findings need to be reconfirmed by 
a larger sample size.   
Plasma viral levels at 24 weeks post HAART was higher in patients who experienced 
virologic failure than those who did not. There was approximately 2.5log10 difference (p<0.001) 
in plasma viral load levels between patients who experienced virologic failure and those who 
experienced virologic suppression at 24 weeks of treatment but there was no difference in their 
CD4+ T-cell count levels (p=0.15). Also both their plasma viral load and CD4+ T-cell counts at 
baseline were not significantly different. Our findings suggest that plasma viral load remains a 
strong predictor for disease prognosis and not CD4+ T-cell counts (Mellors et al., 1996).  
4.3.4 HIV-1 DNA levels are unaffected by drug resistance mutations in drug 
naïve HIV-1 infected patients  
Not much has been studied on the factors that determine the level of HIV-1 IC DNA 
especially among African populations. Transmitted drug resistance mutations alter the kinetics of 
viral infection and may affect levels in HIV-1 IC DNA in HIV infected patients. In a large 
European cohort however, it was determined that TDRMs do not affect HIV-1 IC DNA 
(Demetriou et al., 2010). Little or no information currently exists on the effect of TDRMs on 
HIV-1IC DNA load in Africa. We compared the levels of HIV-1 IC DNA load in patients who 
had TDRMs and those who had no DRMs affecting drug susceptibility. Our data showed no 
significant difference between the median HIV-1 IC DNA in the drug sensitive and resistant 
groups of drug naïve patients assessed. Our results was similar to the observations made in the 
large European cohort studies (Demetriou et al., 2010).  
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4.3.5 Transmitted drug resistance mutations does not alter the levels of 
plasma viral load and CD4
+ 
T-cell counts among drug resistant and 
susceptible HIV infected Burkinabés 
Our data indicated that cellular HIV-1 DNA levels were not affected by TDRMs. 
However we wanted to determine whether a similar pattern existed for the clinically used HIV-1 
infection monitoring markers like CD4+ T-cell counts and HIV plasma viral load. Again there 
was no difference in the levels of CD4+ T-cell counts and plasma viral load in patients with and 
without TDRMs. Nevertheless we observed a trend towards higher CD4+ T-cell counts among 
patients with TDRMs compared to those without (p=0.007). When we further segregated the 
cohort by CDC clinical stages and focused only on group B patients, we observed significantly 
higher CD4+ T-cell counts among clinical stage B patients with TDRMs as compared to those 
without TDRMs. Studies have generally shown that mutant viruses tend to have reduced fitness 
and may be less virulent than wild type viruses and this may affect the degree of CD4+ T-cell 
count reduction in patients (Hirsch et al., 2008). It has also been reported that individuals 
infected with drug resistant viruses have higher initial CD4+ T-cell counts than those infected 
with wild type viruses although the high CD4+ T-cell counts in TDRM groups are usually 
followed by a faster CD4+ T-cell count decline compared to wild type (Hirsch et al., 2008; Pillay 
et al., 2006). Our data indicated a higher level of CD4+ T-cell count in the TDRM group, 
however, analysis of later time point CD4+ T-cell count values would give a clear assessment of 
CD4+ T-cell count decline over time among the two groups of patients.    
4.4 The effect of other indicators of disease progression on HIV-1 
intracellular DNA, Plasma viral load and CD4
+ 
T-cell count in 
HIV-I infected patients 
There are several factors that have been shown to influence HIV infection and disease 
progression among Africans. In this study we assessed the role of hepatitis (HBV) confection, 
predominant HIV subtypes, number of mutations and age on established markers of disease 
monitoring like CD4+ T-cell counts, plasma viral load and HIV-1 IC DNA. Co-infection with 
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Hepatitis B did not alter the levels of HIV-1 intracellular DNA, plasma viral load or CD4+ T-cell 
count among drug naïve patients. Our observation agrees with a meta-analysis done by 
Nikolopoulus et al., 2009, where they assessed the impact of HBV co-infection with HIV-1 on 
HIV disease progression and did not find any significant impact (Jain, 2009; Nikolopoulos et al., 
2009). Also no correlation existed between HIV-1 intracellular DNA and age, HIV subtypes and 
number of mutations among infected patients, and this is in concordance with studies conducted 
by Kostrikis et al., 2002, who also reported the lack of association between HIV-1 IC DNA and 
age, HIV-1 subtypes and number of DRMs in their European cohort (Kostrikis et al., 2002b). 
Finally, principal component analysis of all the variables used to assess markers of disease 
progression in this study also showed that 25% of variations in all the variables examined 
explain HIV-1 disease progression in the study participants. 
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5 Conclusion 
The current phase of the HIV pandemic brings with it hope for infected persons due to 
the effectiveness of HAART. However, challenges still lie ahead that require concerted efforts to 
overcome. The most important challenge involves the development of drug resistance mutations 
and their transmission that may threaten the effectiveness of HAART in the future. Also the need 
for improved clinical tools for monitoring disease states and progression and determination of 
drug resistance mutations is increasing, especially in low-income areas.  
In this study we have shown that drug resistance mutations are quite common in drug 
naïve HIV-1 infected patients in Nouna Burkina Faso, indicating increasing transmission of 
resistant mutations in the African population. There is also a high rate of mutation development 
with treatment on HAART. The high similarity between DNA and RNA mutation rates found in 
this study indicates that the use of DNA can be adopted in drug resistance monitoring since it is 
very stable and would not easily be degraded with changes in temperature as compared to RNA 
which is easily degradable and needs specific temperature conditions to keep it viable for DRM 
testing. Deep sequencing also shows minority DRM variants that may become dominant over 
time or provoke the emergence of DRMs that reduce drug susceptibility. Drug resistance 
mutations in the minority quasispecies could also lower susceptibility to ARTs leading to 
virologic failure. Deep sequencing has on the other hand, proved to be a good tool that could be 
used to resolve disparities in DRMs and suspicious nucleotide differences. Finally, HIV-1 IC 
DNA in our study did not strongly correlate with key markers of disease progression but could 
be used to detect virologic failure at 24 weeks of HAART, signifying that HIV-1 IC DNA or 
HIV-1 STS DNA levels may predict disease progression independently and can be used either 
alone or together with plasma viral load and CD4+ T-cell count to predict disease progression. 
Since our sample size was small, it is recommended that more studies be carried out to assess the 
utility of HIV-1 IC DNA in clinical practice. 
           Outlook  
137 
 
6 Outlook 
This study analyzed an alternative template (DNA) that is more stable and easy to handle, for 
HIV-1 drug resistance genotyping. It also shed light on the importance of detecting TDRMs 
before the initiation of ART, since this may play an important role in clinical decision-making 
and serve as a key to preventing the emergence of multiple drug resistance mutations at later 
time points in the progression of HIV-1 disease. A large-scale study involving deep sequencing 
of treatment naïve and follow-up patients harbouring DRMs should be evaluated to assess 
whether DRMs that occur over time were already present in the minority viral quasispecies. Such 
a study could be expanded to involve mutational linkages and the relevance of minority variants 
in clinical decision-making. 
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APPENDIX 
Appendix I: Ethical clearance from Nouna Burkina Faso 
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Appendix II: Ethical clearance from Heidelberg Germany 
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Appendix III: Reverse transcriptase and nested PCR reagents and 
conditions 
PCR reagents for cDNA and first round DNA synthesis 
 
PCR conditions for cDNA and first round DNA synthesis  
 
 
 
 
 
Component Volume
2X Reaction Mix 25 µl
Template RNA (33- 108ng/ul) 5, 10 or 15µl
10 µM/µl RT1 forward primer 1 µl
10 µM/µl RT-Rev-Stu1  reverse primer 1 µl
SuperScript™ III RT/ Platinum® Taq High 
Fidelity Enzyme Mix* (5U/ul)
1 µl
Nuclease free water to 50 µl
Perform 1 cycle of: Perform 40 cycles of:
55°C or 60°C for 30 minutes
Denaturation, 94°C for 15 
seconds
94°C for 2 minutes
Annealling, 50°C and 
increments of 1°C upto 60°C 
for 30 seconds at each trial
Extension, 68°C for 1 
minute/kb
A: cDNA synthesis and pre-
denaturation 
1 cycle of 68ºC for 5 
minutes
B: PCR amplification C: Final extension 
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PCR reagents for second round DNA synthesis 
 
Second round PCR amplification conditions 
 
Primer groupings for PCR optimizations 
 
F1: Pol1 forward primer; R1: RT-rev-stu1 reverse primer; F2: Prot-for-EcoR forward primer and R2: RT4 reverse 
primer    
Component Volume
5x G-C rich PCR Buffer 5µl
25 mM dNTPs 0.5µl
10 µM/µl RT3 forward primer 1.0µl
10 µM/µl RT4 reverse primer 1.0µl
Verbatim High Fidelity DNA 0.5
Template DNA 5.0µl
Nuclease free water to 50 µl
PCR Step Temperature Duration Number  of Cycles
Initial Denaturation 98°C 30 secs 1 cycle
Denaturation 98°C 10 secs
Extension 72°C 30 secs
Final Extension 72°C 10 mins 1 cycle
Holding 4°C Infinity
Annealing 30 secs 35 cycles
50°C upto with  increments of 
1°C upto 60°C 
Group 
A F1 +R1
B F1 +R2 F2 +R2 
C F2+R1 F2 +R2
D F2 +R2 F2 +R2
Primer combinations 
for cDNA and first 
Primer combinations 
for second round 
F2 +R2
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Appendix IV: HIV-1 IC DNA and CCR5 reagents and PCR 
amplification conditions  
HIV-1 IC DNA PCR amplification reagents  
 
CCR5 DNA PCR amplification reagents 
 
 
 
 
 
 
 
 
Template DNA
to 50 µlNuclease free water 
10 µM LK47 reverse primer 1 µl
Component Volume
10X standard Taq reaction buffer 5 µl
25 mM dNTPs 0.5 µl
5µl
Taq DNA polymerase 0.25 µl
10 µM LK46 forward primer 1 µl
Volume
5 µl
0.5 µl
1 µl
1 µl
0.25 µl
37.25 µl
5µl
to 50 µl
Component
10X standard Taq reaction buffer
25 mM dNTPs
Nuclease free water 
Taq DNA polymerase
Nuclease free water 
10 µM 788 reverse primer
10 µM/µl 623 forward primer
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PCR cycling conditions for HIV-1 and CCR5 DNA 
 
Appendix V: CCR5 gel amplification photograph 
 
   
Appendix VI: TOPO TA cloning reaction set-up 
 
Initial Denaturation
95 °C           10 mins
Denaturation 95 °C             30 secs
Annealing 55 °C     30 secs
Extension 72 °C     30 secs
Final extention 72 °C             10 mins
Hold 4 °C             Infinity
PCR cycling conditions
50 cycles
1 cycle
Component Volume
Fresh PCR product 0.5-4 µl
Salt solution
Nuclease free water add to a total volume of 5µl
1 µl
pCR 4-TOPO plasmid vector 1 µl
 
     L               NC            
1000 
500 
200 
Negative control
Patient derived CCR5 
DNA
237 bpTarget band size
Label on gel
L
NC
SRIN48
Interpretation
100 bp DNA ladder
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Appendix VII: Drug resistance profile of HIV-1 infected drug naïve 
patients from Nouna Burkina Faso 
 
 
DR represents drug resistance; LR represents level resistance Type of template: RNA; Region analyzed: PR 1-99 
codons and RT (2/3) 1-335 codons. Primary resistance mutations are bolded, primary resistance mutations in other 
expert list are bolded and underlined and minor and accessory resistance mutations are italicized.  
Lab Viral load CD4 Tcell Type of Subtype PI NNRTI NRTI
ID Copies/ml counts (cells/ul) Template  PR-RT Mutations Mutations Mutations Low-LR High/ Intermediate -LR
SRIN14 939988 202 RNA CRF06_cpx - Like K20I no mutation
DNA CRF06_cpx - Like K20I
SRIN15 971579 7 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I
SRIN16 707181 10 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN25 54837 152 RNA CRF06_cpx - Like K20I
V106I
DNA CRF06_cpx - Like K20I
V106I
SRIN30 1017643 163 RNA CRF02_AG - Like L10V no mutation
K20I
DNA CRF02_AG - Like L10V no mutation
K20I
SRIN31 172739 271 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN32 430515 177 RNA CRF02_AG - Like  K20I
V118IV
DNA CRF02_AG - Like K20I
V118I
SRIN33 3399058 180 RNA CRF02_AG - Like L10V no mutation
 K20I
DNA CRF02_AG - Like L10V no mutation
 K20I
SRIN34 2801732 3 RNA CRF02_AG - Like K20I no mutation
L10V
DNA CRF02_AG - Like K20I no mutation
L10V
SRIN38 223957 248 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN39 115615 262 RNA G - Like V82I no mutation
K20I
DNA G - Like V82I no mutation
K20I
SRIN41 2314931 144 RNA CRF02_AG - Like V11I no mutation
 K20I
DNA CRF02_AG - Like V11I no mutation
K20I
SRIN47 743697 66 RNA CRF02_AG - Like  K20I no mutation
DNA CRF02_AG - Like  K20I no mutation
SRIN48 2416935 147 RNA CRF06_cpx - Like K43T
K201
Y181C EFV,ETR,NVP,RPV
DNA CRF06_cpx - Like K43T
K201
Y181C EFV,ETR,NVP,RPV
K219N
SRIN51 749061 284 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN52 194086 153 RNA CRF02_AG - Like L10I no mutation
K20I
DNA CRF02_AG - Like L10I no mutation
K20I
Drug Resistance Interpretations Per Resistance Scores
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Appendix VII continued 
 
 
 
 
 
 
 
 
 
Lab Viral load CD4 Tcell Type of Subtype PI NNRTI NRTI
ID Copies/ml counts (cells/ul) Template  PR-RT Mutations Mutations Mutations Low-LR High/ Intermediate -LR
SRIN55 93865 227 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN56 1593082 81 RNA CRF02_AG - Like K20I no mutation
L10V
DNA CRF02_AG - Like K20I no mutation
no mutation
SRIN57 653455 198 RNA CRF02_AG - Like  K20I no mutation
DNA CRF02_AG - Like  K20I
SRIN58 256724 231 RNA CRF02_AG - Like K20I no mutation
L10V
DNA CRF02_AG - Like K20I no mutation
L10V
SRIN60 121581 226 RNA CRF02_AG - Like K20IV no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN61 749061 284 RNA CRF06_cpx - Like K20I no mutation
DNA CRF06_cpx - Like K20I no mutation
SRIN62 2005003 180 RNA CRF02_AG - Like  K20I no mutation
DNA CRF02_AG - Like  K20I no mutation
SRIN63 86731 316 RNA 02A1-Like K20I
V108IV NVP
V90I 
DNA 02A1-Like K20I
V108IV NVP
V90I 
SRIN65 145511 32 RNA  CRF01_AE- like L10I
V179I
DNA  CRF01_AE- like L10I
V179I
SRIN66 227199 140 RNA  CRF01_AE- like L10V
E138A RPV
V179I
DNA  CRF01_AE- like L10V
E138A RPV
V179I
SRIN67 1195067 293 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN68 2201354 411 RNA G - Like K20I no mutation
DNA G - Like K20I no mutation
SRIN69 515487 428 RNA CRF02_AG - Like L10LV no mutation
K20I
L210LW AZT, D4T
DNA CRF02_AG - Like L10V no mutation
 K20I
L210LW AZT, D4T
SRIN70 46747 13 RNA G - Like A71AT
K20I
V90I
DNA G - Like A71T
 K20I
V90I
SRIN71 325435 256 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN72 95911 333 RNA G - Like  K20I
V179I
DNA G - Like   K20I
V179I
Drug Resistance Interpretations Per Resistance Scores
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Appendix VII continued 
 
 
 
 
 
 
Lab Viral load CD4 Tcell Type of Subtype PI NNRTI NRTI
ID Copies/ml counts (cells/ul) Template  PR-RT Mutations Mutations Mutations Low-LR High/ Intermediate -LR
SRIN73 1818940 157 RNA CRF02_AG - Like L10V no mutation
  K20I
DNA CRF02_AG - Like L10V no mutation
  K20I
SRIN74 40625 7 RNA CRF02_AG - Like   K20I V90I
DNA CRF02_AG - Like   K20I V90I
SRIN75 13291 400 RNA CRF02_AG - Like L10LV
 K20I no mutation
DNA CRF02_AG - Like L10V
 K20I
SRIN76 51695 177 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN77 45750 123 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN78 24482 269 RNA D- Like no mutation
DNA D- Like no mutation
SRIN79 11678 256 RNA CRF02_AG - Like   K20I
V179I
DNA CRF02_AG - Like K20I
V179I
SRIN80 23449 152 RNA  CRF01_AE- like no mutation V179I
DNA  CRF01_AE- like no mutation V179I
SRIN81 590908 323 RNA CRF02_AG - Like   K20I, T74S NFV 
K238KR 
DNA CRF02_AG - Like  K20I, T74S NFV 
K238R 
SRIN82 569328 140 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN83 43140 279 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN84 15793 156 RNA CRF02_AG - Like L10I no mutation
DNA CRF02_AG - Like L10I no mutation
SRIN85 1434896 215 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN86 2233224 146 CRF02_AG - Like L10I no mutation
 K20I
CRF02_AG - Like L10I no mutation
 K20I
SRIN87 4040062 65 RNA CRF02_AG - Like L33F
 K20R
I93M
DNA CRF02_AG - Like L33F no mutation
 K20R
I93M
SRIN88 574163 45 RNA CRF02_AG - Like L10V
K20I
V108I no mutation
DNA CRF02_AG - Like L10V
K20I
V108I no mutation
SRIN89 677363 54 RNA 02A1-Like K20I
V179I no mutation
DNA 02A1-Like K20I
V179I no mutation
SRIN90 1379797 236 RNA CRF06_cpx - Like K20I no mutation
DNA CRF06_cpx - Like K20I no mutation
SRIN91 977237 66 RNA CRF06_cpx - Like L10V no mutation
K20I
DNA CRF06_cpx - Like L10V no mutation
K20I
Drug Resistance Interpretations Per Resistance Scores
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Appendix VII continued. 
 
 
 
 
 
 
Lab Viral load CD4 Tcell Type of Subtype PI NNRTI NRTI
ID Copies/ml counts (cells/ul) Template  PR-RT Mutations Mutations Mutations Low-LR High/ Intermediate -LR
SRIN92 561916 282 RNA CRF06_cpx - Like L10I no mutation
K20I
DNA CRF06_cpx - Like L10V no mutation
K20I
SRIN93 10000000 643 RNA CRF02_AG - Like  K20I no mutation
L10V
DNA CRF02_AG - Like K20I no mutation
no mutation
SRIN94 10000000 116 RNA CRF02_AG - Like  K20I
V90I
DNA CRF02_AG - Like no mutation
no mutation
SRIN95 10000000 7 RNA CRF02_AG - Like K20R
L10I
V90I
DNA  K20I
L10I
no mutation
SRIN96 1892979 90 RNA CRF02_AG - Like K20I no mutation
L89I
DNA K20I no mutation
L89I
SRIN97 1581674 106 RNA CRF06_cpx - Like K20I no mutation
T69N
DNA CRF06_cpx - Like K20I no mutation
T69N
SRIN98 10000000 63 RNA CRF02_AG - Like K20I no mutation
L10V
DNA CRF02_AG - Like K20I no mutation
L10V
SRIN99 10000000 322 RNA CRF02_AG - Like K20I no mutation
L10V
DNA CRF02_AG - Like K20I no mutation
L10V
SRIN100 71380 292 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN101 339531 408 RNA CRF06_cpx - Like K20I no mutation
E44D
DNA CRF06_cpx - Like K20I no mutation
E44D
SRIN102 3790705 88 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN103 182608 397 RNA  CRF01_AE- like L10V no mutation
V179I
DNA  CRF01_AE- like L10V no mutation
V179I
SRIN105 98211 218 RNA CRF02_AG - Like K20I no mutation
DNA CRF02_AG - Like K20I no mutation
SRIN106 3589550 176 RNA CRF02_AG - Like K20I no mutation
V108I NVP
V90I
DNA CRF02_AG - Like K20I no mutation NVP
V108I 
V90I
SRIN107 290269 406 RNA CRF02_AG - Like K20I no mutation
L89I
DNA CRF02_AG - Like K20I no mutation
L89I
Drug Resistance Interpretations Per Resistance Scores
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Appendix VII continued. 
 
 
 
 
 
 
 
 
Lab Viral load CD4 Tcell Type of Subtype PI NNRTI NRTI
ID Copies/ml counts (cells/ul) Template  PR-RT Mutations Mutations Mutations Low-LR High/ Intermediate -LR
SRIN108 27833 232 RNA CRF02_AG - Like K20I no mutation
V179I
DNA CRF02_AG - Like K20I no mutation
V179I
SRIN109 405359 313 RNA CRF02_AG - Like K20I no mutation
V179I
DNA CRF02_AG - Like K20I no mutation
V179I
SRIN110 1420627 44 RNA CRF06_cpx - Like K20I no mutation
DNA CRF06_cpx - Like K20I no mutation
SRIN111 236592 212 RNA CRF06_cpx - Like K20I no mutation
DNA CRF06_cpx - Like K20I no mutation
SRIN112 1373030 213 RNA CRF02_AG  Like K20I no mutation
DNA CRF02_AG  Like K20I no mutation
SRIN113 1803350 11 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
SRIN114 21777 349 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
SRIN116 262060 508 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
SRIN117 90498 341 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
SRIN118 2579 279 RNA  CRF01_AE- like L10V no mutation
V179I
DNA  CRF01_AE- like L10V no mutation
V179I
SRIN119 272998 364 RNA CRF06_cpx - Like K20I no mutation
V11I
DNA CRF06_cpx - Like K20I no mutation
V11I
SRIN120 1400866 504 RNA CRF02_AG  - Like K20I no mutation
V11I
L10I
K103N NVP, EFV
DNA CRF02_AG  - Like K20I no mutation
V11I
L10I
K103KN NVP, EFV
SRIN121 224037 281 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
SRIN122 1531228 170 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
SRIN123 976517 301 RNA CRF02_AG  - Like K20I no mutation
E138A RVP
DNA CRF02_AG  - Like K20I no mutation
E138A RVP
SRIN124 225569 467 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
SRIN125 1126782 33 RNA CRF02_AG  - Like K20I no mutation
DNA CRF02_AG  - Like K20I no mutation
Drug Resistance Interpretations Per Resistance Scores
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Appendix VIII: Schematic diagram for the sequencing procedure of 
the PR/RT region of HIV-1 pol 
 
 
a. Reproduced from (Kousiappa et al., 2009) 
b. Diagram A represents the final amplicon containing gag ( p6) and pol ( prot and p51 RT) regions. 
c. The black triangular arrows represents the 5’-end binding positions of the sequencing primers. 
d. The gray cylindrical bars in diagram B represenst the sequence segments obtained from each sequencing primer 
e. The dark asterisks represents alternative DNA segments. This signifies that primer numbered 2734and 2650 can 
be used instead of 2610 and 3539 instead of 3462. 
f. Finally the gray cylindrical bar in diagram C represents the expected final sequenced derieved product after 
aligning the short sequenced fragments as shown above. 
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